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 ABSTRACT 
 
Mediation  of  biological  functions  occurs  via  tightly  regulated  signal  transduction 
pathways. These complex cascades often employ crosstalk with other signalling pathways 
to exert strict control to allow for correct cellular responses. The cyclic AMP signalling 
pathway  is  involved  in a  wide  range  of  cellular  processes  which  require  tight  control, 
including  cell  proliferation  and  differentiation,  metabolism  and  inflammation.  Protein 
Kinase C (PKC) signalling is also involved in the regulation of many biological functions, 
due to the wide range of PKC isoforms, and there is emerging evidence that there are 
critical points of crosstalk between these two central signalling pathways. The aims of this 
research,  therefore,  are  to  identify  the  molecular  basis  underlying  this  pivotal  cross-
communication. 
 
The identification of the complex formed by Receptor for activated C Kinase 1 (RACK1), 
a  scaffold  protein  for  PKC,  and  the  cyclic  AMP-specific  phosphodiesterase  PDE4D5 
demonstrated a potential area of crosstalk between the cyclic AMP and PKC signalling 
pathways although the function of the complex remained largely unknown. In this thesis I 
have outlined a role for RACK1 binding to PDE4D5 to control the enzymatic activity of 
the phosphodiesterase. Although RACK1 does not affect the intracellular localisation of 
PDE4D5,  it  does  afford  structural  stability  to  PDE4D5,  providing  protection  against 
denaturation.  Furthermore,  interaction  with  RACK1  facilitates  high  affinity  binding  of 
PDE4D5  to  cyclic  AMP  and  increases  phosphodiesterase  sensitivity  to  inhibition  by 
rolipram,  a  PDE4-specific  inhibitor  that  is  a  therapeutic  treatment  for  depression  and 
Alzheimer’s disease. Additionally, RACK1-bound PDE4D5 was found to be activated by 
PKCα, providing a route of negative regulation by PKC on cyclic AMP in HEK293 cells.  
 
The discovery of EPAC (Exchange Protein directly Activated by Cyclic AMP) has opened 
up the field of cyclic AMP research, providing an alternative route for the cyclic AMP 
signalling  originally  thought  to  occur  solely  through  Protein  Kinase  A  (PKA).  Recent 
investigations have linked cyclic AMP signalling via EPAC to the control of inflammation, 
through the induction of Suppressor of Cytokine Signalling 3 (SOCS-3) to inhibit IL-6 
signalling. Here I have further delineated this pathway in COS1 to show that induction of 
SOCS-3  by  EPAC  requires  phospholipase  C  (PLC)  ε.  Investigation  into  downstream 
effectors  of  PLC  action  lead  to  the  identification  of  PKCα  and  PKCδ  as  essential 
components of this pathway, further elucidating a mechanism by which cyclic AMP can 4 
 
affect  inflammation  and  revealing  a  point  of  crosstalk  between  the  two  signalling 
pathways. 
 
Further elaborating on the identification of PKC isoforms α and δ as crucial components in 
the control of cytokine signalling by cyclic AMP via EPAC, investigations into the effect 
of cyclic AMP on PKC α and δ activation and autophosphorylation, and on downstream 
effectors, were carried out. It was revealed that cyclic AMP had no influence on PKCδ 
activity, although a role for cyclic AMP signalling through EPAC on the activation and 
autophosphorylation  of  PKCα  was  identified.  Additionally,  phosphorylation  of  the 
downstream kinase ERK was found to occur independently of PKC activation and required 
the presence of EPAC1 in COS1 cells. 
 
The work presented in this thesis therefore begins to delineate a novel pathway in which 
the cyclic AMP and PKC pathways work together to afford cell regulation, including the 
regulation of gene expression, through novel areas of crosstalk.  
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Introduction 
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1.1 Signal Transduction 
 
The  mediation  of  biological  functions  requires  the  use  of  first  messengers,  such  as 
neurotransmitters, cytokines, hormones and growth factors, many of which are unable to 
permeate  the  cell  membrane.  To  carry  out  their  specific  functions,  they  require  the 
induction  of  signal  transduction  cascades,  wherein  a  cell  surface  receptor  is  activated, 
eliciting an intracellular response. A second messenger is often employed in the conversion 
of  the  extra-cellular  biological  system  to  the  intracellular  response.  The  first  point  of 
contact for the extracellular stimuli is the wide range of cell surface receptors. The nature 
of  signal  transduction,  and  the  affected  pathways,  is  determined  by  which  of  these 
receptors are activated by the extracellular stimuli. These membrane associated receptors 
can be divided into three groups; ion-channel linked, enzyme-linked and G-protein linked 
(Berg et al., 2002).  
 
1.1.1 Ion-channel Linked Receptors 
Ion channel linked receptors, such as the nicotinic acetylcholine receptor, are stimulated to 
open  or  close  in  response  to  external  stimuli,  particularly  neurotransmitters  or  peptide 
hormones.  A  conformational  change  upon  ligand  binding  creates  an  open  channel, 
allowing molecules, generally ions specific to the receptor, to pass through. In the case of 
the  nicotinic  acetylcholine  receptor,  this  is  Na
+  ions  (Alberts  et  al.,  2002).  When  the 
internal concentration of the ion is high enough, it causes a depolarisation of the membrane 
and initiates an action potential. Such receptors are common in neurons and other cells 
which require action potentials (Berg et al.,2002).  
 
1.1.2 Enzyme-linked Receptors 
Enzyme-linked receptors are activated by a wide range of hormones and growth factors 
and  are  important  in  signalling  pathways  that  lead  to  cell  growth,  differentiation  and 
proliferation. The cytosolic domains of these receptors are either associated with specific 
enzymes or possess its own enzymatic activity, giving this group of receptors their name 
(Berg et al., 2002). There are four well documented classes of enzyme linked receptors 
found  in  mammalian  systems:  guanylyl  cyclase  receptors,  serine/threonine  kinase 
receptors, receptor tyrosine kinases and tyrosine kinase associated receptors.  
 17 
 
Several signalling molecules, including natriuretic peptides, stimulate guanylyl cyclases. 
This stimulation catalyses the production of cyclic GMP, initiating a signalling pathway by 
activation  of  the  serine/threonine  kinase,  cyclic  GMP-dependent  protein  kinase  (PKG) 
which is involved in neuronal function, smooth muscle relaxation and kidney and intestine 
ion flux (Berg et al., 2002). 
 
The serine/threonine kinase receptors are stimulated by the transforming growth factor β 
super-family which as well as having involvement in cell proliferation, differentiation and 
apoptosis, are involved in immune regulation and tissue repair. There are two structurally 
similar types of serine/threonine kinase receptors, designated type I and type II which work 
together to activate a signalling pathway. Upon ligand binding to a type II homodimer, a 
type I homodimer is activated and recruited to form a tetrameric complex. This complex 
then directly phosphorylates the gene regulating family of proteins called Smad, which 
translocates directly to the nucleus to activate its target genes (Souchelnytskyi et al., 2001). 
 
Receptor tyrosine kinases (RTKs) comprise the largest group of enzyme linked receptors 
and  are  stimulated  by  a  wide  range  of  growth  factors  and  hormones  including  EGF 
(Epidermal Growth Factor), PDGF (Platelet derived growth factor) and VEGF (Vascular 
endothelial growth factor), as well as some cell surface bound signalling proteins such as 
ephrins that are involved in cell adhesion and migration (Gschwind et al., 2004). Upon 
stimulation, RTKs are able to phosphorylate target proteins and have been indicated in a 
number  of  well  studied  pathways  including  MAPK  cascades  (detailed  in  section  1.5). 
Finally,  tyrosine  kinase  associated  receptors  act  via  associated  cytoplasmic  tyrosine 
kinases, such as the Src family of proteins, which phosphorylate both target proteins and 
the receptors themselves (Hubbard and Till, 2000).  
 
The  cytokine  receptors  demonstrate  one  of  the  most  direct  routes  of  external  signal 
transduction to the nucleus, through activation of the Janus kinase/Signal Transducer and 
Activator  of  Transcription  (JAK/STAT)  signalling  pathway.  JAKs  are  a  group  of 
cytoplasmic tyrosine kinases which associate with cytokine receptors. Once activated by 
the receptor, JAKs phosphorylate the gene regulatory STAT proteins, activating them and 
causing them to translocate to the nucleus where they induce transcription of target genes 
(Rawlings et al., 2004). As with other enzyme-linked receptor pathways, this pathway is 
involved  in  cell  proliferation,  differentiation  and  apoptosis,  and  is  also  important  in 
haematopoiesis (Rawlings et al., 2004).  18 
 
1.1.3 G-protein Coupled Receptors (GPCRs) 
G-protein coupled receptors play a crucial role in cell signal transduction, mediating the 
majority of responses to neurotransmitters, hormones and external stimuli (Rosenbaum et 
al., 2009). They comprise a large super-family of transmembrane receptor proteins which 
bind these ligands to transduce signals from outside the cell into an intracellular response. 
Binding of the ligand induces a conformational change, allowing the GPCR to act as a 
guanine exchange factor (GEF). It is then able to activate an associated G-protein through 
the exchange of GTP for its bound GDP. The subunits of the G protein are then able to 
regulate enzymatic effectors which in turn generate second messengers such as calcium 
and  cyclic  AMP  (Rosenbaum  et  al.,  2009)  (Figure  1.1).  Over  800  GPCRs  has  been 
identified in the human genome, with around 460 of these believed to act as olfactory 
receptors and many more with as yet unknown functions (Deupi and Kobilka 2007). These 
800  GPCRs  are  divided  into  5  classes  based  on  function  and  sequence  homology. 
Together,  these  groups  are  known  as  the  GRAFS  (glutamate,  rhodopsin,  adhesion, 
frizzled/taste,  secretin)  classification.  Almost  90%  of  the  known  GPCRs  fall  into  the 
Rhodopsin-like family, while the rest are divided between adhesion, glutamate, secretin 
and  frizzled/taste  groups.  The  Rhodopsin  group  is  further  divided  into  4  subgroups, 
designated α, δ, γ and δ (Huang et al., 2009). The α group includes opsins, melatonins and 
prostaglandins; β comprises peptide hormones; γ, chemokine receptors and somatostatins 
and  opoids;  and  δ  forms  a  group  of  purines,  glycoproteins  and  the  large  number  of 
olfactory receptors. The glutamate group includes calcium sensing receptors, GABAB, and 
the Taste 1 cluster of receptors, while the Adhesion group is made up of GPCRs which are 
fused with an adhesion-like motif containing domains at their N-terminal (Bjarnadottir et 
al., 2005). The Frizzled/Taste group contains, as the name suggests, the frizzled, and Taste 
2 receptors, and the secretin group contains not only secretin receptors, but other large 
peptide receptors including those for calcitonin and glucagon (Deupi and Kobilka, 2007).  
 
Currently, crystallography is only available for three GPCRs- Rhodopsin, Opsin and β2-
Adrenergic receptor (Blois and Bowie, 2009). However, all GPCRs are believed to share a 
structural  similarity  of  seven  hydrophobic  membrane  spanning  α-helical  domains, 
connected by alternating intracellular and extracellular loops, an intracellular carboxy (C)-
terminal end and an extracellular amino (N)-terminal end. Although homology is highly 
conserved  between  GPCRs  with  regard  to  the  transmembrane  domains,  there  is  great 
variation  of  the  intra-  and  extracellular  areas  with  regard  to  complexity  and  size.  The 
extracellular areas are involved in ligand binding, while intracellular regions are required 19 
 
Figure 1.1  
 
 
 
Figure 1.1 GPCR mediated signalling - Upon binding of an external stimulus to the 
outside of the transmembrane GPCR, a conformational change occurs to allow the GPCR 
to act as a GEF for an associated heterotrimeric G protein. Following this activation, the 
Gα subunit dissociates from the Gβγ subunits and acts on effector enzymes which generate 
second messengers such as cyclic AMP and calcium.  20 
 
for signal transduction. The N-terminal and, in some GPCRs, extracellular loops, contain 
N-glycosylation sites and disulphide bridges between the extracellular loops to maintain 
correct protein folding and are conserved across the majority of the GPCRs. Conserved 
across the GPCRs in the C-terminal is a site for palmitoylation (Luttrell, 2008).   
 
GPCRs  may  activate  more  than  one  G  protein,  of  which  there  are  few  in  number  in 
mammalian genomes compared with the number of GPCRs encoded. G proteins comprise 
a  heterotrimer  consisting  of  the  subunits  α,  β and  γ.  Structurally,  Gα  subunits  share  a 
homology  consisting  of  an  α-helical  domain  which  inserts  into  its  Ras-like  GTP-GDP 
binding domain (Bridges and Lindsley, 2008). 12 Gγ and 5 Gβ subunit genes have been 
identified,  and  the  majority  of  these  form  stable  heterodimers  which  are,  like  the  Gα 
subunit, able to regulate effector activity. The Gβ subunits share a seven bladed propeller 
structure made up of β-sheets, and a coiled-coil structure at the N-terminal that associates 
with the Gγ subunit. The Gγ subunits contain a Cys-Ala-Ala-x motif at the C-terminal of 
its α-helical structure which allows for membrane localisation by prenylation (Deupi and 
Kobilka, 2007). There are currently 16 identified Gα subunit genes, with splice variants 
giving  rise  to  around  20  Gα  subunit  proteins,  which  are  divided  into  4  groups.  These 
groups  are  Gαs,  which  include  the  adenylyl  cyclase  stimulatory  subunit  Gαs,  and  the 
olfactory  subunit,  Gαolf;  Gαi  which  comprises  transducin,  the  retinal  subunit,  and 
gustducin,  involved  in  taste,  as  well  as  Gαi  1,  2  and  3,  which  are  adenylyl  cyclase 
inhibitory subunits; Gαq which consists of the regulators of phospholipase C activity Gαq 
and Gα11, as well as Gα14 and Gα15; and finally Gα12 includes Gα12 and Gα13 which 
regulate cytoskeletal assembly and cell growth via RhoGEFs (Luttrell, 2008). As can be 
seen from the stimulatory and inhibitory functions of the Gαs and Gαi subunits, the control 
of adenylyl cyclase by G-proteins is an important component of signal transduction. Since 
the main thrust of the research in this study is centred around new mechanisms of cyclic 
AMP  signal  transduction,  the  next  section  will  concentrate  on  cyclic  AMP  signal 
transduction. 
 
 
1.2 Cyclic AMP Signal Transduction 
The prototypical second messenger, 3’-5’-cyclic adenosine monophosphate, or cyclic AMP 
(cyclic  AMP)  (Figure  1.2)  was  first  identified  in  the  1950s  as  a  small  intracellular 
mediator.  Normal concentrations of cyclic AMP within cells are usually in the region of 
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Figure 1.2 Structural representation of cyclic AMP - The second messenger 3’-5’cyclic 
adenosine monophosphate (cyclic AMP).  22 
 
10
-7M (Cooper, 2003). However, extracellular signals, such as hormones that activate Gs-
coupled GPCR, are able to increase levels by more than twenty fold through activation of a 
family of adenylyl cyclase enzymes (Cooper, 2003). Cyclic AMP is essential for a range of 
critical cellular processes, including the activation of protein kinases and the regulation of 
Ca
2+ passage through ion channels (Cheng et al., 2008). Classically, rises in intracellular 
cyclic AMP levels were thought to elicit cellular responses mainly through the activation 
of cyclic AMP-dependent Protein Kinase A (PKA) (Conti et al., 2003), however it is now 
known  that  cyclic  AMP  can  exert  actions  in  the  cell  through  the  activation  of  other, 
recently  discovered,  cyclic  AMP  effectors,  such  as  cyclic  nucleotide  gated  (CNG)  ion 
channels and exchange protein activated by cyclic AMP (EPAC) (Figure 1.3). 
 
It is widely accepted that cyclic AMP is compartmentalised, with fluorescence-resonance-
energy-transfer  (FRET)  investigations  showing  both  temporal  and  spatial  cyclic  AMP 
gradients within cells (Houslay and Adams, 2003). This compartmentalisation is thought to 
be due to a number of factors, including the actions of GPCRs, adenylyl cyclase, and PKA. 
Cyclic nucleotide phosphodiesterases (PDEs), which hydrolyze cyclic AMP to 5’-AMP 
and are the only means of degradation of cyclic AMP, are thought to play an important role 
in cyclic AMP compartmentalisation and formation of cyclic AMP gradients throughout 
the cell (Houslay and Adams, 2003). Compartmentalisation allows differential activation 
of PKA pools in different locations where they are able to phosphorylate only the target 
proteins in that area. A-kinase Anchor Proteins (AKAPs) anchor PKA isoforms at specific 
sites within the cell, allowing a response of the spatially distinct PKA pools to cyclic AMP 
gradients, resulting in modification of localised target proteins (Baillie and Houslay, 2005). 
AKAPs  target  PKA  to  distinct  subcellular  locations  and  to  specific  substrates  with 
activation status of PKA dependent on localised cyclic AMP concentrations. Regulation of 
Ca
2+ channels also occurs via these localised PKA-AKAP complexes. Differing responses 
and activations from compartmentalised cyclic AMP level changes are probably linked to 
the stimulation of varying receptors resulting in different physiological responses. Here we 
will try to cast light on this complexity by summarising the major components of the cyclic 
AMP signal transduction cascade. 
 
1.2.1 Adenylyl Cyclases 
Cyclic  AMP  is  generated  by  adenylyl  cyclases  (ACs),  large  transmembrane  proteins 
ranging between 120 and 140 kDa (Cooper 2003), which catalyse the conversion of ATP  23 
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Figure 1.3 Cyclic AMP Signalling - Following GPCR mediated activation of adenylyl 
cyclase, cyclic AMP is synthesised by the enzyme from ATP, and is hydrolysed to 5’AMP 
by cyclic AMP specific phosphodiesterases (PDEs). Cyclic AMP levels control signalling 
through three main pathways- via cyclic nucleotide gated (CNG) ion channels to control 
the flux of ions, via EPAC (exchange protein directly activated by cyclic AMP) and Rap1 
where cyclic AMP can control cell adhesion and junction formation, and via PKA where it 
influences the metabolism of glycogen, sugar and lipids, among other actions. 24 
 
 
to cyclic AMP and phosphate. Mammalian systems contain ten ubiquitously expressed 
ACs, nine of which are membrane bound and one which is located in the cytosol (Luttrell, 
2008). Each isoform possesses a differing tissue distribution and regulation requirement, 
allowing increases of cyclic AMP  levels that are both specifically localised and occurring 
under  specific  conditions  (Tabakoff  et  al.,  2001).  Structurally,  ACs  consist  of  a  short, 
variable intracellular N-terminal region, two six-membrane-spanning cassettes termed M1 
and M2, two 40 kDa cytosolic domains designated C1 and C2 which form the catalytic 
site, and an intracellular C-terminal. The catalytic site of ACs is formed between the C1 
and C2 domains upon binding of Gαs or the drug forskolin to the outside of the C2 domain 
and  the  N-terminal  of  the  C1  domain,  causing  a  conformational  change  (Figure  1.4). 
Inhibition  by  G  proteins  can  occur  when  Gαi  binds  to  the  C1  domain,  preventing 
association of the two domains. This conformational change also forms a binding site at 
the opposing ends of the C1 and C2 domains. ATP binds to this interface where it is then 
catalysed into cyclic AMP (Cooper, 2003). The active site is highly conserved across the 
AC  isoforms,  which  also  share  a  high  sequence  and  structural  homology  with  the 
generators of cyclic GMP, the guanylyl cyclases which are discussed above. As well as 
activation by G proteins and forskolin, some AC isoforms are regulated by calcium, either 
in a calmodulin-dependent or -independent manner. Because of the importance of ACs in 
controlling  cyclic  AMP  levels  within  the  cell,  they  have  become  important  targets  for 
therapeutic treatment, for example forskolin analogues are successfully used in Japan for 
the treatment of asthma  (Pierre et al., 2009). 
 
1.2.2 Protein Kinase A (PKA) 
Originally  it  was  believed  that  all  cyclic  AMP  signalling  occurred  via  PKA.  PKA  is 
involved  in  the  regulation  of  a  wide  range  of  physiological  processes,  ranging  from 
metabolism to growth and memory (Cheng et al., 2008). There are two forms of PKA, 
PKAI  and  PKAII,  which  are  determined  by  the  presence  of  specific  regulatory  (R) 
subunits.  Inactivated,  PKA  is  a  tetrameric  complex  of  two  R  subunits  and  2  catalytic 
subunits. While PKAI is found mainly in the cytoplasm of the cell, PKAII is located at 
organelles and cellular structures (Perkins et al., 2001). Unlike PKAI, Type II is generally 
not  a  soluble  species,  but  is  instead  anchored  within  the  cell  by  AKAPs  at  specific 
locations (Feliciello et al., 2001). There are four known PKA R subunits, two of which are 
generally expressed in a variety of tissues, and two that are found almost exclusively in the 
brain, adipose and adrenal tissues (Cheng et al.,  2008). The three types of catalytic (C) 25 
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Figure 1.4  The structure of adenylyl cyclase - The adenylyl cyclase family of enzymes 
share a structure of two cassettes of six transmembrane spanning domains, termed M1 and 
M2 and two ~40 kDa cytoplasmic domains, C1 and C2. These cytoplasmic domains form a 
catalytic site at the C-terminal end of C1 and the N-terminal of C2, where Gα or forskolin 
bind. This binding causes a conformational change which creates an ATP binding site at 
the opposing ends of the cytoplasmic domains where cyclic AMP synthesis occurs.  
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subunits, α, β and γ, appear to have a broad tissue specificity, with C-α the most commonly 
found subunit of PKA (Dodge-Kafka and Kapiloff, 2006). Upon cyclic AMP binding to 
both sites on the R subunit, a conformational change occurs, lowering its affinity for the C 
subunits (Cheng et al., 2008). The complex then dissociates, and the enzyme becomes 
active, allowing the C subunits to target a wide range of proteins at their PKA consensus 
phosphorylation sites (Chang et al., 1993). These include ion channels, the GTPase Rho 
and transcription factors such as CREB (Cheng et al., 2008). Cyclic AMP is also able to 
affect ERK activation (as discussed in section 1.5.4) through the inhibition of the protein 
kinase Raf1 by PKA phosphorylation (Houslay and Baillie, 2003) which is thought to play 
a role in inhibiting cell cycle progression in cells in which cyclic AMP is anti-mitogenic. 
 
1.2.3 A-Kinase Anchor Proteins (AKAPs) 
Because of its wide range of substrates, PKA signalling specificity is obtained through use 
of AKAPs, which anchor PKA at distinct subcellular locations to facilitate interaction with 
specific  groups of substrates.  In this way, AKAPs are able to control aspects of PKA 
signalling. There are more than 50 members of the AKAP family (McConnachie et al., 
2006),  all  structurally  diverse  but  identical  in  three  aspects-  their  ability  to  bind  PKA 
through a PKA anchoring domain, their ability to form a multi-protein complex through 
binding other signalling enzymes, and the ability to target these complexes to specific sites 
within the cell (Beene and Scott, 2007).  PKA anchoring occurs via one of its R subunits 
undergoing a hydrophobic interaction with an α-helical region comprised of between 14-18 
amino  acids,  conserved  across  the  AKAP  family  (McConnachie  et  al.,  2006).  The  N-
terminal of the R subunit binds to this amphipathic region on the AKAP (Dodge-Kafka et 
al., 2008). While the RII subunit of PKA exhibits a higher binding affinity for AKAP than 
RI (Dodge-Kafka et al., 2006), some AKAPs show a preference for binding to the RI 
subunit, while others are dual specific and readily bind either subunit (Wong and Scott, 
2004). Naming of AKAPs was originally based on the molecular weight of each protein 
based on where it rested when run on an SDS-PAGE gel (Wong and Scott, 2004) but due 
to  the  great  and  constantly  increasing  number  of  AKAP  family  members  and  splice 
variants  sharing  similar  molecular  weights  as  already  identified  AKAPs,  proteins 
previously identified for other purposes now shown to act as AKAPs retain their original 
name, such as Gravin or Pericentrin (Smith et al., 2006). The first AKAP to be discovered 
was MAP2 (Microtubule associated protein 2) (Wong and Scott, 2004), initially identified 
through its ability to co-purify with PKA, a means of identification still used today to 
identify other AKAPs (Smith et al., 2006).  27 
 
 
As well as binding and targeting PKA, one of the most important, defining actions of 
AKAPs is the ability to form multi-protein complexes. These complexes can include both 
enzymes involved in signal transduction, as well as enzymes involved in signal termination 
(McConnachie  et al., 2006) allowing both phosphorylation and dephosphorylation of  a 
substrate, and both up-  and down-regulation of  pathways to occur through one AKAP 
multi-protein complex (Smith et al., 2006). This also gives rise to the ability of crosstalk 
between pathways to occur via AKAPs. The first AKAP identified to bind another protein 
alongside PKA was AKAP 150/79, shown to bind not only PKA but also the phosphatase 
protein 2B (PP2B) (Smith et al., 2006). Later, this same AKAP was identified to also bind 
Protein Kinase C (PKC) alongside these two proteins, acting as a multi-protein signalling 
complex (Smith et al., 2006). Several other AKAPs bind PKC alongside PKA, including 
Pericentrin, AKAPLb2, which binds PKA, PKC and PKD with PKA and PKC activating 
PKD, and Gravin which binds PKA and PKC alongside the b2-adrenergic receptor (Wong 
and  Scott,  2004).  Additionally,  AKAP350/450  binds  PKA  and  PKC  along  with 
phosphatase  proteins  1  and  2A  and  also  the  phosphodiesterase  PDE4D3  (Smith  et  al., 
2006). Other AKAPs also bind components of cyclic AMP signalling, such as AKAP110 
which binds PDE4A, and mAKAP which binds both PKA and PDE4D3, as well as PP2A, 
ERK5 and EPAC1 (McConnachie et al., 2006).  
 
The crucial role of AKAPs is the targeting of these multi-protein complexes to distinct 
subcellular locations, with the use of targeting motifs on the AKAP involved in protein-
protein and protein-lipid interactions (Smith et al., 2006). Ensuring signalling components 
are  anchored  in  distinct  sites  within  the  cell  allows  greater  control  and  specificity  of 
signalling. It is important to note that splice variants of the same AKAP can target to 
completely different areas within the cell, while more than one AKAP may be targeted to a 
specific location (Wong and Scott, 2004). Of the complexes listed above, each displays a 
distinct  and  specific  location  of  anchoring,  with  AKAP150/79  targeting  to  the  plasma 
membrane,  while  AKAP350/450  anchors  to  the  centrosomes  and  Golgi  apparatus  of  a 
variety of cell types and Gravin targets the actin cytoskeleton (McConnachie et al., 2006). 
mAKAP targets its complex components to the nuclear membrane of myocytes, brain and 
skeletal muscle cells, and demonstrates a negative feedback loop for control of cyclic AMP 
signalling,  wherein  several  components  including  the  downstream  effectors  PKA  and 
EPAC  1  acting  alongside  a  phosphodiesterase  responsible  for  reducing  cyclic  AMP 
concentration  (McConnachie  et  al.,  2006).  This  ability  of  AKAPs  to  bring  signalling 28 
 
components together at distinct sites within the cell not only provides a useful method of 
signal  transduction  specificity  control  through  compartmentalisation,  but  also  allows 
signalling pathways to converge.  
 
1.2.4 Cyclic nucleotide-gated (CNG) Ion Channels 
CNG  ion  channels  are  non-selective  cation  channels  that  are  members  of  the  voltage 
activated ion channel super-family, despite displaying a low voltage dependence (Kaupp 
and  Seifert,  2002).  CNG  channels  were  first  identified  in  retinal  rod  and  cone 
photoreceptors. Cyclic AMP-dependent CNG ion channels are most commonly located in 
olfactory sensory neurons (OSN), although recently they have been identified in other non-
neural tissues, including heart and liver (Kaupp and Seifert, 2002).  These heterotetrameric 
complexes contain two or three different subunits and are made up of six segments which 
span the membrane, a pore region located between two of the segments, and a C-terminal 
cyclic nucleotide binding domain, to which cyclic AMP is able to bind directly (Schulte 
and Levy, 2007). It is these differing subunits which determine the functions and features 
of each channel, including ligand sensitivity. Upon cyclic AMP binding to the C-terminal 
domain, conformational changes to the CNG structure occur, resulting in the pore area 
opening and allowing the passage of K
+, Na
+ and Ca
2+ ions. In particular, Ca
2+ is important 
in the adaptation and excitation of sensory cells. CNG ion channel activity is also modified 
through both phosphorylation and Ca
2+/calmodulin action (Kaupp and Seifert, 2002). 
 
1.2.5 Exchange protein directly activated by cyclic AMP (EPAC) 
In 1998, de Rooij et al. reported that activation of Rap1 via cyclic AMP and Forskolin was 
independent  of  PKA.  EPAC  was  then  identified  in  a  database  search  for  proteins  that 
contained sequence homology to cyclic AMP binding sites as well as to Ras and Rap1 
GEFs.  Radiolabelled  cyclic  AMP  experiments were  then  used  to  determine  that  cyclic 
AMP binds directly to EPAC. The study also showed that EPAC and the PKA regulatory 
subunit Iα bind to cyclic AMP with a similar affinity. EPAC was then confirmed as a GEF 
for  Rap1  through  co-transfection  experimentation  in  NIH3T3  cells  with  fluorescent 
labelled Rap1 used to show that it is directly activated by EPAC (de Rooij et al., 1998). 
Simultaneously,  both  isoforms  were  discovered  during  a  screen  for  genes  exhibiting 
second messenger binding motifs specific to the brain (Kawasaki et al., 1998). There are 
two EPAC isoforms, 1 and 2, encoded by distinct genes. EPAC1 is expressed abundantly 
throughout all cell types, particularly in the kidney, heart and thyroid glands (Roscioni et 29 
 
al., 2008), while EPAC2 is mostly found within the brain, adrenal and pituitary glands 
(Kawasaki  et  al.,  1998).  Identification  of  these  new  cyclic  AMP  receptors  showed  a 
complexity of cyclic AMP mediated signalling greater than previously thought, and raised 
the possibility that there may be a role for EPAC in some of the effects of cyclic AMP 
believed to act solely through PKA. The ubiquitous expression of both PKA and EPAC in 
all tissues allows for a greater precision of control of cyclic AMP signalling pathways, as a 
rise in intracellular cyclic AMP is able to activate PKA, EPAC as well as other cyclic 
AMP effectors present. This allows cyclic AMP to affect multiple pathways (Cheng et al., 
2008). Tight regulation of EPAC localisation to plasma and nuclear membrane, perinuclear 
regions  and  mitochondria,  as  well  as  subcellular  distribution  suggests  cellular 
compartmentalisation is important for the wide range of signalling properties of EPAC 
(Roscioni et al., 2008).  
 
The discovery of EPAC proteins revolutionised the known cyclic AMP signalling pathway, 
opening up the field because of the wide range of downstream effects of EPAC, including 
extracellular signal related kinase (ERK), phospholipase C (PLC) and protein kinase B 
(PKB)/Akt  (Roscioni  et  al.,  2008).  This  multi-domain  family  of  proteins  have  a  high 
affinity for cyclic AMP binding and also are able to activate the small GTPases Rap1 and 
Rap2, members of the Ras super-family (de Rooij et al., 1998). EPAC has been found to be 
involved in the regulation of crucial processes within the lungs, brain, heart and immune 
systems. For example, EPAC has been shown to be involved in hypertrophy in myocardial 
cells (Morel et al., 2005). In hypertrophy, cell size increases, causing an increase in tissue 
or organ volume. Although this occurs in the  heart ventricles  as a natural response to 
exercise,  hypertrophy  is  also  linked  to  diseases  such  as  hypertension.  Not  only  has 
increased expression of both EPAC isoforms been indicated in myocardial hypertrophy 
(Ulucan et al., 2007) but activation of EPAC in cardiomyocytes has been shown to cause 
activation  of  cardiac  hypertrophy  associated  genes  via  the  involvement  of  the  small 
GTPase  Rac  and  NFAT  (nuclear  factor  of  activated  T-cells),  a  transcription  factor 
regulated by calcium (Morel et al., 2005). Whether NFAT regulation occurs via EPAC 
mediated calcium signalling has yet to be determined. The involvement of cyclic AMP in 
cell  proliferation  is  also  well  documented    (Watson,  1975;  Stork  and  Schmitt  2002; 
Takahashi et al., 2004) and strong evidence links Rap1 to control of cell division (Knox 
and  Brown, 2002). Current research suggests that EPAC is able to both stimulate and 
inhibit  cell  division  depending  on  cell  type.    Studies  in  COS1  cells  have  shown  that 
overexpression of EPAC is believed to play a role in stimulating mitosis (Qiao et al., 2002) 30 
 
while  in  Jurkat  cells  overexpression  of  EPAC  has  been  demonstrated  to  inhibit  cell 
proliferation (Boussiotis et al., 1997).  
 
1.2.5.1 EPAC structure 
The  EPAC1  and  EPAC2  isoforms  share  sequence  homology,  including  a  C-terminal 
catalytic  region,  comprising  a  CDC25  homology  domain  for  nucleotide  exchange 
(CDC25HD) which is found in all eukaryotes, except plants, and is found in all guanine 
nucleotide exchange factors which regulate Ras-like G-proteins Ras, Rap and Ral (van 
Dam et al., 2009). This region also contains a Ras association domain (RA) and a Ras 
exchange  motif  (REM).  The  regulatory  region  of  both  isoforms  contains  a 
Dishevelled/Egl-10/Pleckstrin domain (DEP) as well as a cyclic nucleotide binding (CNB) 
domain (Figure 1.5). This domain is similar to the domain found in both PKA and the 
cyclic AMP receptor protein found in bacteria (Cheng et al., 2008). Additionally, EPAC2 
possesses a second CNB domain at the N-terminal of the DEP domain. Functionally, the 
purpose of this second CNB domain is unknown as it is not required for cyclic AMP 
regulation by EPAC2 (Bos, 2006) and has a low affinity for cyclic AMP binding (de Rooij 
et al., 2000). Interestingly, this is the only common structural aspect between EPAC and 
PKA.  
 
This lack of structural similarity between EPAC and PKA meant that understanding how 
cyclic  AMP  binding  affects  the  structure  of  EPAC,  and  whether  binding  causes  a 
conformational change that allows EPAC to interact with its downstream effectors, could 
not  be  obtained  via  comparisons  with  other  known  cyclic  AMP  receptors.  However, 
recently  the  crystal  structure  of  EPAC2  was  solved,  in  the  absence  of  cyclic  AMP, 
allowing  visualization  of  the  closed  formation  (Rehmann  et  al.,  2007).  Additionally, 
Deuterium Exchange Mass Spectroscopy (DXMS) studies have shown that conformational 
changes in what is termed the ‘switchboard’ section, where the CNB C-terminal and the 
catalytic region of the protein meet, occur upon cyclic AMP binding (Brock et al., 2007). 
This  causes  a  rearrangement  of  the  domains  to  expose  the  catalytic  region  and  allow 
binding of effectors. Binding of cyclic AMP leaves the catalytic region relatively unaltered 
(Brock et al., 2007). Residues on the CDC25HD and the N-terminal helical bundle form an 
ionic latch, and it is theorised that, upon cyclic AMP binding, the CDC25 domain is forced 
to move, breaking the interactions which form the ionic latch (Harper et al., 2008). It is 31 
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Figure 1.5 EPAC structure - EPAC1 and EPAC2 share a common domain structure. The 
catalytic domain at the C-terminal of the protein comprises a CDC25 homology domain 
(CDC25HD) for nucleotide exchange, a Ras association domain (RA) and a Ras exchange 
motif  (REM).  The  regulatory  region  contains  a  Dishevelled/Egl-10/Plekstrin  domain 
(DEP) as well as a cyclic nucleotide binding (CNB) domain. EPAC2 possesses two of 
these CNB domains, which has an as yet unknown purpose. (Adapted from Bos, 2006) 32 
 
interesting to note that the cyclic AMP analogue 8-pCPT-2’O-Me-cyclic AMP (8Me), a 
highly selective EPAC agonist with an affinity for EPAC 10 times greater than cyclic AMP 
(Bos, 2006), causes similar, though not identical, conformational changes as cyclic AMP 
(Harper et al., 2008). 
  
1.2.5.2 EPAC signalling 
Cyclic AMP is well characterised as promoting calcium mobilization and influx (Rubin 
and Adolf, 1994; Cheng et al., 2008) although previously this ability has been solely linked 
to the actions of PKA. Recently, however, EPAC has been shown to regulate calcium 
signalling in three ways. Firstly, it has been suggested that EPAC directly interacts with 
intracellular  calcium  receptors  such  as  ryanodine  receptors  and  inositol  1,  4,  5- 
triphosphate (IP3) receptors (Roscioni et al., 2008) to mediate calcium release in response 
to calcium mobilizing second messengers such as IP3 and NAADP (Holz et al., 2006). 
Supportive  evidence  in  the  form  of  the  identification  of  a  macromolecular  complex 
comprising EPAC1, a muscle specific AKAP (mAKAP), PDE4D3, PKA and RYR2, the 
type 2 isoform of the ryanodine receptor (Dodge-Kafka and Kapiloff, 2006) further links 
EPAC  to  calcium  release.  Secondly,  PKA  independent  phosphorylation  of  ryanodine 
receptors and IP3 receptors to increase their sensitivity to both calcium mobilizing second 
messengers and to calcium itself has been shown to occur via Rap and ERK. It is possible 
that these actions may be mediated by EPAC (Holz et al., 2006). Lastly, EPAC has been 
linked to activation of the PLC isoform, e. PLCe is one of 6 isoforms of the PLC family of 
proteins, which hydrolyse phosphatidylinositol 4, 5- bisphosphate (PIP2) to the second 
messengers, IP3 and diacylglycerol (DAG). To date, little is known about the mechanisms 
of  PLCe  other  than  its unique  ability  for  regulation  by  the  direct  binding  of  small  G-
proteins including Ras, at its CDC25 and Ras-associating domains. This allows PLCe to 
act not just as a PLC, activating PKC via mediation of calcium and DAG, but also as a 
component  in  GTPase  function  (Bunney  and  Katan,  2006).  EPAC  has  been  shown  to 
activate PLCe in HEK293 cells via the GTPase Rap2B upon elevations of cyclic AMP 
(Schmidt  et  al.,  2001)  and  also  to  interact  with  PLCe  in  the  β-adrenergic  receptor 
stimulation of Ca
2+-induced Ca
2+ release (CICR) in cardiac myocytes (Oestreich et al., 
2009). This interaction provides a link between two classical second messenger signalling 
pathways, those of cyclic AMP and calcium. 
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The importance of EPAC-regulated Ca
2+ signalling is highlighted by the fact that EPAC2 
has been shown to be involved in control of insulin exocytosis in pancreatic b-cells via 
cyclic AMP stimulation (Ozaki et al., 2000). This is believed to occur through a Rab3 
interacting protein, Rim2, and a subunit of the K
+-ATP channel, SUR1 (Kashima et al., 
2001). Additionally, as EPAC2 has been shown to couple pancreatic β cell cyclic AMP 
production  to  stimulate  calcium  dependent  exocytosis,  as  well  as  evidence  that  down-
regulation of EPAC2 reduces calcium signalling and insulin secretion by glucagon-like 
peptide 1 (GLP1) (Holz, 2004) strongly links EPAC2 to a role in diabetes. Exocytosis is 
also involved in the release of neurotransmitters (NTs) and recent research has shown a 
potential role for EPAC in NT release at excitatory central synapses (Gekel and Neher, 
2008).  
 
1.2.5.3 EPAC and inflammation 
EPAC has been linked to regulation of inflammation in vascular endothelium cells, via 
both  cytokine  signalling  down  regulation  and  cell-cell  adhesion.  EPAC  is  believed  to 
regulate endothelial cell-cell junction formation by redistribution of vascular endothelial 
cadherin (Kooistra et al., 2005). This redistribution allows the cadherin to bind to binding 
partners  located  on  neighbouring  cells  in  vascular  endothelial  cells,  forming  a  tight 
junction  and  reducing  cell  permeability  (Kooistra  et  al.,  2005).  This  reduction  of 
permeability is essential as increased permeability has been shown to be a characteristic of 
oedema  (Cullere  et  al.,  2005).  Recently,  EPAC  has  also  been  linked  to  control  of 
inflammatory response by mediation of IL-6 signalling via the cytokine suppressor, SOCS-
3  (Sands  et  al.,  2006).  Cytokine  signalling  involves  the  secreted  cytokine  molecules 
regulating a wide range of biological functions, including proliferation, differentiation and 
inflammation.  Cytokines  interact  with  cell  surface  receptors  to  trigger  transmission  of 
signals to the nucleus, which results in transcription (Starr and Hilton, 1998). A family of 
proteins called suppressors of cytokine signalling, SOCS, were identified to negatively 
regulate these cytokine signalling pathways. This family has eight members, SOCS-1-7 
and CIS. All of the SOCS-3 proteins contain a unique N-terminal region, a middle SH2 
domain and a domain termed SOCS box at the C-terminal. This area is conserved not only 
across  the  SOCS  proteins,  but  also  in  several  other  proteins,  including  some  GTPases 
(Starr and Hilton, 1998). SOCS-1 was first discovered in 1997 simultaneously by three 
groups during a screen for similarity for the STAT3 SH2 domain (Naka et al., 1997), as an 
inhibitor of differentiation of myeloid cells in response to IL-6 (Starr et al., 1997) and as a 
protein  that  interacts  with  the  JAK2  kinase  domain  (Endo  et  al.,  1997).  SOCS-3  was 34 
 
identified shortly after and has been shown to display a greater similarity to SOCS-1 than 
to  other  SOCS  proteins,  with  both  SOCS-1  and  SOCS-3  showing  a  kinase  inhibitory 
region not conserved in other family members. Additionally, both SOCS-1 and SOCS-3 
are able to be induced by several cytokines (Gisselbrecht, 1999). SOCS-3 is the major 
SOCS gene in several areas, including the hypothalamus, pituitary, mammary gland and 
liver (Gisselbrecht, 1999).  
 
SOCS-3 interferes with the JAK-STAT pathway, a critical pathway in the signalling of a 
number  of  cytokines  including  IL-6.  SOCS-3  directly  binds  to  and  inhibits  JAKs, 
preventing the phosphorylation of STATs and thus preventing the transcription of target 
genes, inhibiting the IL-6 stimulated response. SOCS-3 was found to be induced by cyclic 
AMP via EPAC1 in HUVECs (Sands et al., 2006) and COS1 cells (Borland et al., 2009) 
through  a  pathway  involving  EPAC  and  Rap1  activation  of  CCAAT/enhancer-binding 
proteins  (C/EBPs)  b  and  d.  C/EBP  transcription  factors  associate  with  the  SOCS-3 
promoter, thereby inducing increased transcription of the SOCS-3 gene (Yarwood et al., 
2008).   
 
1.2.6 Cyclic AMP phosphodiesterases 
Although  intracellular  levels  of  cyclic  AMP  may  be  increased  through  stimulation  of 
multiple adenylyl cyclase enzymes (Cooper, 2003) through the action of many different G-
protein  coupled  receptors,  hydrolysis  to  5’AMP,  via  the  action  of  a  large  family  of 
phosphodiesterase enzymes (PDE), is the only known means of cyclic AMP degradation in 
cells (Lugnier, 2006). While adenylyl cyclases are localized to the plasma membrane, PDE 
activity occurs throughout the cell in the cytosol, cytoskeleton, nucleus and membrane, and 
is therefore essential in the compartmentalisation of cyclic AMP gradients (Bolger et al., 
2003). PDEs are thus not only able to terminate cyclic AMP signals via degradation of 
cyclic AMP, but also have the ability to ‘fine-tune’ levels in specific areas to increase 
signal specificity, through exertion of a combination of intracellular localisation, regulatory 
mechanisms and enzyme kinetics (Terrin et al., 2006).   
 
It is theorised that the actions of PDEs on cyclic nucleotides is through a water molecule, 
induced  by  an  OD2  atom  in  the  Asp318  residue  of  the  PDE,  that  is  able  to  act  as  a 
nucleophile,  attacking  the  cyclic  AMP  phosphorous  atom  (Kang  et  al.,  2006),  thus 
hydrolyzing the 3’ cyclic phosphate bond. The first PDE to be identified was an orthologue 
of the mammalian PDE4 isoforms (Richter et al., 2005), the Drosophila dunce gene, which 35 
 
has been shown to have a role in learning and memory. The number of genes encoding the 
various PDE families varies widely between species. For example, humans possess sixteen 
genes encoding PDE4, while C. elegans has only one (Conti et al., 2003). To date, eleven 
PDE families have been identified, of which 8 contain isoforms with the ability to degrade 
cyclic AMP. This diversity of these isoforms, which, through alternative splicing (Bolger 
et  al.,  1997),  now  number  over  thirty,  suggests  both  a  specificity  of  the  isoforms  to 
regulate distinct mechanisms within the cell, and the possibility of regulation of PDEs 
through alternative signalling pathways (Houslay and Adams, 2003). The members of the 
PDE families appear to share structural homology of their C-terminal domains, with N-
terminals differing greatly between them (Conti et al., 2003) (Figure 1.6). 
 
Of the eight cyclic AMP degrading PDE families, PDE4 isoforms account for the majority 
of cyclic AMP hydrolysis (Conti et al., 2003) and are widely expressed in a variety of 
tissues.  More  than  twenty  PDE4  variants  have  been  characterised  to  be  expressed  in 
mammalian cells (Bender and Beavo, 2006) and are involved in a wide range of cellular 
functions, such as macrophage and monocyte  activation, neutrophil infiltration, cardiac 
contractility  and  brain  function  (Bender  and  Beavo,  2006).  PDE4  isoforms  are 
distinguishable by their ability to be inhibited by the anti-depressant drug rolipram (Conti 
et al., 2003). Inhibitors of PDE4 have also been found to have anti-inflammatory actions, 
and have potential in the treatment of a number of diseases, including chronic obstructive 
pulmonary disease (COPD), asthma and depression (Bolger et al., 2006). This therefore 
makes PDE4 isoforms highly interesting because of their potential as therapeutic targets 
(Houslay et al., 2005). PDE4 isoforms share a catalytic domain composed of 17 α-helices 
that form three subdomains. Located between the subdomains are two metal-ion binding 
sites, with the centre of the domain forming a binuclear motif containing a Zn
2+ and Mg
2+ 
ion  (Castro  et  al.,  2005).  Complete  understanding  of  this  domain  is  important  for  the 
synthesis  of  PDE4  inhibitors,  as  well  as  determining  the  mechanism  of  cyclic  AMP 
binding to the PDE4 isoforms for degradation (Bolger et al., 2003). The majority of the 
catalytic domain, particularly the metal ion binding sites, is conserved across all PDE4 
isoforms,  with  75%  sequence  homology  between  PDE4  isoforms  (Bender  and  Beavo, 
2006). 
 
Cyclic  AMP  is  able  to  self  regulate  its  own  levels  by  activating  PDE4  isoforms  in  a 
number of ways.  PDE4 isoforms are regulated by both phosphorylation as well as at the 
genetic level via alterations in PDE expression. PKA phosphorylation has been shown to  36 
 
Figure 1.6  
 
 
 
Figure 1.6 The phosphodiesterase family - The eleven known phosphodiesterase (PDE) 
families. Eight of these (PDE1, PDE2, PDE3, PDE4, PDE7, PDE8, PDE10 and PDE11) 
hydrolyse  cyclic  AMP,  while  PDE5,  PDE6  and  PDE9  are  cyclic  GMP  specific.  All 
isoforms share a structural homology at their C-terminal, while possessing different, family 
specific, N-terminal regions (Amended from Conti et al., 2000). 37 
 
regulate  long  forms  of  PDE4  isoforms.  Cyclic  AMP  feedback  regulation  has  been 
demonstrated in T cells, monocytes, neurons, Sertoli and thyroid cells, where increased 
cyclic AMP levels result in increased transcription of the PDE4 genes (Park et al., 2003). 
A rise in cyclic AMP levels within the cell leads to increased PDE activity, potentially to 
desensitise processes within the cell to the higher cyclic AMP levels. A sustained, long-
term increase of levels of cyclic AMP results in a rise in levels of mRNA and protein 
expression of PDE4 isoforms. In addition to this, cyclic AMP is able to cause both PKA 
and ERK MAP kinase phosphorylation, resulting in increased kinase activity, by targeting 
specific residues on both their N-terminal and in the UCRs, as shown in PDE4D3 studies 
(MacKenzie et al., 2002). The beginning of this study focuses on novel regulation of a 
member of the type 4D family of cyclic AMP PDEs and so we will concentrate on this 
family in the next section. 
 
 
1.3 Cyclic AMP-specific Phosphodiesterases, Type 4 PDEs 
 
In humans, there are 4 PDE4 genes, encoding more than twenty isoforms in the subfamilies 
PDE4A, PDE4B, PDE4C and PDE4D, distinguishable by their unique N-terminal regions 
(Figure 1.7). The genes themselves are over 18 exons long with a size of approximately 
50kb, but despite this obvious complexity, there is almost complete conservation between 
mouse and human PDE4 genes, indicating a likely strong evolutionary selective pressure to 
maintain concurrence of the genes between species (Conti et al., 2003). The isoforms are 
encoded by alternatively spliced mRNA transcripts (Bolger et al., 1997). The unique N-
terminal domains, by which each isoform can be easily identified, are thought to play an 
important role in intracellular targeting, where they are involved in protein-membrane and 
protein-protein interactions, such as those between PDE4D3 and AKAPs (Wong and Scott, 
2004), and PDE4D5 with receptor for activated C-kinase 1 (RACK1) (Le Jeune et al., 
2002). In addition, members of the PDE4 family can be categorised in three ways based on 
the presence or absence of two domains called upstream conserved regions (UCRs). Those 
termed ‘short’ only have UCR2, and ‘super-short’ lack both UCR1 and possess only a 
truncated UCR2 domain (MacKenzie et al., 2002) (Figure 1.8). UCR 1 and 2 are located 
between the N-terminal and the catalytic site, and have important regulatory roles for the 
catalytic  domain,  where  they  are  able  to  influence  PDE4  activity.  UCRs  appear  to 
influence the differential functions of the isoforms upon catalytic domain phosphorylation,  38 
 
Figure 1.7  
 
 
 
Figure 1.7 Phosophodiesterase 4 - The PDE4 family is responsible for the majority of 
cyclic AMP hydrolysis. Having more than 20 isoforms, this family is encoded by four 
genes, A-D. The isoforms share a basic structural similarity, yet are distinguished by their 
isoform specific N-terminal regions (Amended from Bender and Beavo, 2006).       
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Figure 1.8 The structure of UCRs in long, short and supershort PDE4 isoforms -The 
PDE4 family can be categorised based on the presence or absence of the UCR1 and UCR2 
domains  which  influence  PDE  activity.  Long  PDE4  isoforms  contain  both  of  these 
domains  and  short  PDE4  isoforms  possess  only  the  UCR2  domain,  while  super-short 
PDE4 isoforms lack UCR1 and possess a truncated UCR2 domain.  40 
 
with ERK phosphorylation effects differing depending on the UCRs present (Houslay and 
Baillie, 2003). With UCR1 and 2 domains interacting with each other to form a regulatory 
domain in long isoforms, ERK phosphorylation results in inhibition, while in the short 
isoforms, with only UCR2 present, phosphorylation results in activation (Lim et al., 1999). 
In super-short isoforms, ERK phosphorylation does not result in any activity, indicating 
ERK phosphorylation requires a section of the UCR domain not present in the truncated 
domains found in super-short isoforms (Le Jeune et al., 2002). PKA activation of long 
isoforms results in a Vmax increase of two to three times. Studies using PDE4D3 have 
shown the regulatory module of the two regions is involved in phosphorylation of the 
PDE4 by PKA and ERK MAP kinase (MacKenzie et al., 2000).  
 
1.3.1 PDE4D 
PDE4D mRNA is found in a wide variety of cells, with protein levels being particularly 
high in the brain, liver and heart, and also in inflammatory cells (Bender and Beavo, 2006). 
Given this wide tissue distribution it is perhaps not surprising that PDE4D isoforms have 
been implicated in a number of diseases, including ischemic stroke, atherosclerosis and 
osteoporosis  (Bender  and  Beavo,  2006).  PDE4  activity  is  the  most  dominant  of  PDE 
activity in inflammation, and is found in eosinophils, neutrophils and CD4+ lymphocytes, 
suggesting important roles for PDE4 isoforms in diseases such as COPD and asthma. This 
places PDE4 isoforms as an ideal potential therapeutic target (Le Jeune et al., 2002). In 
particular, PDE4D isoforms are of interest due to their hypothesised ability to mediate the 
effects  of  rolipram  and  other  PDE4  inhibitors  (Richter  et  al.,  2005).  Located  on 
chromosome  5q12,  the  gene  encoding  PDE4D  has  a  complex  genomic  arrangement, 
composed of two major exon clusters which encode the catalytic and regulatory regions 
which are highly conserved, and three exons which encode the specific N-terminals. Nine 
splice variants of the PDE4D gene have been identified, six of which are long isoform and 
each can be distinguished by the unique N-terminal domain (Richter et al., 2005). While 
PDE4D1 and PDE4D2 are found only in the cytosol, PDE4D3, PDE4D4 and PDE4D5 can 
be located in either the cytosol or membranes of the cell, with the majority of PDE4D 
isoforms present in the membranes being PDE4D4 (60%), and only 30% being made up of 
PDE4D5 and PDE4D3 (Bolger et al., 1997). While the Vmax of PDE4D3 appears to be the 
same in both the cytosolic and membrane fractions, those of PDE4D4 and PDE4D5 are 
around 3 times higher in the membrane fraction than the cytosolic (Bolger et al., 1997). 
The range of locations, abundance and activities of the PDE4D isoforms suggests that each 
splice variant has both a highly specific and unique role to play within the cell. It also 41 
 
appears  that  localisation  to  the  particulate  fraction  of  the  cell  has  an  influence  on  the 
PDE4D isoform enzyme properties, such as sensitivity to rolipram, with the adoption of 
conformations different to the cytosolic isoform counterpart (Bolger et al., 1997).  
 
1.3.2 Interactions between PDE4D5 and receptor for activated C-kinase 1 (RACK1) 
PDE4D  isoforms  have  been  shown  to  interact  with  a  number  of  other  proteins.  For 
example,  PDE4D3 binds to myomegalin, a large protein found in cardiac and skeletal 
muscle  (Verde  et  al.,  2001),  PDE4A5  forms  a  complex  with  immunophilin  XAP2,  an 
associated protein of the Hepatitis B virus X protein (Bolger et al., 2003) and PDE4A5, 
PDE4A4 and PDE4D4 all bind with the Src family of tyrosine kinases (McPhee et al., 
1999). Another such interaction is the protein-protein interaction occurring between the 
splice variant PDE4D5 and RACK1 (Yarwood et al., 1999), a protein which has been 
shown  to  act  as  both  an  anchor  and  shuttle  for  a  number  of  proteins  within  the  cell 
(McCahill et al., 2002). PDE4D5 is distinguishable from other PDE isoforms by 88 amino 
acids at the N-terminal of the enzyme, which is unique to PDE4D5 and highly conserved 
between mammalian species, and is responsible for recruitment of PDE4D5 to RACK1 
(Bolger et al., 2002). One attractive hypothesis is that interaction with RACK1 through this 
unique N-terminal region serves to recruit and anchor PDE4D5 into a position where it is 
able to regulate local cyclic AMP levels at the plasma membrane (Le Jeune et al., 2002). 
 
RACK1 is a 36 kDa protein, was originally cloned from a chicken liver cDNA library 
(McCahill et al., 2002) and was identified as a homologue of the β subunit of G proteins. 
Both  Gβ  and  RACK1  are  members  of  the  large  WD  repeat  family,  which  consists  of 
regulatory proteins, all sharing the Trp-Asp40 (WD40) motif. In RACK1, the WD40 motif 
is highly conserved between species with the primary structure of RACK1 having 100% 
homology between human, mouse, chicken, rat and cow (Berns et al., 2000). RACK1 was 
first  discovered  to  bind  PKC  serine/threonine  kinases  following  activation  of  PKC 
isoforms  by  phorbol  esters  or  diacylglycerol  (McCahill  et  al.,  2002).  RACK1  binds 
activated PKC isoforms through a non-substrate binding site and controls specificity of 
PKC-mediated signalling by translocating and anchoring the activated protein to particular 
cell  fractions  (Schechtman  and  Mochly-Rosen,  2001).  As  such,  RACK1  is  mainly 
recognised as an anchoring protein for the PKC family although it has been shown to bind 
a number of proteins, acting as an adaptor or anchoring protein in several protein-protein 
and protein-membrane interactions (McCahill et al., 2002). 42 
 
 
Like  Gβ,  RACK1  has  a  seven  bladed  β  propeller  structure.  Arranged  in  a  rigid  ring 
formation, it is the multiple binding sites of this formation that allows RACK1 to act as an 
adaptor or scaffold protein for a range of proteins (Figure 1.9). RACK1 is believed to 
recruit and anchor these proteins into a signalling cascade by shuttling and anchoring the 
proteins  to  their  appropriate  subcellular  locations,  suggesting  that  RACK1  plays  an 
important role in intracellular signalling (Liedtke et al., 2002). While PKCβII appears to be 
its preferred binding partner, RACK1 has been shown to interact with numerous proteins, 
such as Src, PLC γ, Dynamin-1, ras-GAP, integrins and several viral proteins, for example 
BZLF1, the EBV activation protein, the Adenovirus E1A protein and the Influenza M1 
protein (McCahill et al., 2002). Src is  a tyrosine kinase proto-oncogene activated in a 
number of cancers including breast and colon. Phorbol ester stimulation of PKC activates 
Src  which  causes  Src  to  bind  to  RACK1  by  the  SH2  domain  independently  of  PKC 
activation. However, binding of both kinases to RACK1 can result in cross-talk between 
the serine/threonine kinase and tyrosine kinase pathways (Mamidipudi et al., 2004). The 
signalling enzyme, Phospholipase Cγ (PLCγ), generates diacylglycerol upon activation of 
growth factor receptors and contains a C2 domain where RACK1 binds when cells are 
stimulated with epidermal growth factor (Schechtman and Mochly-Rosen, 2001), while 
Dynamin-1 binds to RACK1 via the PH (Pleckstrin Homology) domain. Dynamin-1 is 
involved in vesicle recycling and its intrinsic GTPase activity is increased 6 times in vitro 
when  bound  to  RACK1  and,  at  high  concentration,  also  competes  with  Gβγ  to  bind 
RACK1 (Dell et al. 2002). Ras is an important protein in cell growth. Its activation is 
terminated by GAP, a GTPase activating protein which binds RACK1 through both the C2 
and SH2 domains. GAP is also a PKC substrate, and RACK1, GAP and PKC are believed 
to form a trimolecular complex in order to increase the proximity of  GAP to PKCIIB 
(Schechtman and Mochly-Rosen, 2001). 
 
There is also some evidence that RACK1 can affect signalling from GPCRs through direct 
protein interactions. For example RACK1 binds to the Gβγ subunit  (Dell et al., 2002) and 
this binding has been shown to result in RACK1 translocating from the cytosol to the 
membrane  of  the  cell.  Although  RACK1  has  no  effect  on  Gβγ  functions,  such  as 
chemotaxis and MAPK signalling, it inhibits activation of both phospholipase C β2 and 
adenylyl cyclase II (Chen et al., 2005). This inhibition of ACII prevents cyclic AMP from 
being generated, thus having an effect on the control of cyclic AMP levels within the cell. 
Interestingly, although Gβγ mediated ACII activation is inhibited, it has no effect on cyclic  43 
 
Figure 1.9 
 
 
 
Figure 1.9 Structure of Receptor for Activated Protein Kinase C - The structure of 
RACK1  shows  its  seven  blade  propeller  structure,  composed  of  WD  repeats,  and  the 
blades involved in interaction with various proteins, including PDE4D5 which interacts 
with WD repeats 5, 6 and 7 (McCahill et al., 2002).  44 
 
AMP signalling controlled by Gαi and Gαs acting receptors. It may also be possible that 
other  RACK1  binding  proteins  maybe  also  be  involved  in  the  regulation  of  the  Gβγ 
functions inhibited by RACK1 (Chen et al., 2004).  
  
The  PDE4D5/RACK1  signalling  complex  is  of  particular  interest  as  it  spans  both  the 
cyclic AMP signalling pathway, and the PKC signalling pathway, and may be an area of 
cross-talk  between  the  two  pathways.  RACK1  and  PDE4D5  are  believed  to  interact 
similarly  to  Gβ,  a  β  propeller  protein,  and  Gγ,  a  helical  signal  transduction  molecule, 
which  exhibit  a  coiled-coil  interaction  between  their  N-terminal  regions,  and  via  an 
interaction between blades 5, 6 and 7 of the Gβ C-terminal and helical and non-helical 
sections of the C-terminal of Gγ, with the helical segment of Gγ fitting into the groove 
created by the blades of Gβ (McCahill et al., 2002). The C-terminal domain of the WD-
repeat protein is clearly important in this helix/groove-like interaction, and this is believed 
to be the case within the RACK1/PDE4D5 complex also (Bolger et al.,2006) (Figure 1.10). 
A subdomain within the 88 amino acids of the unique N-terminal region of PDE4D5 was 
found to be essential in binding to RACK1 (Figure 1.11). The RACK1 interaction domain 
(RAID1)  consists  of  a  segment  of  charged  amino  acids,  and  a  second  section  of 
hydrophobic amino acids. The hydrophobic amino acids, Leu 29 to Leu 38, form a ridge 
along  one  side  of  the  RAID1  helical  structure.  In  addition,  the  Arg34  residue  in  the 
charged amino acid segment of RAID1 was found to be essential in binding to RACK1, 
with  mutations  of  this  residue  preventing  binding  between  the  proteins  (Bolger  et 
al.,2006). As with Gβ in its interaction with Gγ, it is blades 5, 6 and 7 of RACK1 that 
interact  with  PDE4D5,  forming  a  trough  that  the  N-terminal  of  PDE4D5  fits  into 
(McCahill et al., 2002). In fact, only the presence of these blades is required for binding to 
occur,  with  truncated  RACK1  proteins  still  binding  when  these  three  propellers  were 
present (McCahill et al., 2002). Comparisons with other proteins which interact with these 
blades of RACK1, such as β-integrin, show little homology between the binding proteins, 
indicating that PDE4D5 binds to an area within these blades distinct from that which β-
integrin binds to (Steele et al., 2001). 
 
PDE4D5 binds readily to both RACK1 and β-arrestin (Bolger et al., 2003). However, it 
appears binding to both proteins cannot occur at the same time, due to overlapping binding 
sites within the PDE4D5 N-terminal. This suggests that these proteins compete to bind to 
PDE4D5, with studies in HEK293 cells showing that binding to RACK1 is double that of 
β-arrestin, suggesting a preference of PDE4D5 towards RACK1 (Bolger et al., 2006). As 45 
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Figure 1.10 Modelling of the theorised RACK1/PDE4D5 interaction based on the 
Gβ/Gγ subunit interaction - The Gβ protein has a seven bladed beta propeller structure 
similar to that of RACK1. It interacts with the helical protein Gγ through formation of a 
cleft created by blades 5, 6 and 7 (a). It is likely that RACK1/PDE4D5 interact in a similar 
manner (b) via the RACK1 interaction domain (RAID) on PDE4D5 (McCahill et al., 
2002). 46 
 
Figure 1.11 
 
 
 
Figure 1.11 The PDE4D5 RACK1 interacting domain - The RACK1 interaction domain 
(RAID1) is located at the N-terminal region of the PDE4D5 protein. Comprising an 88 
amino acid region, the hydrophobic segment between Leu29 and Leu38 forms a ridge, 
while Arg34, located within the charged region of the domain, is essential in RACK1 
binding. The 16 and 38-mer peptides indicated with horizontal arrows are those tested for 
binding to RACK1, leading to the identification of the RAID1 domain (Bolger et al., 
2002). 47 
 
both  RACK1  and  β-arrestin  also  bind  to  sites  within  the  catalytic  region,  the  proteins 
appear to span across PDE4D5, thus physically blocking the other protein from interacting 
with PDE4D5 (Bolger et al., 2006). That PDE4D5 is only able to exclusively bind one 
protein at a time, but RACK1 may possibly have the ability to bind to other proteins at the 
same time is both interesting and also raises questions as to whether this has an effect on 
the action and purpose of the binding complex, and whether additional proteins may bind 
to RACK1 and influence the function of the complex. PDE4D5 was first identified as a 
RACK1 interacting protein in a yeast two-hybrid screen, and the interaction between the 
two proteins was found to be highly specific (Yarwood et al., 1999). PDE4D5 was not 
found to bind other WD40 repeat proteins, and RACK1 has not been found to interact with 
any other members of the PDE4 family. The interaction of these two proteins is therefore 
both specific and unique, suggesting an important functional role for the complex. While 
different proteins interact with different RACK1 WD40 repeats, repeats 5, 6 and 7 are 
essential in the interaction between PDE4D5 and RACK1, although it is not these repeats 
alone that are necessary for binding,. This was demonstrated by Steele et al. (2001), where 
a RACK1 construct composed of these three repeats was found to be 25% less effective at 
binding PDE4D5 than wild type RACK1, suggesting the propeller structure of RACK1 is 
needed for optimal binding. While PDE4D5 has been shown to bind to RACK1, the effects 
of this anchoring on cellular functions has yet to be determined, although this interaction 
has been shown to increase sensitivity to the inhibitor rolipram. PDE4D5 recruitment by 
RACK1 may also result in modulation of local cyclic AMP levels, thus regulating localised 
effector molecules that have also been recruited to the specific location.  
 
RACK1  is  thought  to  have  numerous  roles  in  cellular  physiology  and,  by  extension, 
several diseases. One such disease is cancer, where concentrations have been found to be 
four times higher in non-small cell lung carcinoma than in normal human lung tissue, and 
almost  twenty  times  higher  in  colon  cancer.  Its  presence  in  the  maturation  of  D. 
melanogaster zygotes (McCahill et al., 2002) suggests an involvement in the growth factor 
and  cell  proliferation  aspects  of  the  regulation  of  cell  development,  as  well  as  cell 
adhesion, where RACK1 is believed to act as a scaffold protein for proteins involved in 
adhesion complexes, such as β integrins (Liliental and Chang, 1998). Over expression of 
RACK1 has been found to increase spreading and actin stress fibres in cells, thus reducing 
their growth rate in anchorage-dependent and -independent conditions. This indicates an 
involvement of RACK1 in both cell growth and movement. Within the cell, as well as 
forming protein-protein interactions, RACK1 has been suggested to be involved in cell 48 
 
migration and cell-cell interactions, prolongation of the G0/G1 phase of the cell cycle, 
inhibition of c-Src kinase activity and NIH3T3 cell growth, as well has having a function 
in  both  growth  factor  dependent  and  apoptotic  intracellular  signalling  pathways 
(Mamidipudi et al.,2004). In addition to this, PKCβII shuttling of RACK1 may increase or 
decrease  phosphorylation  of  neighbouring  substrates  to  activate  proliferation  or  growth 
arrest respectively (Berns et al., 2000). 
 
RACK1 has also been found to be highly upregulated in angiogenesis (Berns et al., 2000) 
and has also been linked to cystic fibrosis through the discovery of its role in epithelial 
chloride  channel  function,  where  it  binds  to  the  Na
+/H
+  exchange  regulatory  factor 
(NHERF1), a binding partner of the cystic fibrosis transmembrane regulator (CFTR). PKC 
regulates cyclic AMP-dependent CFTR chloride function by binding to RACK1 which in 
turn binds NHERF1. RACK1 potentially acts as a scaffold protein, holding the enzyme in 
the locale of CFTR (Liedtke et al., 2002). Evidence also suggests a role for RACK1 in the 
immune response, particularly in the generation of phagocyte produced superoxide anions. 
A  ligand-initiated  activation,  superoxide  anions  are  released  by  the  immune  system  to 
destroy  invading  pathogens  and  it  is  likely  that  RACK1  acts  through  sequestration  of 
PKCβII in order to negatively regulate generation of the anions. It is interesting to note that 
PDE4 inhibitors are able to interfere with the inflammatory functions of neutrophils, where 
PDE4  inhibition  leads  to  blockage  of  oxygen  radical  release  from  ligand  stimulated 
neutrophils, possibly indicating a potential complimentary mechanism between RACK1 
and PDE4 in immune responses (McCahill et al., 2002). 
 
 
1.4 Protein Kinase C Signalling 
 
The  PKC  family  of  Serine/Threonine  kinases  comprises  around  10  isoforms  and  is 
involved  in  a  number  of  signalling  pathways  by  altering  protein  function  by 
phosphorylation.  The  isoforms  can  be  divided  into  three  categories  based  on  their 
activation requirements- conventional, novel and atypical. Conventional PKC isoforms (α, 
βI, βII and γ) and novel isoforms (δ, ε, η and θ) both require DAG for activation, with 
conventional PKCs also requiring calcium. Atypical (ζ and λ/ι) require neither of these 
second messengers to be activated (Parker and Murray-Rust, 2004). This variety of PKC 
isoforms  is  an  integral  part  of  PKC  signalling,  with  each  isoform  expressing  differing 
characteristics,  activity  and  tissue  distribution,  resulting  in  a  wide  range  of  effectors 49 
 
downstream of PKC. Various isoforms have been linked to a number of cell functions, 
including  cell  proliferation  and  differentiation,  cell  adhesion  and  migration,  barrier 
function  and  apoptosis.  A  vast  number  of  PKC  targets  have  currently  been  identified, 
ranging  from  growth  factor  receptors  and  ion  channel  regulators,  to  calcium  and 
calmodulin  binding  proteins,  cytoskeletal  components  and  transcriptional  factors.  This 
range of biological functions means that disruption of PKC regulation can be linked to a 
number of disease states (Mackay and Twelves, 2007). 
 
1.4.1 PKC isoforms 
Activation of conventional and novel PKCs occurs when a GPCR, activated by external 
stimuli,  activates  a  G  protein  which  in  turn  activates  PLC.  PLC  hydrolyses  PIP2  into 
diacylglycerol (DAG) which stays at the plasma membrane where hydrolysis occurs, and 
inositol 1,4,5-triphosphate (IP3) which is freed into the cytoplasm. At sufficiently high 
levels, DAG activates novel PKCs, while conventional PKCs also require the interaction of 
IP3 and calcium channels located on the endoplasmic reticulum to release calcium stores 
into the cytosol, before they can become activated. Upon stimulation, PKC translocates to 
the plasma membrane, where this activation occurs. When inactive, the pseudosubstrate 
domain at the N-terminal of the PKC is bound to the catalytic domain. This holds the PKC 
in  a  folded  conformation,  effectively  blocking  the  catalytic  site  from  interaction  with 
substrates. Activation upon translocation by the binding of C1 to DAG or phorbol esters, 
and/or binding of C2 to calcium or phosphatidylserine, causes a conformational change. 
This  facilitates  the  disassociation  of  the  pseudosubstrate  from  the  catalytic  domain, 
unfolding the protein and allowing PKC to act on its substrates.  
 
1.4.2 PKC structure 
Structurally,  all  PKC  isoforms  possess  a  conserved  catalytic  domain  comprising  
ATP/substrate binding and catalysis motifs and a regulatory domain at the N-terminal, 
joined by a hinge region (Figure 1.12). The catalytic domain, a ~45kDa region at the C-
terminal of the protein, is responsible for ATP binding and substrate docking, sometimes 
termed as C3 and C4 domains respectively (Amadio et al., 2006). PKC isoforms contain 
three  conserved  sites  in  the  catalytic  domain  where  phosphorylation  is required  before 
catalytic  activity  is  obtained    (Cameron  et  al.,  2007).  These  sites  are  located  in  the 
activation loop, the turn motif, and the hydrophobic motif, although atypical PKCs lack the  50 
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Figure  1.12  Structural  representation  of  Protein  Kinase  C  isotype  structure  and 
classification - All PKC isoforms contain a conserved catalytic domain that contains an 
ATP  binding  site  (A)  and  a  turn  motif  (T)  and  in  conventional  and  novel  isoforms,  a 
hydrophobic motif (H) at the C-terminal of the catalytic domain. This region is attached to 
the regulatory region by a hinge. The regulatory domain is comprised of two membrane 
targeting modules, C1 and C2. The C2 domain is involved in calcium binding and is absent 
from atypical PKC structure, and unable to bind calcium in novel PKCs. All three groups 
of PKC isoforms contain the C1 domain of which two repeats, C1A and C1B, are resent in 
conventional and novel PKCs where it acts as a DAG/phorbol ester binding site, while 
atypical  PKCs  possess  a  single  repeat.  All  isoforms  contain  a  psuedosubstrate  domain 
upstream  of  the  N-terminal  of  the  C1  domain,  which  holds  the  isoform  in  a  folded 
conformation until activation through binding to the C-terminal of the PKC protein.  51 
 
latter  (Corbalan-Garcia  and  Gomez-Fernandez,  2006).  This  phosphorylation  rearranges 
PKC into a more stable conformation (Newton, 2003).  
 
The regulatory domain comprises two membrane targeting modules, C1 and C2, acting as 
a DAG and phorbol ester binding site, and a calcium sensor respectively. The C1 domain is 
an 8 kDa cysteine rich  motif (Corbalan-Garcia  and Gomez-Fernandez,  2006) of which 
there are two repeats in conventional and novel PKCs, termed C1A and C1B, and just one 
in atypical PKCs. Each repeat forms a zinc finger-like motif (Brose and Rosenmund, 2002) 
that forms a single ligand binding site between two β sheets (Newton, 2003). In atypical 
PKCs this DAG binding site is disrupted, although the single C1 domain found in these 
isoforms  still  allows  ceramide  and  PIP3  binding,  and  other  protein-protein  interactions 
through a Phox and Bern 1 (PB1) domain in this catalytic region, involved in mediation of 
interaction with scaffolding proteins that also contain PB1 domains (Mellor and Parker, 
1998).  It is this protein-protein interaction that regulates atypical PKCs, in addition to 
phosphorylation by phosphoinositide-dependent kinase 1 (PDK1) (Scott, 2003). All PKC 
isoforms  possess  an  autoinhibitory  pseudosubstrate  that  rests  just  upstream  of  the  C1 
domain, which is involved in holding the PKC in a folded conformation until activation by 
binding to the C-terminal region of the protein (Corbalan-Garcia and Gomez-Fernandez, 
2006).  This  pseudosubstrate  domain  shares  similarity  with  PKC  phosphorylation  sites, 
with the exception of an alanine residue present at the serine/threonine phosphorylation site 
(Mellor and Parker, 1998).   
 
The  C2  domain,  present  in  conventional  and  novel  PKCs  but  absent  from  atypical 
isoforms, is a 12 kDa region (Newton, 2003) that, in conventional PKCs, acts as a calcium 
activated membrane targeting motif (Corbalan-Garcia and Gomez-Fernandez, 2006). This 
domain consists of a β sandwich fold containing three distinct binding sites for calcium, 
termed  Ca1-3.  Calcium  binding  causes  a  conformational  change,  forming  a  cleft  for 
binding of the acidic head of membrane phospholipids, such as phosphatidylserine, which 
targets and anchors PKC to the plasma membrane (Brose and Rosenmund 2002). Novel 
PKCs lack the crucial calcium binding residues so are unable to utilise this mechanism 
(Newton, 2003), but the C2 domain in these isoforms still serves an important function of 
mediating protein-protein interactions such as acting as a phosphotyrosine binding domain 
in PKCδ (Benes et al., 2005). 
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1.4.3 Compartmentalisation of PKC signalling 
Compartmentalisation  of  PKC  isoforms,  as  in  other  signalling  pathways,  is  a  useful 
mechanism to ensure specificity of the signalling response. Many of the PKC isoforms 
have  their  own  distinct  subcellular  locations,  with  a  study  in  NIH3T3  cells  showing 
isoforms to translocate upon activation to specific and diverse locations within the cell. 
PKCs α, βI, βII and η were observed to translocate to cytoskeletal areas, while PKCα also 
translocated to ER. PKCε also, along with γ and δ, translocated to the Golgi apparatus 
(Goodnight et al., 1995) and this spatial distribution of isoforms is often obtained through 
the use of scaffold proteins. Some scaffold proteins such as RACK1 bind activated PKC. 
RACK1,  as  described  above,  is  involved  in  controlling  the  PKC  signal  specificity  by 
translocating and anchoring activated PKC to specific subcellular locations (Schechtman 
and Mochly-Rosen, 2001). The range of scaffold proteins shown to interact with PKC 
range  from  those  which  are  specific  to  one  isoform,  such  as  the  PKCα  scaffold 
plakophilin2 (Bass-Zubek et al., 2008) and some binding to many, like AKAPs. AKAPs 
are well documented as facilitating compartmentalisation of PKC and have been shown, in 
some cases, to also bind PKC. Two examples of this are AKAP12, also known as Gravin, 
which  targets  both  PKC  and  PKA  to  the  cytoskeleton  (Nauert  et  al.,  1997)  and  is 
particularly shown to bind PKCα and PKC βII (Piontek and Brandt, 2003), and AKAP79, 
which forms a complex with PKA, PKC and the protein phosphatase 2B (Perkins, Wang et 
al. 2001). AKAP79 has been shown to bind a number of the PKC isoforms, including α, 
βII, δ, ε and ζ (Faux et al., 1999).  
 
PKCδ has been shown to be involved in differentiation and cell growth, and has been 
linked to apoptosis and tumour development (Gschwendt, 1999). PKCγ, found in high 
concentrations in the brain, has been indicated as important in learning and memory, while 
PKCε is believed to be involved in GABAA receptor function (Brose and Rosenmund, 
2002). PKC θ and ζ have been linked to T cell and B cell receptor signalling respectively, 
and PKCβ has been indicated in some immunodeficiency disorders and in lung, gastric and 
breast  cancers,  as  has  PKCα  (Mackay  and  Twelves,  2007).  PKCα  differs  from  other 
isotypes as it is found in all tissue types. Additionally, PKCα requires phosphorylation at 3 
residues located within its kinase domain before activation can occur (Nakashima, 2002). 
Like other isoforms, PKCα is involved in a multitude of biological processes including 
proliferation, cell migration and adhesion, and cell differentiation and has also been linked 
to haemopoeisis and apoptosis through its ability to phosphorylate Bcl-2 (Ruvolo et al., 
1998).  Additionally  PKCα  has  been  indicated  to  play  a  crucial  role  in  several  disease 53 
 
states, including cardiac hypertrophy, cancer, and immune diseases. Within cells, PKCα 
has been linked to several key functions including the alteration of tight junctions which 
act  as  barriers  between  cells  to  protect  the  cells  internal  balance.  An  increased 
concentration of PKCα activity alters the ability of the cells to form these tight junctions 
properly, allowing foreign molecules into the cell, which has been linked to some cancers. 
Supporting this evidence is that several endothelial cancers have been shown to exhibit 
higher than normal levels of PKCα activity (Rosson et al., 1997). PKCα has also been 
linked to hypertrophy in myocardial tissue (Dorn and Force, 2005) and increased levels of 
PKCα have been shown to interfere with contractility. Additionally PKCα is thought to be 
involved in regulation of erythrocyte development, aiding the differentiation of erythroid 
progenitor cells (Myklebust et al., 2000). Several of the isoforms have been shown to have 
an effect on cell function, such as cell division and migration, through the ERK cascade. 
PKC phosphorylates, or mediates the phosphorylation of Raf, a mitogen activated protein 
kinase kinase kinase (MAP3K), an upstream component of the ERK1/2 signalling cascade 
(Carroll and May, 1994).  
 
1.4.4 Interaction between RACK1 and PKC 
The expression of RACK1 throughout a variety of tissues indicates an important functional 
role (McCahill et al., 2002). In addition because of its importance in PKC signalling, it is 
likely  that  RACK1  plays  a  crucial  role  in  areas  where  PKC  has  a  vital  function. 
Investigations into the presence of RACK1 in rat brains has found a reduction in levels by 
almost  half  in  aged  rats,  compared  to  their  younger  counterparts  as  well  as  PKCβ 
translocation loss (Pascale et al., 1996). PKC isozymes are believed to have an important 
role in learning and memory function due to their high levels in the brain. PKC is also 
involved in other brain functions such as synaptic efficiency and neurotransmitter release 
(Matthies et al., 1987). In some diseases of the brain, such as Alzheimer’s disease, PKC 
activity and translocation is attenuated. Interestingly, PKCβII levels remain unchanged in 
both  cytosolic  and  membrane  fractions,  while  RACK1  levels  are  decreased  in  both 
fractions, indicating a cause for the impaired PKC signalling pathway (McCahill et al., 
2002). Another potential role for RACK1 in the brain is in drug dependence mechanisms. 
For example, ethanol interferes with PKC action on a number of neurotransmitters such as 
glycine, glutamate and GABA (McCahill et al., 2002). As ethanol is able to translocate 
RACK1 to the nucleus, it is possible that this is associated with the altered action of PKC. 
Brain levels of RACK1 have also been shown to be modulated in morphine treated rats 54 
 
alongside PKCα and β levels, where the drug is able to control expression levels of PKC 
isozymes. 
 
 
1.5 Mitogen Activated Kinase Signalling 
 
A common mechanism of signal transduction involves the sequential activation of protein 
kinases in a cascade. One such cascade is the Mitogen Activated Protein Kinase (MAPK) 
cascade  (Figure  1.13).  MAPKs  were  first  identified  as  being  activated  in  response  to 
growth factor stimulation of the cell, giving the kinase its name (Seger and Krebs, 1995). 
MAPK cascades are initiated by either a small GTP-binding protein, such as a Ras family 
protein, or via an adaptor protein (Rubinfeld and Seger, 2005). There  are four MAPK 
cascades, each distinct and named for the subgroup which their MAPK components fall 
into. These are the p38 MAPK cascade and the c-Jun N-terminal kinase (JNK) cascade, 
both involved in the stress response and apoptosis; the big mitogen activated protein kinase 
(BMK)  cascade  involved  in  mitogenic  and  stress  signals;  and  the  ERK  1/2  cascade, 
involved in cell proliferation and differentiation (Shaul and Seger, 2007).  
 
1.5.1 The extracellular regulated kinase (ERK) cascade 
The first MAPK cascade identified and greatly studied is the ERK1/2 cascade (Seger and 
Krebs, 1995), which comprises between three and six levels of protein kinases activated 
sequentially to form the cascade (Figure 1.14). Activation of the ERK cascade can occur 
through  the  action  of  extracellular  stimuli,  including  neurotransmitters,  hormones  and 
growth factors acting via several mechanisms such as GPCRs, ion channels and tyrosine 
kinase receptors (Rubinfeld and Seger, 2005). Adaptor proteins such as Crk and GRB2 
(Growth Factor Receptor Bound Protein 2) link the receptor to a GEF, transducing the 
signal to small GTP-binding proteins such as Ras and Rap1 which in turn activate the main 
cascade (Shaul and Seger, 2007). This protein then transmits the signal to the next level of 
the cascade, known as MAP3K, which includes the Raf family of Raf-1, B-Raf and A-Raf. 
Raf is then able to activate the MAPKKs, MEK1 and 2 via serine phosphorylation at two 
residues,  Ser218  and  Ser222  at  the  activation  loop  (Alessi  et  al.,  1994).  Although 
phosphorylation of one residue allows activation, this is only partial and phosphorylation 
of  both  residues  is  required  for  full  activation  (Seger  et  al.,  1994).  MEKs  can 
phosphorylate both Tyr and Thr residues on ERK, a unique ability that classes them as dual  55 
 
Figure 1.13 
 
 
 
Figure 1.13 The MAPK cascade - All four MAPK pathways follow a similar cascade- 
MAPK kinase kinase (MAPKKK) is activated by a stimulus to activate a MAPK kinase 
(MAPKK) which in turn activates the MAPK for which the cascade is named. This MAPK 
can then act on specific substrates to illicit a biological response.  
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Figure 1.14 
 
 
 
Figure 1.14 The ERK cascade - The ERK cascade is initiated by growth factors and 
mitogens  activating  receptor  tyrosine  kinases  (RTKs)  or  G-protein  coupled  receptors 
(GPCRs) to activate Raf isoforms. Raf activates MEK1/2 which activates ERK1/2. ERK is 
then able to interact with cytoplasmic substrates, or to translocate to the nucleus to interact 
with substrates there and initiate transcription.  57 
 
  
specificity  protein  kinases.  Activation  of  ERK  occurs  when  MEKs  phosphorylate  first 
Tyr185, followed by Thr183 (Rubinfeld and Seger, 2005).  
 
There are 3 MEKs- MEK1, a 45 kDa protein, MEK2 (46 kDa) and MEK1b (43 kDa), an 
inactive,  alternately  spliced  variant  of  MEK1  with  unknown  physiological  roles  and 
lacking  the  ability  to  activate  ERK  or  undergo  autophosphorylation.  MEKs  contain  a 
regulatory N-terminal domain surrounding a catalytic kinase domain, followed by a short 
C-terminal  domain  (Shaul  and  Seger,  2007).  As  well  as  activating  ERK,  they  act  as 
cytoplasmic anchors, holding ERKs at specific locations within the cell (Rubinfeld et al., 
1999).  Downregulation  of  MEKs  mainly  occurs  by  dephosphorylation  at  Ser218  and 
Ser222 by PP2A, a phosphoserine/threonine phosphatase (Sontag et al., 1993).  
 
MEKs  are  highly  selective  for  ERKs,  which  they  activate  by  phosphorylation  at  the 
residues Tyr185 and Thr183 at the activation loop. ERK1/2 are serine/threonine kinases of 
the MAPK group of proteins, which possess the ability to phosphorylate a wide range of 
proteins,  the  majority  of  which  are  regulatory  proteins.  There  are  two  genes  encoding 
ERKs, ERK1 which gives a 44 kDa protein, and ERK2, a 42 kDA protein, as well as 
alternative spliced variants, all of which share the Thr-X-Tyr motif at the activation site 
(Boulton et al., 1991). ERK1/2 are proline-directed protein kinases, phosphorylating serine 
or threonine residues that are adjacent to proline resides. ERKs possess a catalytic domain 
surrounded by regulatory regions containing the activation motif, and a C-terminal area 
important in interaction with MEK (Rubinfeld et al., 1999) and also with other proteins, 
termed the common docking (CD) domain. (Tanoue et al., 2000). ERKs are inactivated by 
dephosphorylation  at  either  one  or  both  of  the  Thr/Tyr  residues,  mediated  by  MAPK 
phosphatases, Ser/Thr phosphatases such as PP2A, or protein-Tyrosine phosphatases such 
as PTP-S2 (Shaul and Seger, 2007). While the components of the ERK cascade are located 
within  the  cytosol,  activation  by  external  stimuli  causes  translocation  of  Raf-1  to  the 
membrane (Leevers et al., 1994), and of MEKs and ERKs to the nucleus (Jaaro et al., 
1997) where they accumulate for extensive periods, remaining even when inactive. This 
suggests the nucleus as a potential site of ERK signal termination (Volmat et al., 2001). 
 
Hundreds of substrates for ERK have been identified, and as well as targeting a number of 
kinases  which  are  further  involved  in  signal  transduction  to  target  proteins,  such  as 
Ribosomal  S6  Kinases  (RSKs),  Mitogen-  and  stress-activated  kinases  (MSKs),  and 58 
 
MAPK-interacting kinases (MPKs), ERK also activates the cytoskeletal proteins paxillin 
and synapsin1; cytosolic phospholipase A2 which is involved in regulation of arachidonic 
acid release; and transcription factors such as ELK1, c-Fos and p53. ERKs have also been 
shown to act on MAPK cascade proteins upstream of itself, including MEKs, Raf-1 and 
growth  factor  receptors,  creating  a  feedback  mechanism  to  control  its  own  activity 
(Dougherty et al., 2005).  
 
1.5.2 Functions of the ERK cascade 
Due to the large number of proteins identified as being phosphorylated by ERK, ERK has 
been linked to a number of physiological roles and disease states. The most extensively 
studied role of ERK is its involvement in cell proliferation and, by extension, its role in 
tumour development. ERKs are rapidly activated by mitogenic signals, the transduction of 
which  lead  to  proliferation  at  an  accelerated  level.  If  unchecked,  this  accelerated 
proliferation can lead to oncogenesis (Hoshino et al., 1999) and a number of oncogenes 
have been shown to encode proteins which are involved in signalling via the ERK cascade 
(Zhang  and  Lodish,  2004).  Additionally,  a  specific  MEK  inhibitor  has  been  shown  to 
inhibit  mouse  tumour  growth  (Sebolt-Leopold  et  al.,  1999).    Elevated  levels  of  ERK 
activation have been observed in a number of cell lines derived from a wide range of 
organs (Rubinfeld and Seger, 2005). ERKs located in the brain have also been implicated 
in learning and memory function (Berman et al., 1998), and activation of ERK has been 
shown to be required for cell cycle switch from G1 to S phases in a number of cells, 
allowing DNA replication (Pages et al., 1993). ERK has also been implicated in monocyte 
differentiation (Kharbanda et al., 1994) and T cell maturation (Alberola-Ila et al., 1995), as 
well as having anti-apoptotic ability wherein reduction in ERK activation is required for 
the apoptotic response. Upstream of ERK itself, Raf-1 has been shown to prevent apoptosis 
through phosphorylation of Bad, which prevents its interaction with Bcl-2 (Blagosklonny 
et al., 1997).  
 
As with other signalling pathways, specificity of ERK cascade effects is important, as is 
determined through a number of factors. These include control of the length and intensity 
of the signal, localisation within the cell and the use of scaffold proteins, and crosstalk with 
other signalling pathways. Duration and strength of the ERK cascade signal is a useful 
mechanism of controlling specificity as transient and prolonged ERK activation causes 59 
 
varying cellular effects, through regulation by phosphatases or feedback loops leading to 
downregulation of upstream components (Marshall, 1995).  
 
1.5.3 Compartmentalisation of ERK signalling 
Compartmentalisation of the ERK cascade to specific subcellular locations also allows for 
control  of  specificity  of  the  cascade  effects  (Harding  et  al.,  2005),  with  cytoplasmic 
distribution of ERK controlled by a variety of scaffold proteins (Chuderland and Seger, 
2005). ERK is released from these proteins upon extracellular stimulation and can then 
translocate  to  the  nucleus  via  a  mechanism  still  largely  unknown,  although 
homodimerisation of ERKs (Khokhlatchev et al., 1998) and interaction with nuclear pore 
proteins  (Matsubayashi  et  al.,  2001)  have  been  proposed  as  possible  mechanisms  of 
translocation. Scaffold proteins are utilised to bring ERK cascade components to specific 
subcellular locations and into the vicinity of other components and effectors. There are a 
number  of  scaffolds  shown  to  be  involved  in  the  ERK  cascade,  each  having  distinct 
localisations  and  effects  on  the  cascade.  Some  serve  as  spatial  regulators  of  the  ERK 
cascade.  An  example  of  this  is  Sef,  a  transmembrane  protein  located  on  the  Golgi 
apparatus which is involved of activated MEKs, which allows ERK phosphorylation. This 
interaction  prevents  ERK  translocating  to  the  nucleus,  allowing  ERK  to  phosphorylate 
proteins in the cytosol (Torii et al., 2004). MEK Partner 1 (MP1) acts in a similar way, 
localising to endosomes where it specifically promotes activation of ERK1, and shows no 
interaction with ERK2 or MEK2 (Teis et al., 2002), while paxillin is involved in ERK 
activation at focal adhesion sites, binding inactivate ERK, MEK and active Raf. Activated 
ERK phosphorylates paxillin, allowing binding of focal adhesion kinases, resulting in focal 
adhesion  complex  formation  and  epithelial  morphogenesis  (Ishibe  et  al.,  2004).  Other 
scaffolds, such as the multi-domain protein KSR (Kinase Suppressor of Ras), are involved 
in facilitating the activation of ERK at the plasma membrane, where it acts as a scaffold for 
ERK, MEK and Raf (McKay and Morrison, 2007). 
 
1.5.4 Crosstalk between the ERK and cyclic AMP signalling pathways 
Crosstalk with other pathways is also an important method of specificity and control of the 
ERK  cascade.  ERK  has  been  shown  to  exhibit  crosstalk  with  several  other  pathways, 
perhaps  most  importantly  the  cyclic  AMP  signalling  pathway  (Figure  1.15).  The 
mechanisms  by  which  crosstalk  occurs  between  the  cyclic  AMP  and  ERK  signalling 
pathways is both complex and controversial. In 1993, three studies were published  60 
 
Figure 1.15 
 
 
 
Figure 1.15 Crosstalk between the cyclic AMP and ERK pathways - The cyclic AMP 
and ERK pathways have been shown to have cell specific points of crosstalk. Cyclic AMP 
has been shown to activate ERK via Rap1 action on B-Raf either via PKA or in a PKA-
independent manner through EPAC. PKA has also been shown to inhibit ERK activation in 
response to elevated cyclic AMP levels by inhibition of Raf-1 action. ERK itself is able to 
act on cyclic AMP specific phosphodiesterases, activating short forms isoforms to increase 
cyclic  AMP  levels,  or  inhibiting  long  and  super-short  forms  to  reduce  cyclic  AMP 
concentrations, forming a feedback loop.                                                                   61 
 
identifying the ability of cyclic AMP to block ERK activation stimulated by growth factors 
in Rat1 (Wu et al., 1993; Cook and McCormick, 1993) and NIH3T3 fibroblasts (Burgering 
et al., 1993). Since then, investigations in other cell types have shown several instances of 
crosstalk between the pathways. 
There  are  a  number  of  distinct  points  of  crosstalk  between  the  cyclic  AMP  and  ERK 
signalling  pathways.  The  most  closely  examined  of  these  is  the  Raf  family  of  protein 
kinases, which in an isoform specific manner is able to effect ERK activation in both a 
positive  and  negative  manner  in  response  to  cyclic  AMP  (Houslay  and  Baillie,  2003). 
Three genes encode for the isoforms A-Raf, B-Raf and C-Raf, also known as Raf-1. All 
three share a common structure and all activate MEK. Rafs are activated at the plasma 
membrane  with  phosphorylation  of  different  sites  for  each  isoform  a  requirement  of 
activation (Dumaz and Marais, 2005). Raf1 has been shown, in several cell types including 
vascular muscle cells and fibroblasts, to be involved in blocking ERK activation (Stork and 
Schmitt, 2002). Phosphorylation of Raf1 at residue Ser259 by either PKA or Akt/PKB 
blocks activation of Raf1 by Ras, effectively blocking the ERK cascade. PKA has also 
been suggested to phosphorylate Raf1 at Ser621 to inhibit its action and block the cascade 
(Houslay and Kolch, 2000). Another model of cyclic AMP influence on ERK via Raf1 is 
theorised in Dumaz and Marais (2005) wherein the binding of the regulatory protein 14-3-
3  to  phosphorylated  sides  on  Raf1  holds  the  Raf  isoform  in  a  closed  and  inactive 
conformation.  Ras  activation  would  then  cause  translocation  of  Raf1  to  the  plasma 
membrane, displacing 14-3-3 and allowing activation of Raf1. However, in the presence of 
high cyclic AMP levels, PKA phosphorylation of Raf1 would create an additional binding 
site for 14-3-3, where Ras activation couldn’t cause its dissociation, thus inhibiting both 
Raf1 activation and translocation to the plasma membrane (Dumaz and Marais, 2005). 
 
Another Raf isoform, B-Raf, has also been linked to the involvement of cyclic AMP in 
ERK signalling, causing activation of ERK in PC12 and other neuronal cells through the 
small GTPase Rap1 (Houslay and Kolch, 2000). B-Raf is found in abundance in the brain, 
and in a range of other cells from endothelial to endocrine, as well as in various organs 
(Stork and Schmitt, 2002). There is much debate as to the mechanism by which activation 
of  B-Raf  leads  to  ERK  activation  and  whether  this  occurs  in  a  PKA  dependent  or 
independent manner via EPAC, which is well documented as a GEF for Rap1 (Houslay 
and Kolch, 2000). The Src family of kinases and PP1 have also been suggested to be 
involved in this mechanism (Dumaz and Marais, 2005). While PKA has been shown to 
phosphorylate B-Raf in PC12 cells, experiments in FRTL-5 cells showed EPAC to mediate 62 
 
Rap1 activation of B-Raf in response to elevated cyclic AMP levels (Dumaz and Marais, 
2005).  
The outcome and mechanisms of crosstalk between ERK and cyclic AMP appears to be a 
cell type specific occurrence, as demonstrated by the ability of ERK to interact with PDE4 
isoforms. ERK has been shown to inactivate long form PDE4s by phosphorylation, thus 
causing an increase in cyclic AMP levels which in turn inhibits ERK activation, creating a 
negative feedback loop that allows ERK to suppress its own activation. Conversely, ERK 
has also been shown to activate short form PDE4s, promoted the breakdown and therefore 
reduction in cyclic AMP levels within the cell (Houslay and Kolch, 2000). The actions of 
ERK on controlling cyclic AMP levels therefore depends on the relative amounts of long 
and short form PDE4s within the cell, showing that self control of ERK signalling via 
cyclic AMP depends on the cell type and PDE4 distribution.  Indeed, even within the same 
cell,  the  effects  of  cyclic  AMP  on  ERK  activation  can  differ  depending  on  culture 
conditions, as demonstrated in PC12 cells. In response to nerve growth factor (NGF) PC12 
cells display  cyclic AMP activation of Rap1 through EPAC, which causes a sustained 
activation of B-Raf and ERK by Rap1. However, in response to epidermal growth factor 
(EGF) a transient ERK activation by cyclic AMP via activation of Raf-1 mediated by Ras 
can  be  seen  in  PC12  cells  (as  reviewed  in  Dumaz  and  Marais,  2005).  These  different 
results suggest that the control exhibited by cyclic AMP over the ERK cascade, and vice 
versa, is clearly cell type specific.  
 
 
1.6 Thesis aims 
 
The aim of this research is to identify novel mechanisms of crosstalk between the cyclic 
AMP and PKC signalling pathways. In Chapter 3, we elucidate on the RACK1/PDE4D5 
complex and its role as a point of crosstalk between the cyclic AMP and PKC pathways by 
testing  the  hypothesis  that  binding  to  RACK1  affects  PDE4D5  targeting,  activity  and 
regulation by PKC. In Chapter 4 the role of both cyclic AMP and PKC in the control of 
cytokine activity by the SOCS-3 protein is outlined, investigating the hypothesis that PKC 
isoforms are involved in the induction of SOCS-3 by cyclic AMP via EPAC. Finally, in 
Chapter 5, the theory that cyclic AMP via EPAC influences PKC autophosphorylation in 
COS1 cells is investigated.  63 
 
 
 
 
CHAPTER 2 
 
 
 
Materials and Methods 64 
 
2.1 Materials 
2.1.1 General reagents 
All reagents were ordered from Fisher Scientific UK Ltd, Loughborough, Leicestershire, 
UK or Sigma-Aldrich Company Ltd, Gillingham, Dorset, UK unless stated below.  
Reagents  Supplier 
Syringes  BD Biosciences, Oxford, UK 
26½  gauge needles  BD Biosciences, Oxford, UK 
Thinwall Ultra-Clear™ 5 ml tubes, 13 x 51 
mm 
Beckman Coulter (UK) Ltd, High 
Wycombe, Buckinghamshire, UK 
Protease inhibitor cocktail  Boehringer Ingelheim Ltd., Bracknell, 
Berkshire, UK 
Bio-Rad Bradford protein assay reagent  Bio-Rad Laboratories Ltd, Hemel 
Hempstead, Hertfordshire, UK 
All horseradish peroxidase (HRP)-
conjugated secondary antibodies 
GE Healthcare Life Sciences, Little 
Chalfont, Buckinghamshire, UK 
Enhanced Chemiluminescence (ECL)  GE Healthcare Life Sciences, Little 
Chalfont, Buckinghamshire, UK 
X-ray film  Kodak Ltd, Hemel Hempstead, 
Hertfordshire, UK 
Pre-stained broad range protein marker (6-
175 kDa) 
New England Biolabs (UK) Ltd, Hitchin 
Hertfordshire, UK 
Marvel low-fat milk powder  Premier Brands UK, Knighton, Adbaston, 
Staffordshire, UK 
Complete and complete EDTA-free protease 
inhibitor tablets 
Roche Diagnostics Ltd, Burgess Hill, UK 
 
30% acrylamide/bisacrylamide 
 
Severn Biotech Ltd, Kidderminster, 
Worcestershire, UK 
Protran
® nitrocellulose  Whatman plc, Maidstone, Kent, UK 
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2.1.2 Cell culture materials 
 
Reagents  Supplier 
BD Falcon
™ 10 cm plates, 6-well plates, 12-
well plates and 96-well plates 
BD Biosciences, Oxford, UK 
75 cm
2 flasks  Corning B.V. Life Sciences, 
Schiphol-Rijk, The Netherlands 
DOTAP (N-[1-(2,3-Dioleoyloxy)propyl]-
N,N,N-trimethylammonium methyl 
sulphate) Liposomal Transfection Reagent 
Roche Diagnostics Ltd, West Sussex, UK 
Dulbecco’s Modified Eagle Medium 
(DMEM) 
Invitrogen Ltd, Paisley, UK 
Foetal bovine serum (FBS, US origin)  Invitrogen Ltd, Paisley, UK 
Lipofectamine™ 2000  Invitrogen Ltd, Paisley, UK 
Newborn calf serum 
(NCS, New Zealand origin) 
Invitrogen Ltd, Paisley, UK 
Penicillin and streptomycin  Invitrogen Ltd, Paisley, UK 
Phosphate Buffered Saline (PBS)  Invitrogen Ltd, Paisley, UK 
0.25 % (w/v) Trypsin-EDTA  Invitrogen Ltd, Paisley, UK 
 66 
 
2.1.3 Chemical reagents 
 
Reagent  Properties  Working 
Concentration 
Supplier 
1, 2-
diaoctanoyl-sn-
glycerol 
DAG analogue and 
PKC activator 
10 M, 50 M, 
100 M 
Sigma-Aldrich 
8-pCPT- 2’0- 
Me-cyclic AMP 
Activator of EPAC  10 M  Biolog Life Science 
Institute 
8-pCPT-cyclic 
AMP 
Activator of EPAC 
and PKA 
10 M  Biolog Life Science 
Institute 
BAPTA-AM  Calcium chelator  10 M  Merck Biosciences 
Forskolin  Activator of Adenylyl 
Cyclase 
10 M  Merck Biosciences 
GF 109203X  PKC inhibitor, with 
specificity towards α 
and βI isoforms 
50 M  Merck Biosciences 
Isoproterenol  β-Adrenoreceptor 
agonist, with 
specificity towards β1 
and β2 
10 M  Merck Biosciences 
MG-132  Proteasome inhibitor  6 M  Merck Biosciences 
Phorbol 12-
myristate 13-
acetate 
PKC activator  10 M  Merck Biosciences 
Ro31-7549  PKC inhibitor, with 
specificity towards α, 
βI and βII, γ and ε. 
50 M  Merck Biosciences 
Rolipram  PDE4 inhibitor  10 M  Merck Biosciences 
U73122  PLC inhibitor  10 M, 50 M  Merck Biosciences 
U73343  Negative control for 
U73122 
10 M, 50 M  Merck Biosciences 67 
 
2.1.4 Antibodies 
Protein  Type  Dilution  Source  Supplier 
EPAC1  Polyclonal  1:1000  Rabbit  generously provided by 
Professor Johannes Bos, 
University of Utrecht, The 
Netherlands 
EPAC2  Polyclonal  1:1000  Goat  Santa Cruz 
p42/44 MAP 
Kinase (ERK) 
Polyclonal  1:1000  Rabbit  Cell Signaling Technology 
Phospho-
p42/44 MAP 
Kinase (ERK) 
Polyclonal  1:1000  Rabbit  Cell Signaling Technology 
GAPDH  Monoclonal  1:100000  Mouse  Ambion 
Anti-HA  Polyclonal  1:1000  Rabbit  Sigma-Aldrich 
PDZ-GEF1  Polyclonal  1:1000  Rabbit  Generously provided by 
Dr. Daniela Rotin, 
University of Toronto, Canada 
PKCα  Polyclonal  1:1000  Rabbit  Cell Signaling Technology 
Phospho-
PKCα/βII 
Polyclonal  1:1000  Rabbit  Cell Signaling Technology 
PKCδ  Polyclonal  1:1000  Rabbit  Cell Signaling Technology 
Phospho-
PKCδ/θ 
Polyclonal  1:1000  Rabbit  Cell Signaling Technology 
PLC ε  Polyclonal  1:1000  Rabbit  Upstate Cell Signaling 
solutions 
RACK1  Monoclonal  1:1000  Mouse  BD Transduction Laboratories 
SOCS-3  Polyclonal  1:1000  Goat  Santa Cruz Biotechnology Inc 
Anti Vesicular 
Stomatitis 
Viris (VSV) 
Polyclonal  1:1000  Rabbit  Sigma-Aldrich 
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2.1.5 siRNA 
 
2.1.6 General Buffers 
 
Laemmli Electrophoresis Sample Buffer 5x 
10% (w/v) SDS, 300mM Tris HCl, pH 6.8, 0.05% (w/v) bromophenol blue, 50% (v/v) 
glycerol, 10% (v/v) β-mercaptoethanol 
 
Lysis Buffer 
10mM  Tris  HCl,  pH  7.5,  0.1mM  EDTA,  containing  protease  inhibitor  cocktail 
(Boehringer) 
  
PBS 
137mM NaCl, 2.7mM KCl, 4.3mM Na2HPO4, 1.47mM KH2PO4, pH 7.4 
 
PDE Assay Buffer 
40mM Tris HCl, 5mM MgCl2, 3.75mM β-mercaptoethanol  
 
Running Buffer 5x for SDS-PAGE 
25mM Tris, 250mM glycine, 0.1% (w/v) SDS 
 
 
siRNA  Target Sequence  Supplier      Cat #         Product Name 
EPAC1  GCCCGGAACUUGCC
UGUUU 
Dharmacon  D-00 
7676-03 
siGenome siRNA 
Human RAPGEF3 
PLC ε  CAGGGTCTTGCCAGT
CGACTA 
Qiagen  SI 
00115521 
HP GenomeWide 
siRNA 
Hs_PLCE1_1 
PKCα  CGCAGTGGAATGAG
TCCTTTA 
Qiagen  SI 
00605927 
HP Validated siRNA 
Hs_PRKCA_6 
PKCd  AACTCTACCGTGCCA
CGTTTT 
Qiagen  SI 
00301329 
HP GenomeWide 
siRNA 
Hs_PRKCD_7 69 
 
TBS 
20mM Tris HCl, pH 7.6, 137mM NaCl 
 
TBST 
20mM Tris HCl, pH 7.6, 137mM NaCl, 1% (v/v) Tween 20 
 
Transfer Buffer for Western blotting 
25mM Tris, 192 mM glycine, 20% (v/v) methanol 
 
 
2.2 Methods 
 
2.2.1 Mammalian Cell Culture 
Cell culture techniques were performed using standard aseptic techniques. 
 
2.2.1.1 Maintenance of cell lines 
Established and confluent cells lines were resuspended in cell freezing medium (9ml cell 
growth medium, 1ml DMSO) in 1ml aliquots,  frozen at  -80°C and then transferred to 
liquid  nitrogen  storage.  Cells  were  stored  long  term  in  liquid  nitrogen,  ensuring  the 
integrity of the cell lines. Cells were revived by individual vials being quickly thawed and 
directly  added  to  10ml  of  pre-warmed  growth  medium.  Cells  were  sedimented  by 
centrifugation at 1000 x gmax for 5 minutes, the supernatant removed and the cell pellet 
resuspended in complete medium. 
 
2.2.1.2 COS1 cells 
The COS1 cell line is derived from African green monkey kidney cells, wherein the CV-1 
cell line was immortalized via transformation with the SV40 virus (Jensen et al., 1964). 
 
Cells were cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% (v/v) 
foetal bovine serum, 2mM L-glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin, 
at  37°C,  5%  (v/v)  CO2.   Cells  were  passaged  at  approximately  90%  confluence  by 
removing  growth  media  and  washing  cells  in  10ml  of  pre-warmed  sterile  phosphate 
buffered saline (PBS; Invitrogen). 2ml of trypsin-EDTA solution was added and the cells 70 
 
were incubated at 37°C for 5 minutes. Cells were examined microscopically to ensure 
efficient  cell  detachment,  and  then  10ml  of  growth  media  was  added  to  inactivate  the 
trypsin-EDTA  solution.  Cells  were  centrifuged  at  1000  x  gmax  for  5  minutes,  the 
supernatant removed and the cell pellet resuspended in the required volume of growth 
media. 1ml of resuspended cells was added to 9ml of fresh grown media in sterile flasks. 
Cells were then incubated as above until required.  
 
2.2.1.3 HEK293 cells 
The human embryonic kidney 293 (HEK293) cell line were derived by transformation of 
human embryonic kidney cells with DNA from human adenovirus type 5 (Graham et al., 
1977). This cell line was cultured as described above for COS1 cells.  
 
2.2.1.4 DOTAP liposomal transfection 
Fresh medium was added to 100mm plates and a DOTAP/DNA mixture was prepared by 
diluting 7.5µg DNA in DMEM to 75µl in a microcentrifuge tube while 45µl of DOTAP 
was diluted in DMEM to 140µl in a separate microcentrifuge tube. The DNA solution was 
then transferred to the DOTAP solution and mixed by pipetting. The mixture was then 
incubated at room temperature for 15-30 minutes, before being added to the fresh medium 
in the appropriate plates. Cells were incubated overnight at 37°C, 5% (v/v) CO2.  
 
2.2.1.5 siRNA transfection 
COS1 cells were seeded into 6 well plates at approximately 1x10
5 cells/cm
2. Cells were 
then transfected with the appropriate siRNA at concentrations noted in the figure legends, 
using  Lipofectamine  2000  (Invitrogen)  transfection  reagent  according  to  the 
manufacturer’s instructions. Transfection was repeated the following day, and experiments 
carried out 48 hours later. 
 
2.2.1.6 Preparation of whole cell lysates 
Confluent cells were harvested on ice into 1x Laemmli Electrophoresis Sample Buffer 
(Laemmli, 1970). The growth media was removed and cells were washed in chilled PBS. 
The PBS was then aspirated and an appropriate volume of the buffer was added. Cells were 71 
 
then scraped into a 1.5ml microcentrifuge tube. Lysates were either used immediately, or 
frozen at -20°C until required.  
 
2.2.1.7 Sub-cellular fractionation 
Confluent cells were harvested on ice into an appropriate buffer. The growth media was 
removed  and  cells  were  washed  in  chilled  PBS.  The  PBS  was  then  aspirated  and  an 
appropriate volume of the required buffer was added. Cells were then scraped into a 1.5ml 
microcentrifuge  tube.  Lysates  were  either  used  immediately,  or  frozen  at  -80°C  until 
required.  Cells  were  then  scraped  into  a  1.5ml  microcentrifuge  tube.  Cells  were 
homogenised by 7 strokes of a 26½ G needle and 1ml syringe, and then centrifuged at 
1000 x gmax in a bench-top, refrigerated centrifuge for 5 minutes at 4°C. The supernatant 
was transferred to an ultra-centrifuge tube and the pellet (containing the P1 fraction: nuclei 
and unbroken cells) discarded. The supernatant was centrifuged in a bench top ultrafuge at 
100,000 x gmax for 30 minutes at 4°C. The supernatant (SN fraction: enriched cytosolic 
proteins)  was  retained  and  the  pellet  (P2  fraction:  plasma  membrane,  endoplasmic 
reticulum,  Golgi  vesicles,  endosomes  and  lysosomes)  resuspended  in  lysis  buffer  and 
centrifuged again at 100,000 x gmax for 30 minutes at 4°C. The resulting supernatant was 
discarded  and  the  pellet  resuspended  in  cell  lysis  buffer  and  placed  in  a  1.5ml 
microcentrifuge tube. SN and P2 fractions were either used immediately or frozen until 
required.  
 
2.2.1.8 Protein concentration determination 
To determine the protein concentration of cell lysates, a Bradford Assay was carried out, 
using bovine serum albumin (BSA) as the standard in this spectroscopic assay. In a clear, 
96 well plate, a standard curve of known BSA concentrations between 0 and 10 µg was 
diluted to a final volume of 50µl with distilled water. The protein samples were diluted in 
distilled water at a 1:10 ratio, also to a final volume of 50µl. Bradford reagent from Bio-
Rad was diluted 1:5 with distilled water and 200µl added to each well. This reagent causes 
a colour change from brown to blue, the intensity of which is directly proportionate to the 
concentration of the protein. The 96 well plate  was read at 560nm using a microplate 
reader, which provided protein concentrations of each sample.  
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2.2.2 Biochemistry techniques 
2.2.2.1 SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is a common 
method of separating proteins based on their molecular weight. Protein samples at required 
concentrations were denatured in 1x  Laemmli electrophoresis sample buffer (Laemmli, 
1970). Samples were boiled for 5 minutes and then loaded into wells in either 10% (w/v) 
(8.4ml dH2O, 5ml 1.5M Tris-HCl pH 8.8, 6.6ml 30% (w/v) acrylamide mix, 0.1ml 10% 
(w/v) SDS, 0.1ml 10% (w/v) ammonium persulphate, 0.01 TEMED) or 12% (w/v) (6.6ml 
dH2O, 5ml 1.5M Tris-HCl pH 8.8, 8.4ml 30% (w/v) acrylamide mix, 0.1ml 10% (w/v) 
SDS, 0.1ml 10% (w/v) ammonium persulphate, 0.01 TEMED) polyacrylamide gel with a 
5% stacking gel (6.8ml dH2O, 1.25ml 0.5M Tris-HCl, 1.7ml 30% (w/v) acrylamide mix, 
0.1ml 10% (w/v) SDS, 0.1ml 10% (w/v) ammonium persulphate, 0.01ml TEMED). 10µl 
of pre-stained molecular weight protein marker was also loaded into a well as a guide for 
determining the molecular weight of the sample proteins. Electrophoresis was carried out 
overnight at 14mA.  
 
2.2.2.2 Western immunoblotting 
Western immuno-blotting is a method of visualising proteins separated by SDS-PAGE. It 
allows the detection of the individual proteins using specific anti-sera. Proteins separated 
by SDS-PAGE were transferred to Whatman nitrocellulose membrane in transfer buffer at 
300mA for 4 hours. Following transfer, Ponceau staining (0.1% (w/v) Ponceau S, 5% (v/v) 
acetic  acid)  was  used  to  confirm  effective  transfection  and  protein  loading.  The 
nitrocellulose was then washed in 1x TBST for half an hour, then blocked in 5% (w/v) 
milk powder (Marvel) or 5% (w/v) BSA in TBST for 30 minutes at room temperature. 
Primary antibody was added at required dilution (see section 2.1.4) in a 1% (w/v) milk 
powder/TBST  or  BSA/TBST  solution.  The  nitrocellulose  and  primary  antibody  were 
sealed in a plastic container and incubated either overnight at 4°C or for 1 hour at room 
temperature. The nitrocellulose was then washed with TBST for 3x 10 minutes washes, 
and an appropriate horseradish peroxidase (HRP) conjugated anti-immunoglobulin G (IgG) 
secondary antibody added, diluted 1:2500 in 1% (w/v) milk powder/TBST or BSA/TBST 
solution.  Nitrocellulose  and  secondary  antibody  were  incubated  for  1  hour  at  room 
temperature in a sealed plastic container. The nitrocellulose was then washed with TBST 73 
 
and  the  enhanced  chemiluminescence  (ECL)  western  immuno-blotting  kit  was  used  to 
visually detect the bound antibodies. After being treated with ECL solution the membrane 
was exposed to blue-light sensitive autoradiography film, which was developed using the 
Kodak X-Omat processor.  
 
2.2.2.3 Phosphodiesterase activity assay 
Measurement of PDE activity was carried out using a radioactive cyclic AMP hydrolysis 
assay as previously described (Bolger et al., 1997). Hydrolysis of cAMP by PDE isoforms 
results in 5’AMP being formed. In this assay, cyclic AMP is hydrolysed along with [8-
3H] 
adenosine 3’, 5’-cyclic phosphate (Amersham). Snake venom from Crotalus atrox (Sigma-
Aldrich)  is  added  to  prevent  the  recirculation  of  hydrolysed  cyclic  AMP  by  further 
hydrolysis  to  adenosine,  while  the  Dowex  (Sigma-Aldrich)  binds  the  non-hydrolysed 
cyclic AMP (Bolger et al., 1997). 
 
Preparation and activation of Dowex-1 
Dowex slurry was prepared by washing Dowex in 1M NaOH for 15 minutes. The resin 
was allowed to settle and the fines decanted. Distilled water was added and left overnight, 
and then the resin was washed with distilled water until pH 9.0. The resin was then washed 
for 10 minutes in 1M HCl, and allowed to settle. The resin was washed with distilled water 
until pH 4.0 and then made up with distilled water at a 1:1 ratio and stored at 4°C until 
required. This slurry was used in the assay after the addition of 100% ethanol at a 2:1 ratio. 
 
Assay Procedure 
PDE activity was assayed as a measurement of cyclic AMP hydrolysed by PDE. The assay 
used a 0.2µM cAMP solution containing 5µCi [
3H] cAMP (Amersham) per ml prepared in 
PDE assay buffer. 50µl of this substrate solution was placed in a 1.5ml microcentrifuge 
tube  with  an  appropriate  amount  of  cell  extract  diluted  to  50µl  in  assay  buffer.  This 
mixture was incubated for 10 minutes at 30°C and then boiled for 2 minutes to stop the 
reaction by inactivating the PDE. Tubes were transferred to watery ice and left to cool 
completely. 25µl of 1mg/ml snake venom from Crotalus atrox was then added and the 
tubes incubated for 10 minutes at 30°C. The tubes were then returned to ice and 400µl of 
previously prepared Dowex/ethanol slurry was added to each tube. The tubes were left on 
ice for 15 minutes, with occasional vortexing, and then centrifuged at 13000rpm for 2 
minutes  at  4°C  in  a  refrigerated  bench  top  centrifuge.  150µl  of  supernatant  from  the 74 
 
reaction tubes was added to scintillation tubes containing 4ml Ecoscint scintillant fluid, 
with total counts being obtained by the addition of 50µl cAMP substrate solution added to 
4ml of scintillant and then assayed in a scintillation counter.  
 
Determination of Phosphodiesterase Activity 
The resulting data was processed using the following calculation to give the cyclic AMP 
activity for each sample: 
 (Net  counts  per  minute/total  counts  per  minute)  x  (392/150)  x  (total  cyclic  AMP 
(pmol)/time (min))  x (100/47),  wherein 392/150 is the volume correction for the volume 
of supernatant measured in scintillant fluid and 100/47 provides the reaction correction 
factor as 47% of the reaction binds to the Dowex slurry (Bolger et al., 1997). 
 
 
2.2.2.4 RACK1 Co-immunoprecipitation experiments 
Equal amounts of cell pellet or supernatant protein were prepared in equal amounts of lysis 
buffer. Following this 0.1% (v/v) Triton X-100 was added to each sample and incubated on 
ice for 15 minutes. At this stage 50 l per sample was retained and boiled in Laemmli 
electrophoresis sample buffer (Laemmli, 1970) as input controls. Samples were pre-cleared 
by adding 5 g of mouse IgM (Sigma-Aldrich) and 50 l anti-mouse IgM agarose (Sigma-
Aldrich) to each sample. Samples were then incubated on an orbital shaker for 30 minutes 
at 4 ºC. Beads were then pelleted and the supernatant transferred to fresh microcentrifuge 
tubes.  Duplicates  of  each  sample  were  then  treated  with  either  5mg  of  anti-RACK1 
antibody (IgM clone) or 5 g mouse IgM and incubated on a wheel in cold room for 30 
min. 50 l of anti-mouse IgM-agarose was then added to each microcentrifuge tube and 
samples incubated at 4 ºC for a further 30 minutes. The agarose beads were then pelleted 
for 30 seconds at 13000 x gmax and washed 3 times with 500 l lysis buffer. Beads were 
then boiled in electrophoresis buffer and separated by SDS-PAGE along with the retained 
input controls.  
 
 
2.2.2.5 Densitometry and statistical analysis 
Non-saturating exposures from multiple experiments were quantified densitometrically 
using ImageJ software. Densitometric values were normalized to the expression of either 
GAPDH or RACK1 protein levels in the same sample. Statistical significance was 
determined using Student’s two-tailed t-test. 75 
 
 
 
 
CHAPTER 3 
 
 
 
Coordination of Regulatory Crosstalk Between the Cyclic AMP and 
Protein Kinase C (PKC) Signalling Pathways by the Receptor for 
Activated C-Kinase 1 (RACK1)/ Cyclic AMP-specific Phosphodiesterase 
4D5 (PDE4D5) Signalling Complex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76 
 
3.1 INTRODUCTION 
 
Cyclic  AMP-specific  phosphodiesterases  (PDEs)  are  crucial  components  of  the  cyclic 
AMP signalling system and represent the only means of reducing cyclic AMP levels in 
cells through hydrolysis to 5’AMP (Lugnier, 2006). Of the 11 known classes of cyclic 
nucleotide PDEs, eight are able to hydrolyse cyclic AMP (Bolger et al., 1997; Houslay and 
Adams, 2003). The PDE4 cyclic AMP-specific group is widely expressed in a variety of 
tissues and accounts for the majority of cyclic AMP hydrolysis activity in cells (Conti et 
al., 2003). PDE4 isoforms are encoded by four genes, termed A-D, that through complex 
alternate splicing of cognate mRNAs, give rise to around twenty PDE isoforms (Conti et 
al., 2003). The PDE4D group is distinguishable by unique N-terminal regions that have 
been found to readily interact with other cellular proteins (Conti et al., 2003). For example, 
the phosphodiesterase PDE4D5 has been found to interact with the ubiquitously expressed, 
WD40 signalling scaffold protein, RACK1 (Yarwood et al., 1999; McCahill et al., 2002) 
although  to  date  the  precise  function  of  this  signalling  complex  is  largely  unknown. 
Whether RACK1 binding to PDE4D5 effects the intracellular localisation of the complex 
or a conformational change of the bound PDE, or has any influence on PDE activity, has 
yet to be determined. However, it has been demonstrated that interaction with RACK1 in 
vitro  has  been  shown  to  increase  the  sensitivity  of  PDE4D5  to  the  PDE4-selective 
inhibitor,  rolipram,  which  suggests  that  RACK1  may  have  some  influence  on  the 
conformation  of  bound  PDE4D5  (Yarwood  et  al.,  1999).  In  addition,  the  influence  of 
RACK1-binding  partners,  other  than  PDE4D5,  on  the  status  of  PDE4D5  is  largely 
unknown and may reveal key areas of novel signalling regulation and crosstalk.  
 
The interaction between PDE4D5 and RACK1 is highly specific since, to date, RACK1 
has not been shown to bind to any other members of the cyclic AMP specific PDE4 family, 
nor does PDE4D5 bind to other WD40 repeat proteins (Yarwood et al., 1999). RACK1 and 
PDE4D5  are  believed  to  interact  in  a  manner  similar  to  the  heterotrimeric  G-protein 
subunits, Gβ and Gγ (McCahill et al., 2002). In this model blades 5, 6 and 7 of the RACK1 
b-propeller form a groove to which the N-terminal of PDE4D5 binds (McCahill et al., 
2002). An 88 amino acid sub-domain, termed the RACK1 interaction domain (RAID1), 
located in the N-terminal region of PDE4D5 was identified as an essential requirement for 
RACK1 binding (Bolger 2002). In addition, a low affinity RACK1 binding site has also 
been located in the PDE4D5 catalytic domain (Bolger et al., 2006). Further studies have 
shown that while PDE4D5 is only able to bind one protein at a time (Bolger et al., 2006), it 77 
 
is likely that RACK1 is able to bind other proteins at the same time as PDE4D5 such as Src 
(Mamidipudi  et  al.,  2004),  integrin  b-subunits  (Liliental  and  Chang,  1998)  and  PKC 
isoforms (McCahill et al., 2002). This ability raises questions as to whether additional 
proteins binding to RACK1 influence the function and specificity of the complex, with 
possible  impact  on  the  function  of  RACK1-bound  PDE4D5.  This  chapter  aims  to 
investigate  this  eventuality  by  exploring  whether  RACK1  binding  affects  PDE4D5 
targeting, activity and regulation by the classical RACK1-interacting partner, PKCα (see 
section 1.4.4). 
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3.2 MATERIALS AND METHODS 
 
All Materials and Methods as outlined in Chapter 2 with variations described below.  
 
 
Thermodenaturation 
Microcentrifuge tubes containing equal amounts of protein from fractionated samples were 
placed in a 45ºC water bath at 1 minute intervals. After a total time of 10 minutes, all 
samples were placed on ice and used in a phosphodiesterase enzyme assay.  
 
Densitometry and Statistical Analysis                                                                                  
Non-saturating  exposures  from  multiple  experiments  were  quantified  densitometrically 
using ImageJ software. Densitometric values of PDE4, anti-VSV and PKCα levels were 
usually normalised to the expression of RACK1 protein levels, as a loading control, in the 
same sample. Statistical significance was determined using Student’s two-tailed t-test. 
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3.3 RESULTS 
 
3.3.1 Isoproterenol promotes PDE activation in membrane and cytosolic fractions of 
HEK293 cells - As a first step to elucidating whether or not interactions with RACK1 
affect the activity and intracellular localisation of PDE4D5 we first sought to determine the 
impact  of  elevating  intracellular  cyclic  AMP  on  the  activation  of  PDE4  isoforms  in 
HEK293 cells. HEK293 is a well characterised cell line that has been used previously in 
the  study  of  cyclic  AMP  signalling  and  in  particular  the  interaction  of  RACK1  and 
PDE4D5 (Lynch et al., 2007). PDE4 isoforms are responsible for 68% of PDE activity in 
HEK293  cells,  with  PDE4B2,  PDE4D3  and  PDE4D5  providing  the  majority  of  this 
activity  (Lynch  et  al.,  2005).  Cells  were  treated  for  various  times  in  the  presence  or 
absence  of  10mM  isoproterenol,  fractionated  into  high  speed  pellet  and  cytosolic  S/N 
fractions and assessed for PDE activity in the presence or absence of the PDE4 specific 
inhibitor,  rolipram,  as  described  in  Materials  and  Methods.  Although  the  fractionation 
technique is crude, it is sufficient to show differences between cytosolic and membrane 
activity and is advantageous over use of whole cell lysates for this reason. Isoproterenol is 
a b2-adrenoreceptor agonist which increases production of cyclic AMP in cells through the 
activation of adenylyl cyclases by Gsa (Higgins and David, 1976) and has been shown to 
affect cyclic AMP levels in HEK293 cells up to a 13-fold increase (Jones et al., 2003). 
Protein levels were assessed by Bradford assay to ensure equal amounts of protein were 
analysed. Analysis of total PDE activity in the pellet fraction showed a significant increase 
in  PDE  activity  following  15  minutes  isoproterenol  stimulation,  which  was  ablated  by 
inclusion of rolipram in the assay (Figure 3.1). This indicates that isoproterenol promotes 
activation of PDE4 isoforms in this fraction of HEK293 cells. Analysis of the supernatant 
fraction  demonstrated  a  similar  trend,  with  isoproterenol  stimulating  cell  PDE  activity, 
peaking  at  15  minutes  with  an  approximate  1.6  fold  increase  when  compared  to  non-
stimulated  cells.  Again,  inclusion  of  rolipram  in  PDE  assays  completely  ablated 
isoproterenol-stimulated PDE activity in supernatant fractions indicating that isoproterenol 
specifically activates PDE4 isoforms in HEK293 cells. These results show that an increase 
in cyclic AMP levels following isoproterenol stimulation causes a significant increase in 
PDE4 activity in soluble and particulate fractions of HEK293 cells.  
 
 
3.3.2 RACK1 and PDE4D5 do not undergo activation-coupled translocation in HEK293 
cells - Although RACK1 and PDE4D5 have been established to form a stable complex in  80 
 
Figure 3.1  
 
 
Figure  3.1  Enhanced  PDE4  activity  following  stimulation  of  HEK293  cells  with 
isoproterenol - HEK293 cells were stimulated with 10mM isoproterenol for the indicated 
times and then harvested and fractionated into high speed pellet and supernatant fractions. 
Samples of pellet and supernatant fractions were then assayed for PDE hydrolytic activity 
in the presence or absence of the type 4 PDE inhibitor, rolipram (10mM). Values obtained 
from three separate experiments were normalised against control and plotted as means ± 
SEM  for  each  cellular  fraction.  Significant  differences  relative  to  control  (t=0)  are 
indicated by * , p<0.01 and **, p<0.001.  
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cells (Yarwood et al., 1999), the effects of PDE4D5 binding to RACK1 on the cellular 
localisation and activity of PDE4D5 have yet to be determined. We therefore sought to 
determine  whether  translocation  of  PDE4D5/RACK1,  as  previously  reported  for  the 
PDE4D5/b-arrestin signalling complex (Perry et al., 2002), contributed to the increases in 
particulate  PDE  activity  following  isoproterenol  stimulation  described  in  Figure  3.1. 
Firstly, to investigate whether the PDE4D5/RACK1 complex undergoes activation-coupled 
translocation,  HEK293  cells  were  stimulated  with  or  without  10 M isoproterenol,  at  a 
range  of  time  points  between  0  and  60  minutes.  Following  stimulation,  cells  were 
harvested and fractionated by high-speed centrifugation into crude membrane (pellet or P2) 
and cytosolic (supernatant or S/N) fractions. Equal amounts of protein from each fraction 
were then separated by SDS-PAGE and immunoblotted with antibodies to RACK1 and 
PDE4D, which  recognises all PDE4D isoforms, as PDE4D5 is known  to interact with 
RACK1  (Figure  3.2).  The  immunoblots  demonstrate  that  although  RACK1 
immunoreactivity  is  detectable  in  both  pellet  and  supernatant  fractions,  it  is  clearly 
enriched in the pellet fraction of HEK293 cells (Figure 3.2). Immunoblotting with the anti-
PDE4D antibody also demonstrated the presence of the PDE4D isoforms, PDE4D3 and 
PDE4D5, as previously described (Yarwood et al., 1999). Immunoblots also demonstrated 
that  although  PDE4D3  and  PDE4D5  are  enriched  in  the  supernatant  fraction  of  cells, 
immunoreactivity for both isoforms is clearly detectable in the pellet fraction (Figure 3.2).  
 
Stimulation with isoproterenol however seemed to have little effect on the distribution of 
PDE4D3, PDE4D5 or RACK1 between pellet and supernatant fractions at any of the time 
points  tested  (Figure  3.2).  To  test  that  isoproterenol  stimulation  does  indeed  cause 
activation  of  the  cyclic  AMP  signalling  pathway  in  HEK293  cells,  experiments  were 
carried out to confirm that the isoproterenol could stimulate the phosphorylation of the 
PKA-substrate  cyclic  AMP  response  element  binding  protein  (CREB),  which  is 
phosphorylated in response to increased cyclic AMP levels in a wide variety of cell types 
(Yamamoto et al., 1988). As CREB activation occurs through PKA action in response to 
an elevation in cyclic AMP levels, and PKA is also able to activate PDE4D isoforms, 
measurement  of  CREB  phosphorylation  is  a  reasonable  assay  for  determining  that 
isoproterenol stimulation can cause activation of the cyclic AMP signalling pathway in 
HEK293  cells.  In  this  experiment  the  dephosphorylation  and  inactivation  of  CREB 
coincides with activation of PDEs as demonstrated in Figure 3.1, indicating that following 
PDE activation cyclic AMP levels become lowered and CREB is inactivated. Immunoblots 
using an antibody that recognises the phosphorylated and active form of CREB show a  82 
 
Figure  3.2  RACK1  and  PDE4D5  do  not  undergo  activation-coupled  translocation 
following isoproterenol stimulation of HEK293 cells  
 
HEK293  cells  were  stimulated  with  10µM  isoproterenol  at  the  indicated  time  points 
ranging from 0 to 60 min. Following stimulation, cells were harvested and fractionated by 
high-speed centrifugation into pellet and supernatant fractions. Equal amounts of protein 
were  separated  by  SDS-PAGE  and  immunoblotted  with  anti-PDE4D  and  anti-RACK1 
specific antibodies. The immunoblots show an enrichment of RACK1 (36kDa) in the pellet 
fraction, while PDE4D5 (105kDa, upper) and PDE4D3 (95 kDa, lower) are enriched in the 
supernatant fraction. Densitometry was carried out on immunoblots from three separate 
experiments and the results plotted as means on the graph. 
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significant  increase  in  phospho-CREB  levels  following  15  minutes  isoproterenol 
stimulation  (Figure  3.3),  with  no  concomitant  translocation  of  PDE4D3,  PDE4D5  or 
RACK1.  These  results  indicate  that  isoproterenol  is  able  to  stimulate  elevations  in 
intracellular cyclic AMP levels in HEK293 cells; however, the RACK1/PDE4D5 does not 
appear  to  undergo  activation-coupled  translocation  in  response  to  elevated  levels  of 
intracellular cyclic AMP in this cell type.  
 
3.3.3 The effect of RACK1 on PDE4D5 subcellular localisation - Having established that 
RACK1  and  PDE4D5  do  not  undergo  activation  coupled  translocation  in  response  to 
elevations in intracellular cyclic AMP, the role of RACK1 in the intracellular targeting of 
PDE4D5  was  investigated.  HEK293  cells  were  transfected  with  VSV-tagged  cDNA 
encoding  wild  type  PDE4D5  (PDE4D5-WT)  or  with  VSV-tagged  PDE4D5  where  the 
leucine at position 33 in the unique N-terminal had been mutated to aspartate (PDE4D5-
L33D). The PDE4D5-L33D mutation in PDE4D5 has previously been shown to prevent 
interaction with RACK1 (Bolger et al., 2006). Although this mutation may also interfere 
with β-arrestin binding the binding of both RACK1 and β-arrestin are mutually exclusive. 
The  PDE4D5-L33D  mutant  is  therefore  a  useful  tool  for  investigating  the  interaction 
between  RACK1  and  PDE4D5.  To  confirm  that  this  mutation  does  in  fact  prevent 
interaction with RACK1 in HEK293 cells immunoprecipitation experiments were carried 
out  from  transfected  cells  using  an  anti-RACK1  antibody.  Results  demonstrated  that 
whereas  PDE4D5-WT  precipitated  with  RACK1,  there  was  no  significant  association 
detected between RACK1 and PDE4D5-L33D (Figure 3.4). To check whether association 
with RACK1 affected the intracellular distribution of PDE4D5, HEK293 cells transfected 
with  PDE4D5-WT  or  PDE4D5-L33D  were  harvested  and  fractionated  by  high-speed 
centrifugation. Equal amounts of protein from both PDE4D5-WT– and PDE4D5-L33D- 
transfected  cells  and  untransfected  fractions  were  separated  by  SDS-PAGE  and  then 
immunoblotted  with  anti-RACK1  and  anti-VSV  specific  antibodies.  Immunoblots 
demonstrated (Figure 3.5) that RACK1 immunoreactivity was enriched in the membrane 
fractions  of  untransfected,  PDE4D5-WT  and  PDE4D5-L33D  transfected  cells,  while 
PDE4D5 protein levels, indicated by the anti-VSV reactive bands in the PDE4D5-WT and 
PDE4D5-L33D transfected cell fractions are enriched in the cytosolic fraction with lower 
levels of expression in the particulate fractions. Densitometric analysis of immunoblots 
demonstrated  that  the  relative  distributions  of  PDE4D5-WT  and  PDE4D5-L33D  were 
approximately equal between the two fractions (Figure 3.5) and that while the majority of 
RACK1 is found in the pellet fraction, binding with PDE4D5 has little effect on its  85 
 
Figure 3.3 
 
 
 
Figure  3.3  Isoproterenol  stimulation  of  HEK293  cells  induces  phosphorylation  of 
CREB  on  Ser  133  -  HEK293  cells  were  stimulated  with  10 M  isoproterenol  for  the 
indicated times between 0 and 60 min. Cells were then harvested and equal amounts of 
protein from whole cell extracts were separated by SDS-PAGE and immunoblotted with 
anti-CREB  and  anti-phosphoCREB  (Ser133)  specific  antibodies.  Densitometric  values 
taken from three separate experiments were plotted as means with significant differences 
relative to control (t=0) indicated by **, p<0.001. 
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Figure 3.4  
 
 
 
 
Figure 3.4 Wild-type  PDE4D5, but not  PDE4D5-L33D, associates  with RACK1 in 
HEK293  cells  -  HEK293  cells  were  transfected  with  VSV-tagged  PDE4D5  wild  type 
(PDE4D5-WT)  or  VSV-tagged  PDE4D5  L33D  mutant  (PDE4D5-L33D).  Whole  cell 
lysates were then prepared and immunoprecipitated with control (IgM) antibody or anti-
RACK1  (IgM  clone)  antibodies.  Immunoprecipitates  and  whole  cell  lysates  were  then 
separated by SDS-PAGE and immunoblotted with anti-VSV antibodies to detect PDE4D5 
forms  (upper  bands),  or  anti-RACK1  antibody.  The  immunoblot  shown  here  is 
representative of an experiment carried out on three separate occasions with similar levels 
of expression across all transfections.   
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Figure  3.5  Distribution  PDE4D5-WT  and  PDE4D5-L33D  activity  and 
immunoreactivity between soluble and particulate fractions of HEK293 cells  
HEK293 cells were transfected with VSV-tagged, PDE4D5 wild type (PDE4D5-WT) or 
VSV-tagged,  PDE4D5  L33D  (PDE4D5-L33D)  non-RACK1  binding  mutant  DNA,  and 
then fractionated to give pellet (P2) and cytosol (S/N) fractions. Equal amounts of protein 
from  transfected  and  untransfected  cell  fractions  were  separated  by  SDS-PAGE  and 
immunoblotted with anti-RACK1 and anti-VSV specific antibodies. The blot shows an 
enrichment of RACK1 in the membrane fraction, while the PDE4D5 protein, as indicated 
by the VSV bands on the blot, are enriched in the cytosolic fractions of both the WT and 
mutant. Densitometric values were obtained from non-saturating immunoblots from three 
separate experiments and plotted on the upper graph to show the relative distributions of 
PDE4D5-WT and PDE4D5-L33D between fractions, while the middle graph shows the 
proportional  distribution  of  RACK1  in  the  pellet  and  supernatant  fractions  when  in 
association with and without PDE4D5. PDE assays were also carried out on fractions from 
transfected cells, displayed on the lower graph. 
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distribution within the cell. Together this data suggests that association with RACK1 does 
not  play  a  significant  role  in  determining  the  subcellular  distribution  of  PDE4D5  in 
HEK293 cells. 
 
3.3.4 The effect of interaction with RACK1 on the conformation of PDE4D5 - Having 
determined that there was little difference in terms of intracellular distribution between 
PDE4D5-WT and PDE4D5-L33D, denaturation experiments were carried out to determine 
whether binding to RACK1 affected the structural stability of PDE4D5. Denaturation of an 
enzyme  reduces  substrate  binding  and  prevents  enzyme  activity.  The  use  of  complex 
formation to prevent denaturation can be seen in examples such as the Arp2/3 complex (Le 
Clainche et al., 2001) which provides protection against enzyme denaturation when the 
complex  components  are  bound  in  complex.  The  effects  of  thermodenaturation  on 
PDE4D5  activity  was  examined  following  transfection  of  HEK293  cells  with  cDNA 
encoding  VSV-tagged  PDE4D5-WT  and  PDE4D5-L33D.  Cells  were  harvested  and 
fractionated into high-speed pellet and supernatant fractions which were then heated for 
various times at 45
oC. This temperature was chosen after initial optimisation experiments 
were carried at 40
oC, 45
oC and 50
oC to determine the appropriate temperature. The results 
from  this  initial  experiment  showed  that  40
oC  resulted  in  little  denaturation  after  the 
longest time point, while 50
oC resulted in high denaturation at the earliest time point to a 
degree that enzymatic activity was negligible. 45
oC, having resulted in a linear decay, was 
therefore chosen for this experiment. Samples were then assayed for PDE activity (Figure 
3.6). Results demonstrated that all samples decayed with a single exponential; however 
there was a pronounced difference between the activity decay between PDE4D5-WT and 
PDE4D5-L33D  expressed  in  the  pellet  fraction,  with  PDE4D5-L33D  decaying  more 
rapidly (Figure 3.6). In contrast, the rate of decay in PDE activity of PDE4D5-WT in the 
supernatant fraction was found to be slightly greater than PDE4D5-L33D. The supernatant 
fraction shows a decline in PDE activity of PDE4D5-WT falling by 50% by 10 minutes 
heat treatment, and PDE4D5-L33D falling by 20 minutes.  The pellet fraction displays a 
decline of only 10% of PDE activity over 10 minutes in PDE4D5-WT PDE4D5 transfected 
cells, while PDE4D5-L33D mutant PDE4D5 transfected cells exhibit a decline in PDE 
activity  of  almost  70%  at  the  same  time  point.  A  decay  of  pellet  PDE4D5-WT  was 
observed at higher temperatures, but as the decay was non- linear the results were not 
meaningful and are not shown. While only 10% of PDE4D5-WT activity is found in the 
pellet fraction of HEK293 cells (Figure 3.5), inhibition with rolipram occurs with a similar 
IC50 to that seen in the supernatant fraction (Figure 3.1). This indicates that these  90 
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Figure  3.6  Thermal  denaturation  of  particulate  and  soluble  PDE4D5-WT  and 
PDE4D5-L33D - HEK293 cells were transfected with cDNAs encoding either PDE4D5-
WT or PDE4D5-L33D. Cells were then harvested and fractionated into soluble (S/N) and 
pellet (P2) fractions. Equal amounts of protein from each fraction were then heated in a 
water bath heated to 45
oC and removed at minute intervals, ranging between 1 and 10 min, 
and placed on ice. PDE assays were then carried out and mean enzyme activities from 
three  separate  experiments  normalised  to  non-heat  treated  control  at  t=0  (100%  PDE 
activity). 91 
 
experiments were carried out within the linear range of the assay. Additionally, despite 
only possessing 10% of PDE4D5-WT activity, the pellet fraction has been shown to be 
sufficient  to  regulate  activity  of  the  β2-adrenoreceptor  (Perry  et  al.,  2002)  indicating 
functionality at the plasma membrane. 
 
These results show that PDE4D5 that is able to bind RACK1 has a lower rate of decay of 
activity in response to high temperature than PDE4D5 incapable of binding RACK1. As 
PDE4D5  activity  is  based  on  its  ability  to  interact  with  its  substrate  cyclic  AMP,  the 
lessened activity decay seen here in PDE4D5 bound to RACK1 suggests that it is this 
binding that may be responsible for providing some structural stability to the catalytic site 
of PDE4D5 and allowing PDE4D5 to hydrolyse cyclic AMP even under high temperature 
conditions. This supports the hypothesis that interaction with RACK1 may play a role in 
altering the conformation of PDE4D5 in particulate and soluble fractions of HEK293 cells. 
 
To investigate this further we next determined whether interaction with RACK1 influences 
the enzymatic activity of PDE4D5. HEK293 cells were transfected with either PDE4D5-
WT  or  PDE4D5-L33D  cDNAs,  harvested  and  fractionated  into  soluble  and  particulate 
fractions by high-speed centrifugation. Experiments were then carried out to determine the 
maximum rate of catalysis (Vmax) of PDE4D5-WT or PDE4D5-L33D and the affinity of 
PDE4D5-WT or PDE4D5-L33D for cyclic AMP (Michaelis-Menton constant or Km) by 
varying the amount of substrate (ranging between 1 M and 25 M). The PDE activity of 
each  fraction  was  plotted  using  GraphPad  Prism4  to  give  a  Lineweaver-Burk,  double 
reciprocal plot (1/PDE activity against 1/cyclic AMP concentration; Figure 3.7). The y 
intercept of plots provided the value of 1/Vmax, while the x intercept provided -1/Km. Vmax 
values determined for pellet fractions of both PDE4D5-WT and PDE4D5-L33D were low, 
at 0.32 ± 0.07 and 0.87 ± 0.09 pmol/min/mg respectively, while the supernatant fractions 
displayed higher rates of catalytic activity, with PDE4D5-WT possessing a Vmax of 9.71 ± 
2.09  pmol/min/mg,  greater  than  the  PDE4D5-L33D  Vmax  value  of  7.14  ±  1.62 
pmol/min/mg.  The  higher  rate  of  catalysis  observed  in  the  supernatant  fractions  of 
PDE4D5-WT and PDE4D5-L33D transfected HEK293 cells, contrasted with the relatively 
low  Km  values  of  16.7  ±  1.3  and  10.0  ±  1.5   M  respectively.  The  pellet  fraction  of 
PDE4D5-WT, however, shows a comparatively lower Km value of 6.3 ± 0.9  M, indicating 
a higher affinity for its substrate. Conversely, the non-RACK1 binding PDE4D5-L33D 
mutant pellet fraction has a Km value of 20.0 ± 0.9  M, demonstrating a loss of affinity for 
cyclic  AMP  when  compared  to  the  other  PDE4D5  forms  in  the  other  fractions.  As 92 
 
  Figure 3.7 
                
      
Figure  3.7  Determinations  of  Vmax  and  Km  for  PDE4D5-WT  and  PDE4D5-L33D 
HEK293 cells were transfected with cDNAs encoding PDE4D5-WT DNA or PDE4D5-
L33D. Cells were then harvested into assay buffer and fractionated into particulate (P2) 
and soluble fractions (S/N) by high-speed centrifugation. PDE assays were then carried out 
on  equal  amounts  of  fraction  protein  in  the  presence  of  cyclic  AMP  at  concentrations 
ranging between 1 M and 25 M. Mean PDE activities from three separate experiments 
were then used to produce Lineweaver-Burk plots for each fraction and Vmax and Km 
values were calculated. 93 
 
Lineweaver-Burk  plots  are  prone  to  error  as  the  reciprocals  used  in  this  plot  distort 
experimental errors, these values were confirmed by fitting to the hyperbolic form of the 
Michaelis-Menten equation. Although there appears to be little difference in the catalytic 
rates  between  PDE4D5-WT  and  PDE4D5-L33D  mutant  PDE4D5,  the  significant 
difference in Km values indicates that the binding of RACK1 to PDE4D5 in particulate 
fractions  is  essential  for  maintaining  high  affinity  of  PDE4D5  for  cyclic  AMP  in  the 
membrane  fractions  of  cells.  Next  we  determined  the  effect  of  RACK1  binding  on 
susceptibility of PDE4D5 to a specific enzyme inhibitor was investigated by measuring the 
dose  response  of  PDE4D5-WT  and  PDE4D5-L33D  to  the  PDE4  inhibitor,  rolipram 
(Yarwood  et  al.,1999).  HEK293  cells  were  transfected  with  either  PDE4D5-WT  or 
PDE4D5-L33D  and  then  fractionated  by  high-speed  centrifugation.  Equal  amounts  of 
protein  were  treated  with  a  range  of  rolipram  concentrations,  ranging  from  0.01nM  to 
1mM,  and  then  PDE  activity  was  determined.  The  dose  response  curves    (Figure  3.8) 
depicting  the  responses  of  supernatant  fractions  to  rolipram  show  that  the  response  of 
PDE4D5-WT and PDE4D5-L33D to inhibition by rolipram are very similar, while the 
pellet fraction graph shows a clear difference in the dose response of PDE4D5-WT and 
PDE4D5-L33D. The PDE4D5-L33D mutant curve is clearly to the left of the PDE4D5-
WT  curve  and  shows  that  the  PDE4D5-L33D  mutant  in  the  pellet  fraction  is  less 
susceptible  to  inhibition  by  rolipram.  As  outlined  above,  despite  the  pellet  fraction  of 
HEK293  cells  only  containing  10%  of  PDE4D5-WT  activity,  the  IC50  of  rolipram 
inhibition in this fraction is similar to that of the supernatant fraction (Table 3.1), and 
therefore the effects seen in response to rolipram are significant. In the pellet fraction, 
PDE4D5 not bound to RACK1 is less susceptible to rolipram inhibition than PDE4D5 that 
can  bind  RACK1.  This  suggests  that  RACK1  may  allow  easier  interaction  between 
rolipram and PDE4D5. As rolipram also interacts with the catalytic site of PDE4D5, it is 
likely that RACK1 binding holds PDE4D5 in a conformation where rolipram can readily 
access the catalytic site. These results (summarised in Table 3.1) and those from Figure 3.6 
suggest  that  interaction  of  PDE4D5  with  RACK1  is  important  to  allow  high  affinity 
binding of PDE4D5 to its substrate cyclic AMP and for effective inhibition by rolipram in 
the membrane fraction of HEK293 cells. Moreover, the rolipram inhibition experiments 
suggest that RACK1 binding to PDE4D5 is important for allowing effective inhibition by 
low concentrations of rolipram in this fraction.  
 
3.3.5 The effect of interaction with RACK1 on the activation of PDE4D5 - Given these 
strong influences on the conformation of particulate PDE4D5 we next sought to investigate  94 
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Figure  3.8  Dose-response  of  PDE4D5-WT  and  PDE4D5-L33D  to  inhibition  by 
rolipram - HEK293 cells were transfected with cDNAs encoding either PDE4D5-WT or 
PDE4D5-L33D. Cells were fractionated and equal amounts of protein were then treated 
with various concentrations of the PDE4 inhibitor, rolipram, ranging from 0 to 1mM, for 
15 minutes and then assayed for PDE activity. PDE activities obtained from three separate 
experiments were then plotted using GraphPad Prism4 as means ± SEM. 
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Table 1 Km, Vmax and IC50 values for PDE4D5-WT and PDE4D5-L33D Expressed in 
HEK293  Cells  Km  and  Vmax  determinations  were  done  over  a  range  of  substrate 
concentrations  between  1 M  and  40 M  cyclic  AMP,  defined  experimentally  and 
confirmed  by  fitting  to  the  hyperbolic  form  of  the  Michaelis-Menten  equation  using 
GraphPad InStat 3. Dose-dependent inhibition by rolipram was determined in the presence 
of 0.2 M cyclic AMP over a range of rolipram concentrations between 0.01nM and 1mM. 
Significant  differences  relative  to  pellet-associated  PDE4D5-WT  (*,**  and  ***)  or 
PDE4D5-L33D (#, ## and ###) are indicated (p<0.05, p<0.01 and p<0.001, respectively). 
Transfection  Fraction  Km (m m m mM)  Vmax (pmol/min/mg)  IC50 Rolipram 
(m m m mM) 
PDE 4D5- WT  Pellet  6.3 ± 0.9  0.32 ± 0.07  0.10 ± 0.01 
PDE 4D5- WT  S/N  16.7 ± 1.3**  9.71 ± 2.09**
, ##  0.08 ± 0.02
### 
PDE 4D5- L33D  Pellet  20.0 ± 0.9 
*** 
0.87 ± 0.09  10 ± 0.90*** 
PDE 4D5- L33D  S/N  10.0 ± 1.5
##  7.14 ± 1.62*
, #  0.09 ± 0.02
### 96 
 
 
whether interaction with RACK1 has an effect on the ability of particulate PDE4D5 to be 
activated by isoproterenol, which is a potent regulator of PDE4 activity in HEK293 cells 
(Figure 3.1). RACK1 was immunoprecipitated from the pellet and soluble fractions of 
HEK293 cells that had  been stimulated with isoproterenol (10mM) for  15 minutes and 
PDE4D5  activity  associated  with  the  immunoprecipitates  determined  by  PDE  assay 
(Figure 3.9). Results demonstrated that isoproterenol stimulation provoked a significant 1.6 
fold  increase  in  PDE4D5  activity  associated  with  RACK1  immunoprecipitates  from 
solubilised particulate fractions, but not from soluble fractions (Figure 3.9). This indicates 
that association with RACK1 causes a conformational change in PDE4D5 associated with 
particulate fractions that enables PDE4D5 activation by the cyclic AMP signalling cascade.  
 
Given  that  RACK1  was  originally  identified  as  a  scaffold  protein  for  activated 
conventional PKC isoforms (McCahill et al., 2002), and that cyclic AMP elevation has 
recently been linked to the activation of PKC in a number of cell types (Borland et al., 
2009),  we  next  investigated  whether  conventional  PKC  isoforms  could  be  involved  in 
mediating the actions of isoproterenol on RACK1-bound PDE4D5. Firstly we found that 
stimulation  of  cells  with  the  PKC  activator,  phorbol  myristate  acetate  (PMA;  10mM), 
provoked similar levels of PDE4D5 activation as isoproterenol in the particulate fraction, 
but not soluble fraction, of HEK293 cells (Figure 3.9). PMA was also found to stimulate 
rapid activation and translocation of the PKCα isoform from the supernatant to the pellet 
fractions of HEK293 cells (Figure 3.10). Cells were stimulated with 10mM PMA over a 0 – 
60 minute time course and showed a maximal association of activated PKCα in response to 
PMA  after  5  minutes.  No  effect  on  RACK1  distribution  within  the  cell  was  seen  in 
response  to  PMA  stimulation  across  the  time  course.  Although  PMA  provokes  a  fast 
degradation of PKC, the time course of PDE4D5 activation in response to PMA (Figure 
3.9) occurs before disappearance of PKC and therefore this does not affect the results.  
 
Next, in order to determine whether isoproterenol can provoke PKC activation, HEK293 
cells  were  stimulated  with  PMA  and  then  cells  were  harvested  and  fractionated  into 
particulate and soluble fractions which were then immunoprecipitated with anti-RACK1 
antibodies (Figure 3.11).  Equal amounts of protein from fractions together with RACK1 
immunoprecipitates  were  separated  by  SDS-PAGE  and  then  immunoblotted  with  anti-
RACK1 and anti-PKCα antibodies (Figure 3.11). PKCα was clearly found to translocate to 
the particulate fraction in response to PMA stimulation. Translocation from the cytosol to  97 
 
Figure 3.9  
 
 
 
 
Figure 3.9 Isoproterenol and PMA stimulate PDE4 activity associated with RACK1 
immunoprecipitates  from  HEK293  cells  -  HEK293  cells  were  stimulated  with  either 
10mM  isoproterenol  or  10mM  PMA  for  15  minutes  and  then  fractionated  and 
immunoprecipitated with anti-RACK1 antibodies. RACK1 immunoprecipitates were then 
assayed for associated PDE activity in the presence or absence of rolipram as indicated in 
the histogram. Means ± SEM from three separate experiments were plotted as fold change 
relative to non-stimulated cells. Significant differences relative to control are indicated, * = 
p<0.01. 
 98 
 
Figure  3.10  Stimulation  of  HEK293  cells  with  PMA  triggers  intracellular 
translocation of PKCα but not RACK1 
 HEK293 cells were stimulated with 10 M PMA at time points between 0 and 60 min 
following which cells were fractionated into soluble (S/N) and particulate (pellet) fractions. 
Equal  protein  amounts  of  cell  fractions  were  separated  by  SDS-PAGE  and  then 
immunoblotted with anti-RACK1 and anti-PKCα antibodies. The immunoblots show that 
PKCα  translocates  from  the  supernatant  to  the  pellet  fraction  within  5  min  of  PMA 
stimulation.  Densitometry  was  carried  out  on  immunoblots  from  three  separate 
experiments  and  plotted  as  means  ±  SEM.  Significant  differences  relative  to  non-
stimulated control are indicated, * = p<0.05 and ** = p<0.01. Results are representative of 
an experiment carried out on three separate occasions. 
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Figure 3.11  
 
Figure 3.11 PMA or isoproterenol stimulation promotes the association of PKCα with 
RACK1 in the particulate fraction of HEK293 cells - HEK293 cells were stimulated 
with diluent (DMSO), isoproterenol or PMA for 15 minutes and cells were harvested and 
fractionated. Fractions were solubilised with 0.1% (v/v) Triton X-100 and then samples 
were pre-cleared with mouse IgM. Following this, samples were immunoprecipitated with 
either  mouse  IgM  (negative  control)  or  anti-RACK1  (IgM  clone)  antibody. 
Immunoprecipitates  and  lysate  samples  were  separated  by  SDS-PAGE  and  then 
immunoblotted with anti-RACK1 and anti-PKCα antibodies. Densitometric values from 
the RACK1-immunoprecipitated samples were plotted as means ± SEM and represent the 
fold change in PKCa interaction with RACK1 in each fraction. Significant differences in 
PKCa  immunoreactivity  are  indicated,  *  =  p<0.05  and  **  =  p<0.01.  Results  are 
representative of an experiment carried out on three separate occasions. 
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the plasma membrane is a well documented indicator of PKC activation (Lin et al., 2007) 
in response to PMA stimulation (Lim et al., 1999) allowing for a clear indication of PKCα 
activation in these experiments, and it was found to associate with RACK1 as determined 
by  immunoprecipitation  (Figure  3.11).  Surprisingly,  isoproterenol  stimulation  also 
provoked  an  increase  in  PKCa  immunoreactivity  in  pellet  fractions  and  in  RACK1 
immunoprecipitates  from  pellet  fractions  (Figure  3.11).  These  results  demonstrate  that 
isoproterenol stimulation provokes a significant activation of RACK1-associated PKCa in 
HEK293 cells. 
 
The establishment of an interaction between RACK1 and PKCα in the particulate fraction 
of cells leads to the question as to whether the interaction between PKCα, and RACK1 has 
any effect on RACK1-bound PDE4D5 activity. Our results from PDE assays carried out on 
RACK1 immunoprecipitates (Figure 3.9) suggest that this might be the case, however to 
test this idea further the effect of PMA was tested on  HEK293 cells transfected with 
PDE4D5-WT or the PDE4D5-L33D non-RACK1 binding mutant. Transfected cells were 
stimulated in the presence or absence of PMA for 15 minutes, before being harvested, 
fractionated  and  the  PDE4D5  activity  in  fractions  assayed  by  PDE  assay.  Results 
demonstrated an almost 3.5 fold increase in PDE4D5 activity in the pellet fraction from 
PDE4D5-WT transfected cells stimulated with PMA, in comparison with non-stimulated 
PDE4D5-WT  pellet  fraction  (Figure  3.12).  In  contrast,  the  pellet  fraction  from  PMA-
stimulated  PDE4D5-L33D  cells  shows  a  PDE  activity  fold  change  of  around  only  1.5 
(Figure 3.12). These results show that interaction with RACK1 in the particulate fraction 
of HEK293 cells causes a greater increase in PDE activity in the presence of PMA than 
when  PDE4D5  is  not  bound  to  RACK1,  suggesting  that  interaction  with  RACK1  is 
important for high levels of PDE activity in response to PKC activation. 
 
Finally, to demonstrate that it is PKC activation per se, and not the effects of downstream 
effectors, that is responsible for the activation of PDE4D5 in the particulate fraction of  
HEK293 cells, cells were treated with general PKC and MEK specific inhibitors and PDE 
activity levels determined (Figure 3.13). HEK293 cells were pre-treated with U0126, a 
specific inhibitor of MEK1 and 2, a known downstream effector of PKC signalling (Favata 
et al., 1998), or  with the PKC specific inhibitors Ro-31-7549 or GF109203X (GFX) for 30 
minutes, then stimulated for 15 minutes with or without PMA. Cells were then harvested 
and equal amounts of lysate protein were separated by SDS-PAGE and then  102 
 
 Figure 3.12  
 
 
 
Figure 3.12 Association with RACK1 is required for PDE4D5 to be activated by PMA 
in the particulate fraction of HEK293 cells - HEK293 cells were transfected with either 
PDE4D5-WT or PDE4D5-L33D and then stimulated with PMA for 15 minutes. Following 
this, cells were harvested and fractionated by high-speed centrifugation PDE assays were 
carried out and activities were then plotted as means ± SEM and represent fold change 
relative  to  non-stimulated,  pellet  sample.  Significant  differences  relative  to  control  are 
indicated, ** = p<0.01. Results are representative of an experiment carried out on three 
separate occasions. 
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Figure 3.13  
 
 
 
Figure 3.13 Activation of RACK1-associated PDE4D5 by PMA requires PKC and not 
ERK 
a) HEK293 cells were transfected with cDNA encoding PDE4D5-WT and then pre-treated 
for 30 minutes with either DMSO or inhibitors U0126, Ro-31-7549 or GF109203X (GFX) 
and then stimulated with or without PMA for 15 minutes. Cells were then harvested and 
equal amounts of whole cell extract were separated by SDS-PAGE and immunoblotted 
with total ERK and phospho-ERK antibodies. Results represent a single experiment carried 
out on three separate occasions with similar results. 
b) PDE4D5-WT-transfected cells were pre-treated with U0126, Ro-31-7549 or GFX prior 
to  15  minutes  PMA  stimulation.  Cells  were  then  fractionated  and  PDE4D5  activity 
associated with the particulate fraction of cells was assessed by PDE assay. Results are 
expressed as percentage of maximum (PMA-treated cells) and are means  ± SEM for three 
separate experiments. Significant differences relative to PMA-treated cells are indicated, 
**, p<0.01.  104 
 
immunoblotted for total ERK and phospho-ERK to determine the efficacy of the inhibitors 
(Figure 3.13a). Immunoblots demonstrate a robust activation of phospho-ERK following 
PMA  stimulation,  which  is  completely  ablated  following  U0126,  Ro-31-7549  or  GFX 
treatment. In contrast, treatment with U0126 failed to block particulate PDE4D5 activation 
following PMA stimulation, whereas treatment of PMA stimulated cells with Ro-31-7549 
and GFX caused a significant reduction in PDE activity (Figure 3.13b). These results show 
that activation of PDE4D5 by PMA-stimulated PKC isoforms is a direct effect of PKC on 
PDE4D5 and not through activation of the downstream effector, MEK. 105 
 
3.4 DISCUSSION 
 
The regulation of cyclic AMP levels within the cell allows control of numerous cellular 
processes (Cheng et al., 2008). To fully appreciate these pleiotropic actions of cyclic AMP 
a thorough investigation into the role of specific cyclic AMP PDEs, their interaction with 
cellular proteins and the effects of this interaction on PDE activity is important to fully 
understand the complex regulation of cellular cyclic AMP levels. To date our knowledge 
of this level of sophisticated regulation is far from complete. Progress is starting to be 
made in this direction, particularly in the characterisation of protein interactions with the 
cyclic  AMP-specific  phosphodiesterase,  PDE4D5  and  the  scaffold  protein,  β-arrestin 
(Bolger et al., 2003; Lynch et al., 2005). This complex is recruited from the cytosol to the 
plasma membrane in response to activation of β2-adrenergic receptor (Bolger et al., 2003). 
The recruitment of the β-arrestin/PDE4D5 complex not only blocks the synthesis of cyclic 
AMP, but allows PDE4D5 to specifically hydrolyse cyclic AMP in the vicinity of the β2-
adrenergic receptor, contributing to the control of compartmentalisation of cyclic AMP. In 
the  current  investigation  we  examined  whether  the  RACK1/PDE4D5  was  similarly 
recruited to the plasma membrane in response to β2-adrenergic receptor activation. While 
we found that isoproterenol stimulation was sufficient to activate PDE4 activity in general 
in HEK293 cells (Figure 3.1), and PDE4D5 specifically associated with RACK1 in the 
particulate  fraction  of  cells  (Figure  3.9),  we  did  not  see  any  translocation  of  the 
RACK1/PDE4D5 complex. This may not be surprising since the binding of RACK1 and  
β-arrestin  to  PDE4D5  appears  to  be  mutually  exclusive  and,  furthermore,  interactions 
between PDE4D5 and RACK1 appear to inhibit interaction with β-arrestin (Bolger et al., 
2006). The RACK1/PDE4D5 complex may therefore perform different cellular functions 
than the β-arrestin/PDE4D5 complex. Indeed, the translocation of PDE4D5 and its cognate 
binding partners in response to β2-adrenergic receptor activation may depend on the cell 
context.  In  this  respect  β-arrestin/PDE4D5  translocation  seems  to  occur  in  cells  that 
express β2-adrenergic receptors to a high level, for example in cardiomyocytes (Lynch et 
al., 2007) or HEK293 cells stably transfected to express high levels of receptor (Baillie et 
al., 2003), and may reflect the ability of b-arrestin to develop high affinity interactions 
with this receptor type. Indeed, little translocation of β-arrestin/PDE4D5 is seen in wild 
type  HEK293  cells,  with  no  overexpression  of  the  β2-adrenergic  receptor  (Dr.  George 
Baillie, personal communication). The β2-adrenergic receptor may therefore present an 
effective  recruitment  site  for  β-arrestin/PDE4D5  signalling  complexes,  but  not  for 
RACK1/PDE4D5  complexes.  It  therefore  remains  to  be  determined  what  structural 106 
 
influences direct the recruitment of RACK1/PDE4D5 complexes at the particulate fraction 
of cells. 
 
Although  RACK1  does  not  appear  to  act  on  targeting  of  PDE4D5  to  specific  cellular 
localisations, it does appear to act upon PDE4D5 structural stability. Enzymes are readily 
denatured when exposed to extreme or unfavourable conditions, and the stability of the 
protein effects how  rapidly this denaturation occurs. To date, little is known as to the 
purpose of the RACK1/PDE4D5 complex. However, in this study, binding to RACK1 was 
found  to  afford  PDE4D5  some  protection  against  denaturation  in  thermal  denaturation 
studies (Figure 3.6), with plasma membrane localisation non-RACK1 binding PDE4D5 
showing a greater rate of denaturation when exposed to a temperature of 45
oC compared to 
RACK1 binding PDE4D5 under the same conditions, implying that the inability to bind 
RACK1 affects the stability of PDE4D5 and increases its susceptibility to denaturation. If 
RACK1 affects the conformational stability of PDE4D5, this is predicted to exert some 
effect  on  the  enzymatic  activity  of  RACK1-bound  PDE4D5.  Indeed,  we  found  that 
RACK1  binding  was  necessary  to  maintain  high  affinity  binding  of  PDE4D5  for  its 
substrate, cyclic AMP (Figure 3.7), implying that the conformational change in PDE4D5 
exerted  by  RACK1  binding  to  PDE4D5  in  the  particulate  fraction  of  cells  sensitises 
PDE4D5 toward its substrate, perhaps priming PDE4D5 for activation in this fraction. As 
RACK1 appears to cause a conformational change that aids interaction of PDE4D5 with 
cyclic AMP, this change is also likely to affect the interaction of PDE4D5 with the PDE4 
specific inhibitor rolipram, which also interacts with the active site of the enzyme (Huai et 
al.,  2003).  Indeed,  dose-response  experiments  (Figure  3.8)  revealed  that  that  while 
cytosolic PDE4D5 exhibited a similar response to rolipram concentrations regardless of its 
RACK1  binding  ability,  PDE4D5  located  in  the  particulate  fraction  of  cells  was  more 
susceptible to inhibition by rolipram if bound to RACK1. These results are particularly 
intriguing  as binding of RACK1 to PDE4D5 appears to allow lower concentrations of 
rolipram to inhibit the phosphodiesterase activity. Rolipram, with its anti-depressant and 
anti-inflammatory properties is a drug used to treat a variety of diseases, ranging from 
depression (Wachtel, 1983) to Alzheimer’s (Gong et al., 2004). Unfortunately, the drug 
has a number of side effects, the most prominent being its emetic effect (Houslay et al., 
2005). The implication of RACK1 binding to PDE4D5 requiring a lower concentration of 
rolipram to produce the same levels of inhibition of non-RACK1 bound PDE4D5 provides 
the possibility of RACK1 or a synthetic analogue being therapeutically taken alongside a 107 
 
lower dose of rolipram to produce the same biological effect with potentially lessened side 
effects.  
 
RACK1  is  a  multi-domain  protein,  possessing  different  sites  for  interaction  with  other 
proteins (Yarwood et al., 1999). It is likely, therefore, to be able to form multi-protein 
complexes.  As  RACK1  was  originally  identified  by  its  ability  to  bind  activated 
conventional  PKC  isoforms,  the  RACK1/PDE4D5  complex  forms  a  point  of  crosstalk 
between the cyclic AMP and PKC signalling pathways. The effect of activation of the PKC 
isoform α on the PDE4D5/RACK1 complex was investigated to determine its effect on 
localisation and on RACK1-bound PDE4D5 activity. PKCα and RACK1 were determined 
to interact in the particulate fraction of HEK293 cells (Figure 3.11) and the potent phorbol 
ester PMA, which causes PKC activation and translocation from the cytosol to the plasma 
membrane was found to cause similar levels of PDE4D5 activity in the membrane fraction 
of HEK293 cells to those induced by isoproterenol stimulations (Figure 3.9). Furthermore, 
PDE  activity  assays  on  RACK1-bound  PDE4D5  and  non-RACK1  binding  mutant 
PDE4D5 expressing cells stimulated with PMA showed that the RACK1 interaction is 
essential to allow efficient activation of PDE4D5 by PKCα (Figure 3.12). That PKCα was 
the cause of the PDE4D5 activation and not downstream effectors of PKC was confirmed 
by treatment with various PKC and MEK specific inhibitors prior to determination of PDE 
activity (Figure 3.13). Further experiments to investigate the importance of RACK1 in 
anchoring PKCα at the plasma membrane, and its effects on PKC function and activation 
of PDE4D5 activity, by stable over-expression and anti-sense depletion of RACK1 would 
provide  insight  into  whether  RACK1  is  required  for  PKC  translocation  and  by 
investigating the effects of variation of RACK1 levels on the phosphorylation of ERK, a 
downstream  effector  of  PKC  would  further  demonstrate  the  requirement  of  RACK1 
binding on PKC action  on PDE4D5. Additionally, the use of peptide inhibitors of the 
PKCα/RACK1 interaction would further determine the importance of PKCα anchoring to 
the  membrane  on  PKCα  function.  Additionally,  PDE4D5  binds  both  RACK1  and  β-
arrestin in a mutually exclusive way although the affinity of PDE4D5 to each of these has 
yet  to  be  measured.  Further  experimentation  to  determine  whether  PKCα  can  promote 
PDE4D5 activity when PDE4D5 is bound to β-arrestin would expand on the importance of 
RACK1 on the ability of PKCα to influence PDE4D5 activity.  
 
The complex formed between PDE4D5 and RACK1 provides a point of crosstalk between 
the cyclic AMP and PKC signalling pathways as well as a potential point of feedback as 108 
 
increased cyclic AMP levels have been shown to activate PKC (Borland et al., 2009), and 
PKC activation increases PDE activity (Figure 3.12) which in turn reduces cyclic AMP 
levels. The results outlined in this chapter show the importance of RACK1 binding by 
PDE4D5  in  its  enzymatic  activity  and  the  effects  of  PKC  activation  on  the 
phosphodiesterase activity of PDE4D5. To conclude, therefore, this chapter outlines a role 
for  the  RACK1/PDE4D5  complex  in  causing  a  conformational  change  to  affect  the 
enzymatic activity of the phosphodiesterase, and its response to the inhibitor rolipram. 
Furthermore, the complex forms a point of crosstalk between the cyclic AMP and PKC 
signalling pathways, with PKCα interacting with RACK1 at the plasma membrane and 
causing increases upon activation of RACK1 bound PDE4D5 activity, thus showing that 
the activation of PKC can negatively regulate cyclic AMP levels in HEK293 cells. As 
regulation  of  cyclic  AMP  levels  allows  control  of  a  wide  range  of  cellular  processes, 
negative control of cyclic AMP signalling by PKC activation not only goes some way 
towards  elucidating  how  cyclic  AMP  levels  are  lowered  within  the  cell  but  may  also 
provide  a  therapeutic  target  with  which  to  control  cyclic  AMP  signalling  in  disease 
associated with elevated cyclic AMP levels.  
 
In conclusion, this chapter shows a novel point of crosstalk between the cyclic AMP and 
PKC signalling pathways wherein PKC activation leads to activation of RACK-1 bound 
PDE4D5, thus forming a negative feedback loop to control intracellular cyclic AMP levels 
in HEK293 cells.  
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CHAPTER 4 
 
 
 
The Roles of Exchange Protein Activated by Cyclic AMP (EPAC) 1 and 
Protein Kinase C (PKC) Isoforms in the Induction of the Suppressor of 
Cytokine Signalling (SOCS) 3 gene by cyclic AMP 
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4.1 INTRODUCTION 
 
The EPAC (exchange protein activated by cyclic AMP) proteins, EPAC1 and EPAC2, are 
multi-domain proteins that act as guanine nucleotide exchange factors (GEFs) for the small 
GTPase Rap1, in response to elevations in intracellular cyclic AMP (de Rooij et al., 1998). 
EPAC proteins have a high affinity for cyclic AMP and have been found to be involved in 
the regulation of a number of important physiological processes in the brain, lungs, heart 
and  immune  system,  including  cell  differentiation  and  proliferation,  apoptosis,  muscle 
contraction, calcium handling and inflammation (as reviewed in Borland et al., 2009). Due 
to  these  roles,  EPAC  activity  has  been  linked  with  the  development  of  a  number  of 
metabolic, neurodegenerative and inflammatory diseases; for example EPAC2 has been 
linked  to  autoimmune  diseases,  inflammatory  disorders  such  as  chronic  asthma, 
cardiovascular disorders and Alzheimer’s (McPhee et al., 2005). Its downstream effector, 
Rap1,  is  involved  in  the  regulation  of  several  crucial  cell  functions,  including  cell 
proliferation, integrin-mediated cell adhesion and leukocyte migration (Hattori and Minato, 
2003). Many of these functions have been found to be disrupted in some cancers such as 
leukaemia (Hattori and Minato, 2003), prostate (Bailey et al., 2009) and breast cancers 
(Itoh et al., 2007), while the reported ability of EPAC2 to promote exocytosis of insulin-
containing granules from pancreatic beta cells suggests a role in combating diabetes (Holz, 
2004). While traditionally the majority of cyclic AMP signalling was believed to occur via 
phosphorylation of intracellular proteins by PKA (Conti et al., 2003), the discovery of 
EPAC has provided a novel mechanism for the mediation of cyclic AMP signalling in a 
variety of tissues, although these mechanisms are largely unknown.  
 
Recent studies have outlined a PKA-independent pathway in which EPAC mediates the 
induction of the anti-inflammatory Suppressor of Cytokine Signalling (SOCS-3) gene by 
cyclic AMP (Sands et al., 2006). SOCS proteins are an eight member family of proteins 
that  act  as  negative  regulators  of  cytokine  signalling  (Starr  and  Hilton,  1998).  SOCS 
proteins usually have a low level expression in cells but are rapidly induced by cytokines. 
This allows the inhibition of JAK-STAT signalling, which forms a negative feedback loop 
(Shuai and Liu, 2003). SOCS-3 interferes with the JAK-STAT pathway by directly binding 
to Tyr1007 and inhibiting Janus Kinase 2 (JAK2), preventing the tyrosine phosphorylation 
and activation of Signal Transducers and Activators of Transcription (STATs) 1 and 3 
(Auernhammer  and  Melmed,  2001).  The  JAK-STAT  pathway  is  critical  for  the 
propagation of intracellular signalling from a range of cytokine receptors and is therefore 111 
 
involved in a number of cellular functions, such as the immune response, haematopoiesis 
and  cell  growth  and  proliferation  (Rawlings  et  al.,  2004).  The  JAK-STAT  pathway  is 
activated by a range of cytokines, including interleukin-6 (IL-6), a class I cytokine that is 
involved in the activation of a range of genes involved in cell proliferation, apoptosis and 
differentiation (Heinrich et al., 2003). IL-6 is involved in both initiation and maintenance 
of  immune  and  inflammatory  responses  and  strict  regulation  is  therefore  required. 
Disruption of IL-6 signalling has been linked to a number of diseases, particularly those 
linked  to  the  immune  response  such  as  rheumatoid  arthritis,  Castleman  disease  and 
Crohn’s disease (Ishihara and Hirano, 2002). Increased levels of IL-6 have been implicated 
in  a  range  of  disorders,  including  osteoporosis,  psoriasis,  (Jones  et  al.,  2001)  multiple 
myeloma  (Ishihara  and  Hirano,  2002)  and  renal  cancer  (Takenawa  et  al.,  1991).  IL-6 
signalling involves the binding of the IL-6 receptor (IL6R) to the transmembrane gp130, a 
glycoprotein also employed by other members of the IL-6 family (Carroll et al., 1998). 
These  IL-6  family  members  are  structurally  distinct  but  share  the  gp130  subunit  and 
include  Interleukin-11  (IL-11),  Cardiotrophin-1  (CT-1),  Oncostatin  M  (OSM)  and 
Leukaemia Inhibitory Factor (LIF) (Carroll et al., 1998). A complex is formed, activating 
the receptor and initiating the signal transduction cascade through activation of the JAK-
STAT pathway (Jones et al., 2005). JAKs bind to the cell surface cytokine receptor where 
activation  of  JAKs  creates  phosphotyrosine  residues  on  the  receptor.  This  triggers 
recruitment of STAT3 to the receptor, where the residues act as docking sites for SH2 
domains located on STAT3 and mediates the homodimerisation of STAT3 by tyrosine 
phosphorylation (Schindler et al., 2007). The homodimerised complex then translocates to 
the nucleus where it recruits transcriptional co-activators, binds specific DNA elements 
and then is able to initiate transcription of genes responsive to IL-6 (Borland et al., 2009). 
The induction of SOCS-3 by cyclic AMP, however, prevents this, thus inhibiting the IL-6 
stimulated response, as SOCS-3 binds directly to the phosphorylated receptors by its SH2 
domain,  also  inhibiting  JAKs  and  preventing  both  recruitment  and  phosphorylation  of 
STAT3, thus inhibiting IL-6 stimulated gene expression (Sands et al., 2006) (Figure 4.1). 
As  SOCS-3  induction  by  cyclic  AMP  occurs  after  5  hours,  elevations  in  cyclic  AMP 
attenuate  STAT  activation.  In  this  way,  SOCS-3  is  able  to  interfere  with  cytokine 
signalling, providing a means of negative control as well as a potential target for influence 
of IL-6 signalling. Expression of the SOCS-3 gene can occur in response to cytokines as 
well as other proteins. The minimal functional promoter of SOC-3 consists of two STAT-
responsive elements (SREs), a GC-rich region and an A/T-rich region, and an AP1 
(activation protein 1 element, with STATs acting at the proximal SRE and the GC- and 112 
 
Figure 4.1  
 
 
 
                Adapted from Rønn et al. 2007 
 
Figure 4.1 SOCS proteins inhibit the JAK-STAT pathway 
 
a)  Following IL-6 binding, JAKs bind to the cell surface cytokine receptor. Activation of 
JAKs creates phosphotyrosine residues on the receptor which act as docking sites for the 
SH2  domain  of  STATs  and  mediate  homodimerisation  of  STATs.  Dimerised  STATs 
translocate to the nucleus where they activate transcription of target genes.  
b)  SOCS proteins inhibit the JAK-STAT pathway by binding to the phosphorylated receptors, 
preventing STAT binding and homodimerisation.  113 
 
 A/T-  rich  regions  (Barclay  et  al.,  2007).  No  functional  CREs  (cyclic  AMP  response 
elements) are contained within the SOCS-3 promoter, as evidenced by the inability of PKA 
activation to induce SOCS-3 (Yarwood et al., 2008). While the ability of cyclic AMP to 
affect  gene  transcription  was  thought  to  occur  via  PKA  activation  of  the  transcription 
factor  CREB,  recent  studies  have  found  that  cyclic  AMP  is  able  to  influence  gene 
transcription independently of PKA through CCAAT/enhancer-binding proteins (C/EBPs) 
(Yarwood et al., 2008). In COS1 cells, a role has been found for C/EBPβ in the activation 
of SOCS-3 by cyclic AMP (Borland et al., 2009).  
 
As the inflammatory response requires tight regulation, it is important to have a complete 
understanding of the mechanisms controlling SOCS-3 induction, a major mechanism in the 
control  of  the  JAK-STAT  pathway.  While  it  has  been  shown  that  EPAC1  plays  an 
important role in SOCS-3 induction by cyclic AMP in vascular endothelial cells (Sands et 
al., 2006), MEFs (Yarwood et al., 2008) and COS1 cell lines (Borland et al., 2009), the 
pathway between these two points has not been fully expounded upon. While there are a 
multitude of possible downstream effects of EPAC1 in cells  including other Ras family 
GTPases, PKB/Akt, Phospholipase D, ion channel activation and MAP kinases (Cheng et 
al., 2008; Roscioni et al., 2008), reports of an interaction between EPAC1 and the PLC 
isoform ε (Oestreich et al., 2009), provided an avenue of investigation, both into the role of 
PLC itself, the products of its intracellular activity and their downstream effects, on SOCS-
3 induction by cyclic AMP. Prior to this investigation nothing was known as to the effects 
of  PLC  ε  on  SOCS-3  induction.  This  chapter  aims  to  investigate  the  downstream 
components  of  an  EPAC1-activated  signalling  pathway  leading  from  cyclic  AMP 
generation to SOCS-3 induction in COS1 cells. This elucidated pathway shows a critical 
point  of  regulatory  crosstalk  between  the  cyclic  AMP  and  PKC  signalling  pathways, 
forming part of a pathway which results in SOCS-3 gene induction, and the potential to 
regulate IL-6 signalling.  The previous results chapter demonstrated that PKC activation 
leads to activation of RACK1-bound PDE4D5. This chapter investigates the hypothesis 
that the PKC signalling pathway is involved in the EPAC1 mediated induction of SOCS-3 
by cyclic AMP, thus forming a point of crosstalk between the two pathways. The findings 
from Chapter 3, together with the findings presented in the current chapter, go some way 
towards  defining  a  novel  cyclic  AMP-regulated  signalling  system  with  the  ability  to 
control key, disease-associated, transcriptional events in human cells. 
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4.2 MATERIALS AND METHODS 
 
All Materials and Methods as outlined in Chapter 2 with variations described below.  
 
 
Inhibitor treatment of COS1 cells 
For SOCS-3 induction experiments, confluent COS1 cells were treated for 5 hours with 
PKC inhibitors Ro31-7549 or GF 109203X, or the PLC inhibitor U73122 in the presence 
or absence of cyclic AMP stimulating forskolin (10µM) plus rolipram (10µM) or 8Me 
(50µM).  Samples  were  lysed  directly  into  Laemmli  electrophoresis  buffer  (Laemmli, 
1970) and analysed by SDS-PAGE followed by Western blotting with anti-SOCS-3 and 
anti- Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) specific antibodies. For PKC 
down-regulation experiments, COS1 cells were stimulated with 1µM phorbol 12-myristate 
13-acetate  (PMA)  or  dimethyl  sulphoxide  (DMSO)  for  48  hours.  Cells  were  then 
stimulated  for  5  hours  with  10µM  PMA,  F/R,  or  8Me.  Cell  lysates  were  then 
immunoblotted  using  anti-PanPKC,  anti-SOCS-3  and  anti-GAPDH  specific  antibodies. 
Experiments were all carried out in the presence of MG132 (6µM), a proteasome inhibitor, 
to prevent SOCS-3 degradation after synthesis.  
 
Densitometry and Statistical Analysis 
Non-saturating  exposures  from  multiple  experiments  were  quantified  densitometrically 
using ImageJ software. Densitometric values for SOCS-3 were usually normalized to the 
levels of GAPDH protein expression found in the same sample, while PKC levels were 
normalized  to  the  expression  of  RACK1  protein  levels  in  the  same  sample.  Statistical 
significance was determined using Student’s two-tailed t-test. 
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4.3 RESULTS 
 
4.3.1  EPAC1  mediates  SOCS-3  induction  in  COS1  cells  -  The  link  between  EPAC1 
activation  and  SOCS-3  induction  originally  identified  in  human  umbilical  vascular 
endothelial cells (HUVECs) provides a novel pathway, independent of PKA, by which 
cyclic AMP is able to negatively control cytokine signalling and provides a new pathway 
of  potential  therapeutic  targets  (Sands  et  al.,  2006).  In  order  to  demonstrate  that  this 
pathway occurs in other cell types, it was decided to investigate its components in COS1 
cells, which are highly amenable to transfection with siRNA. 
 
In 1998, double stranded RNA (dsRNA) was found to be able to silence gene expression, a 
process called RNA interference (RNAi). RNAi uses the RNA-induced silencing complex 
(RISC)  to  guide  dsRNA  that  has  been  cleaved  into  short  interfering  RNA  (siRNA) 
fragments by the enzyme Dicer, to the target mRNA. Synthetically made siRNA, that is 
usually 21-23 nucleotides long, bypasses the need for cleavage by Dicer. RISC unwinds 
the siRNA and guides it to bind and degrade the complementary mRNA, thus silencing the 
gene (reviewed in Whitehead et al., 2009). This allows an effect experimental method to 
investigate the effects of knockdown of a gene within a cell line. To show that EPAC1 is 
necessary for SOCS-3 induction in COS1 cells, knockdown of EPAC1 was achieved via 
transfection of COS1 cells with EPAC1 specific siRNA (GCCCGGAACUUGCCUGUUU, 
Dharmacon)  or  non-targeting  control  siRNA  (Qiagen).  Although  sequences  for  this 
negative  control  siRNA  are  unavailable,  the  siRNA  has  no  homology  to  any  known 
mammalian  gene  and  has  been  confirmed  to  enter  RISC.  In  this  experiment  mock 
transfected  cells  were  checked,  but  as  there  was  no  effect  of  control  siRNA  all 
comparisons were made against control siRNA treated cells.  
 
Cells were then stimulated for 5 hours with a combination of forskolin and rolipram (F/R) 
or 8-pCPT-2’-O-Me-cyclic AMP (8Me), a cell permeable cyclic AMP analogue that is 
specific for EPAC, which it activates independently of PKA (Holz et al., 2008). Forskolin 
elevates cyclic AMP levels within the cell by activation of adenylyl cyclase isoforms to 
increase cyclic AMP production within cells (Insel and Ostrom, 2003). Rolipram is a cell 
permeable phosphodiesterase 4 (PDE4) inhibitor, with documented anti-inflammatory and 
anti-depressant properties (Wachtel, 1983; Kehr et al., 1985). As a specific PDE4 inhibitor, 
rolipram prevents breakdown of cyclic  AMP and is preferable in these experiments to 
general  PDE  inhibitors  such  as  isobutyl-methylxanthine  (IBMX)  which  may  give  non-116 
 
specific effects due to its ability to act as an adenosine receptor antagonist (Schultz et al., 
1982).  The  use  of  forskolin  and  rolipram  together  is  a  common  means  of  causing  an 
increase  of  intracellular  cyclic  AMP  levels  through  increased  production  and  reduced 
breakdown and although Gs coupled receptors are present in COS-1 cells, the combination 
of F/R was chosen to maximally activate the system. The proteasome inhibitor MG132 was 
used in these experiments to prevent degradation of SOCS-3 upon synthesis. Cell lysates 
were  prepared  from  stimulated  cells  and  immunoblotted  with  anti-SOCS-3  and  anti-
GAPDH antibodies (Figure 4.2). GAPDH acts as a loading control due to its stable and 
high expression in these cells, making it a useful housekeeping gene (Barber et al., 2005). 
The immunoblot clearly shows that SOCS-3 is induced in control siRNA treated cells, with 
the greatest induction seen in F/R treated cells. Additionally the immunoblots shows that 
treatment with 8Me is sufficient to induce SOCS-3, suggesting a role for EPAC. There is a 
significant reduction in SOCS-3 induction in EPAC1 siRNA treated cells stimulated with 
both 8Me and F/R compared to control siRNA treated cells stimulated with F/R, indicating 
that EPAC1 is required for SOCS-3 induction, as has been previously shown in human 
umbilical vein endothelial cells (HUVECs) and mouse embryonal fibroblasts MEFs (Sands 
et al., 2006; Yarwood et al., 2008).  
 
4.3.2  Induction  of  the  SOCS-3  gene  in  COS1  cells  is  dependent  on  PLCε  -  Having 
confirmed the involvement of EPAC1 in SOCS-3 induction by cyclic AMP in COS1 cells, 
efforts were made to identify the down-stream signalling components in this new pathway. 
Given the reported potential involvement of PLC e as a novel downstream target of cyclic 
AMP and Rap2B (Schmidt et al., 2001), this was considered as a potential starting point. 
Traditionally PLC signalling was thought to occur through two routes of activation- by 
tyrosine kinases via binding of the Src homology 2 (SH2) domain on PLCγ to tyrosine 
autophosphorylation sites found on activated tyrosine kinases, or through activation by G 
protein coupled  receptors that activate Gq proteins, which in turn  causes activation of 
PLCβ  isoforms  mediated  by  its  Gqα  subunits  (Schlessinger,  1997).  However,  the 
identification of 6 PLC isoform families has expanded the range of PLC signalling as each 
isoform has unique requirements for regulation (Harden and Sondek, 2006). Recent studies 
have  indicated  an  interaction  between  one  such  PLC  isoform,  PLCe,  with  EPAC, 
demonstrating that this interaction is involved in the b-adrenergic receptor stimulation of 
Ca
2+-induced Ca
2+ release (CICR) in cardiac myocytes (Oestreich et al., 2009), and that in 
HEK293 cells the activation of PLCε, via the GTPase Rap2B, occurs through elevations in 
intracellular cyclic AMP that stimulates EPAC (Schmidt et al., 2001). This link between  117 
 
Figure 4.2  
 
 
 
Figure 4.2 EPAC is necessary for SOCS-3 induction in COS1 cells.  
 
COS1 cells were transfected with control siRNA or EPAC1 siRNA using Lipofectamine 
2000 according to the manufacturer’s instructions. Cells were then incubated for 5 hours 
with MG132 and either 10mM F/R or 50mM 8Me. Cell lysates were immunoblotted with 
EPAC1, SOCS-3 or GAPDH specific antibodies. Densitometry was carried out and the 
values plotted on a histogram with control siRNA treated F/R stimulated cells treated as 
100% and all other values expressed relative to this. The blots show a clear knockdown of 
EPAC in cells treated with the EPAC-specific siRNA. Densitometry was carried out on 
immunoblots  from  three  separate  experiments  and  the  results  plotted  as  means  on  the 
graph with significant differences between SOCS-3 levels in EPAC specific siRNA treated 
cells  compared  to  control  siRNA  treated  cells,  indicated  by  *  =  p<0.05  against  F/R 
stimulation in control siRNA cells. 118 
 
PLC signalling and EPAC raises the possibility of a role for PLCε in the EPAC mediated 
SOCS-3 induction pathway.    
 
To investigate an involvement of PLC isoforms downstream of EPAC1, endogenous PLC 
activity  in  COS1  cells  was  inhibited  using  U73122,  an  aminosteroid  that  specifically 
inhibits  PLC,  at  10 M  and  50 M.  Although  the  precise  mechanisms  of  action  of  this 
inhibitor are unknown, it has been shown to inhibit PLC in numerous cell types (Muto et 
al.,  1997).  While  little  is  known  of  its  actions  on  PLCε  itself,  U73122  inhibits  the 
phosphatidylinositol-specific  PLC  isoform  family,  of  which  PLCε  is  a  member.  The 
inactive analogue U73343 was used as a negative control at the same concentrations of 
U73122. COS1 cells were treated with these PLC inhibitors in the presence and absence of 
F/R for five hours. Cells were then harvested and immunoblotting carried out using anti-
SOCS-3 and anti-GAPDH antibodies (Figure 4.3). Immunoblots demonstrated that there 
was a clear reduction in SOCS-3 induction by F/R in cells treated with 50 M U73122 
resulting in a reduction of SOCS-3 expression by approximately 90%, in comparison to 
both the untreated and negative control treated cells (Figure 4.3). As U73122 appears to 
block SOCS-3 induction, this indicates a potential role for one or more PLC isoforms in 
SOCS-3 induction by cyclic AMP in these cells.  
 
To further confirm a role for PLC in SOCS-3 induction and the role of PLCε in particular, 
COS1  cells  were  treated  with  various  concentrations  of  PLCε-specific  siRNA 
(CAGGGTCTTGCCAGTCGACTA,  Qiagen)  (Figure  4.4a)  and  non-targeting  siRNA 
(Qiagen) as a specificity control, in the presence and absence of F/R (Figure 4.4b). PLCε 
siRNA treatment clearly reduced PLCε expression in the cells and inhibited induction of 
SOCS-3  when  stimulated  with  F/R.  This  suggests  that  PLCε  is  required  for  SOCS-3 
induction by cyclic AMP in COS1 cells. To determine whether PLCε is involved in SOCS-
3 induction by EPAC1, cells were treated with PLCε siRNA as above, in the presence of 
8Me, F/R or PMA, a phorbol ester which activates conventional and novel PKC isoforms 
(Figure 4.4c). 200nM of PLCε siRNA was chosen for this experiment as this concentration 
was shown in the previous experiments to be sufficient to knockdown PLCε expression in 
COS-1 cells. While 8Me, F/R and PMA all induce SOCS-3 in control cells, knockdown of 
PLCε expression clearly inhibited the ability of 8Me and F/R to induce SOCS-3 in these 
cells. This indicates that PLCε is found downstream of EPAC1 and that therefore PLCε is 
located  within  the  EPAC1  induced  SOCS-3  induction  pathway  in  COS1  cells.  As 
expected, SOCS-3 levels induced by PMA shows little reduction in cells treated with  119 
 
Figure 4.3 
 
 
 
Figure 4.3 Effect of Phospholipase C inhibitors on SOCS-3 induction  
 
COS1 cells were stimulated for 5 hours with 6 M of the proteosome inhibitor MG132, and  
10mM F/R in the presence or absence of 10mM or 50 mM of the PLC inhibitor U73122 or 
10mM  or  50  mM    of  the  inactive  control  inhibitor  U73343.  Cell  lysates  were  then 
immunoblotted with SOCS-3 and GAPDH specific antibodies. The SOCS-3 blot shows 
endogenous SOCS-3 induction in cells not stimulated with F/R, which is slightly reduced 
by  the  presence  of  U73122  at  both  concentrations.  Densitometry  was  carried  out  on 
immunoblots from three separate experiments and normalised to DMSO, F/R treated cells. 
The results were then plotted, with significant differences, relative to non-stimulated cells, 
indicated by ** = p<0.01 and *** = p<0.001.  
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 Figure 4.4 
 
 
 
Figure 4.4 Effect of Phospholipase C epsilon siRNA on SOCS-3 induction 
 
a)  COS1  cells  were  transfected  with  control  siRNA  or  PLCε  specific  siRNA  using 
Lipofectamine 2000 according to the manufacturer’s instructions at 200, 300 and 400 nM.  
Cells  were  harvested  and  lysates  immunoblotted  with  PLCe  and  GAPDH  specific 
antibodies. The PLCε blot shows a clear knockdown of PLCε in COS1 cells, with the 
300nm and 400nm concentrations showing the greatest levels of knockdown.  
 
b)  COS1  cells  were  transfected  with  control  siRNA  or  PLCε  specific  siRNA  using 
Lipofectamine 2000 according to the manufacturer’s instructions at 200, 300 and 400nm. 
Cells were then incubated for 5 hours with 6 M MG132, in the presence or absence of 
10mM  F/R.  Cell  lysates  were  then  immunoblotted  with  SOCS-3  and  GAPDH  specific 
antibodies. Cells treated with PLCε specific siRNA show almost no SOCS-3 induction in 
cells in which F/R is absent, but in cells stimulated with F/R there is a clear reduction in 
the levels of SOCS-3, at all 3 concentrations of PLCε siRNA. 
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Figure 4.4 continued. 
 
   
 
 
c)  COS1 cells were transfected with 200nM of control siRNA or PLCε specific siRNA using 
Lipofectamine  2000  according  to  the  manufacturer’s  instructions.  Cells  were  then 
stimulated with either 10mM F/R, 50mM 8-pCPT-2’-O-Me-cyclic AMP (8Me) or 10mM 
PMA for 5 hours. Cell lysates were then immunoblotted with either SOCS-3 or GAPDH 
specific antibodies. In cells treated with the control siRNA, SOCS-3 is induced by 8Me, 
F/R and PMA, with F/R and PMA giving the highest levels. In cells treated with the PLCε 
siRNA, SOCS-3 induction by 8Me and F/R is clearly reduced. Densitometry was carried 
out on immunoblots from three separate experiments and normalised to DMSO, control 
siRNA treated cells. The results were then plotted, with significant differences, relative to 
non-stimulated cells, indicated by * = p<0.05 and ** = p<0.01.  122 
 
 
PLCε siRNA as PKC activation occurs downstream of PLC. However the reduction in 
SOCS-3  induction  in  response  to  PLCε  knockdown  suggests  a  role  for  downstream 
effectors of PLC, such as PKC isoforms in the SOCS-3 signalling pathway. 
 
4.3.3 Involvement of PKC isoforms in SOCS-3 induction - The actions of PLC isoforms 
in  cells  is  well  documented.  Hydrolysis  of  PIP2  results  in  cleavage  into  the  second 
messengers  IP3  and  diacylglycerol  (DAG).  DAG  production  causes  activation  of  PKC 
isoforms, while IP3 production causes mobilisation of Ca
2+ by binding to IP3 receptors on 
endoplasmic and sarcoplasmic reticulum. These IP3 receptors control the influx of internal 
Ca
2+ stores through the opening and closing of calcium channels on the membranes of the 
organelles (Mikoshiba, 2007). Having established a potential role for a PLC isoform in the 
SOCS-3 induction pathway, the potential roles of PLC products on the induction of the 
SOCS-3 by cyclic AMP and EPAC1 was investigated in COS1 cells.  
 
Firstly,  the  involvement  of  Ca
2+  was  tested  using  a  cell-permeable  calcium  chelator, 
BAPTA-AM  (1,2-bis-(o-aminophenoxy)-ethane-N,N,N’,N’-tetraacetic  acid, 
tetracetoxymethyl ester) that acts as an effective intracellular chelator of cytosolic calcium. 
COS1  cells  were  stimulated  with  various  concentrations  of  8Me  (Figure  4.5a)  or  F/R 
(Figure 4.5b) in the presence or absence of this chelator to test whether the removal of 
endogenous Ca
2+ levels affected SOCS-3 expression, therefore determining whether the 
presence  of  Ca
2+  was  required  for  SOCS-3  induction.  Cell  lysates  were  prepared  and 
separated by SDS-PAGE and immunoblotted with SOCS-3 or GAPDH specific antibodies. 
These immunoblots clearly show an increase in SOCS-3 induction upon stimulation with 
either  8Me  or  F/R  and  a  significant  reduction  in  both  stimulations  in  the  presence  of 
BAPTA-AM. From these results, it appears that endogenous intracellular Ca
2+ is required 
for SOCS-3 induction by cyclic AMP and EPAC1 in COS1 cells. To determine the effects 
of the other PLC product DAG, a cell permeable DAG analogue, 1, 2-diaoctanoyl-sn-
glycerol (OAG) that activates PKC was used at varying concentrations to test its ability to 
stimulate SOCS-3 in COS1 cells. Cells were incubated for 5 hours with either F/R or OAG 
in the presence or absence of BAPTA-AM. Cell lysates were immunoblotted with SOCS-3 
or  GAPDH  antibodies  (Figure  4.5c).  The  immunoblot  shows  that  OAG  treatment  is 
sufficient to induce SOCS-3 expression, while co-stimulation with BAPTA-AM results in 
an ablation of this induction. This suggests that OAG action requires the presence of Ca
2+, 
indicating that DAG production in COS1 cells is sufficient for Ca
2+ dependent induction of  123 
 
Figure 4.5 
 
 
Figure  4.5  Calcium  is  required  for  both  EPAC  and  DAG  stimulated  SOCS-3 
induction in COS1 cells.  
 
a)   Effect of the presence of calcium on EPAC stimulated SOCS-3 induction.  
COS1 cells were stimulated with 8Me at five concentrations ranging from 0.1 M to 10 M, 
in the presence or absence of the calcium chelator BAPTA-AM (10mM) for 5 hours. Cell 
lysates were then immunoblotted with SOCS-3 or GAPDH specific antibodies. The blots 
show that chelation of calcium prevents SOCS-3 induction in response to 8Me. Although 
untreated control cells were omitted from this experiment, no difference between 0 and 
0.1 M 8Me was observed in other experiments.  
 
b)  Effect of presence of calcium on F/R stimulated SOCS-3 induction. 
COS1 cells were stimulated for 5 hours with 10mM F/R in the presence or absence of 
10 M BAPTA-AM. Cells lysates were immunoblotted with SOCS-3 or GAPDH specific 
antibodies. The blots indicate that the presence of  BAPTA-AM is sufficient to reduce 
SOCS-3 induction by F/R. 124 
 
Figure 4.5 continued. 
 
 
 
c)  Effect of presence of calcium and OAG on SOCS-3 induction. 
COS1 cells were stimulated for 5 hours with either 10mM F/R, or 10, 50 or 100 M of the 
cell permeable DAG analogue OAG in the presence or absence of 10mM BAPTA-AM. 
Cell  lysates  were  then  immunoblotted  with  SOCS-3  or  GAPDH  specific  antibodies. 
Immunoblots reveal that expression of SOCS-3 in response to OAG stimulation is ablated 
by the presence of BAPTA-AM.  
 
d)  Densitometric  values  were  obtained  from  figures  4.4  a-c,  and  combined  to  plot  as  a 
histogram, with control cells pre-treated with DMSO and then stimulated with DMSO 
expressed as 100% and all other values expressed relative to this.                                   125 
 
SOCS-3. This implies a role for downstream signalling of PLC in the SOCS-3 regulatory 
pathway. 
 
The main intracellular targets for DAG and Ca
2+ in cells are the PKC family of signalling 
proteins. A number of PKC isoforms are activated by the products of PLC activation. 
Conventional PKC (α, β and γ) activation requires both DAG and Ca
2+, while novel PKC 
(δ, ε, η and θ) activation requires DAG but not Ca
2+. Atypical PKCs (ζ, ι and λ) require 
neither (Parker and Murray-Rust, 2004). The above results indicate a potential role for 
either conventional or novel PKCs in SOCS-3 induction as it appears their activators DAG 
and  Ca
2+  are  required  for  SOCS-3  induction.  The  involvement  of  PKC  in  SOCS-3 
induction was therefore investigated by stimulating COS1 cells with 8Me, F/R or PMA, a 
cell permeable activator of PKC, in the presence and absence of 50 M  cell permeable 
PKC inhibitors Ro 31-7549 or GF 109203X (GFX). Ro-31-7549 acts on the ATP binding 
site of PKC, making it a selective PKC inhibitor (Wilkinson et al., 1993) while GFX is 
also believed to interact with the ATP binding site, acting as a competitive inhibitor of 
ATP and making it a potent selective PKC inhibitor (Toullec et al., 1991). Cells were then 
harvested and immunoblotting carried out using anti-SOCS-3 and anti-GAPDH antibodies 
(Figure 4.6). Results demonstrated that PMA is sufficient to induce expression of SOCS-3. 
SOCS-3 induction is clearly inhibited in cells stimulated with 8Me, F/R and PMA and 
treated  with  Ro  31-7549  or  GFX,  while  stimulated  cells  absent  of  inhibitor  treatment 
display SOCS-3 induction at varying levels, with F/R showing the greatest induction. GFX 
inhibits SOCS-3 induction in cells stimulated with 8Me and PMA, and significantly lowers 
SOCS-3 induction in F/R-stimulated cells, while Ro 31-7549 completely inhibits SOCS-3 
induction  with  all  stimulations.  As  the  PKC  inhibitors  block  SOCS-3  induction,  this 
suggests that one or more PKC isoforms are required for SOCS-3 induction by cyclic 
AMP in COS1 cells. 
 
To further investigate the role of PKC isoforms in SOCS-3 induction by EPAC in COS1 
cells,  PKC  down-regulation  was  achieved  using  prolonged  PMA  stimulation.  Chronic 
stimulation with PMA results in down-regulation of conventional and novel PKC isoforms, 
leading to both a loss of responsiveness to PMA stimulation as well as a loss of PKC 
activity in the cells (Blumberg, 1988). This allows investigation into the requirement of 
activity of PKC isoforms on SOCS-3 induction. Cells were chronically stimulated with 
PMA  for  48  hours  before  further  stimulation  with  8Me,  F/R  or  PMA  for  5  hours. 
Immunoblotting  using  anti-panPKC,  anti-SOCS-3  and  anti-GAPDH  antibodies  (Figure 126 
 
 Figure 4.6 
 
Figure 4.6 Effect of PKC inhibitors on SOCS-3 induction by cAMP 
COS1 cells were stimulated for 5 hours with 6 M MG132 plus DMSO, 50mM 8Me, 10mM 
F/R, or 10mM PMA in the presence or absence of the PKC inhibitors 50mM Ro-31-7549 
(Ro) or 50mM GF-109203X (GFX). Cell lysates were immunoblotted with SOCS-3 or 
GAPDH specific antibodies. The blot shows that Ro and GFX inhibit SOCS-3 induction in 
response to PMA and F/R stimulation. Densitometry was carried out and the values plotted 
on a histogram with DMSO pre-treated treated F/R stimulated cells treated as 100% and all 
other values expressed relative to this. Significant differences relative to non-stimulated 
are indicated by * = p<0.05 and *** = p<0.001. 127 
 
4.7) showed that the prolonged stimulation by PMA ablated PKC levels and inhibited the 
ability  of  8Me,  F/R  and  PMA  to  induce  SOCS-3.  It  is  important  to  note  that  chronic 
stimulation with PMA may have other consequences besides the down-regulation of PKC 
and that down-regulation of PKC itself for that length of time would likely affect the health 
of  the  cells.  However,  the  reduction  in  SOCS-3  expression  seen  in  these  results  does 
provide  another  piece  of  evidence  that  PKC  isoforms  are  involved  in the  induction  of 
SOCS-3 by EPAC1 in COS1 cells and that due to the ability of PMA to influence this, the 
isoforms involved are likely to be conventional or novel PKCs.   
 
4.3.4 The role of PKC isoforms α and δ in SOCS-3 induction by EPAC1 in COS1 cells - 
As not all PKC isoforms are found in every cell type I aimed to identify the particular PKC 
isoforms that are involved in SOCS-3 induction in COS1 cells. Firstly, cell lysates from 
COS1,  HeLa  and  Jurkat  cells  were  separated  by  SDS-PAGE  and  immunoblotted  with 
panPKC,  RACK1  and  a  range  of  PKC  isoform  specific  antibodies  (Figure  4.8).  The 
immunoblots clearly show the presence of PKC isoforms α, δ, ι and λ in COS1 cells. Cells 
were also screened for PKCg or PKCh but expression of these isoforms were not found in 
any of the cell types investigated. 
 
Both the PKC down regulation (Figure 4.7) and Ca
2+ and DAG requirement (Figure 4.5) 
experiments above imply that conventional or novel PKC isoforms are involved in SOCS-
3 induction downstream of EPAC1. The isoform screen above (Figure 4.8) implicates the 
involvement of either, or both, PKCα and PKCd. Of these two isoforms, PKCα is known 
to be abundantly found in COS1 cells and because of this, knockdown of this isoform 
using  siRNA  was  carried  out  to  test  the  isoform’s  involvement  in  SOCS-3  induction. 
COS1  cells  were  transfected  with  either  PKCα  specific 
(CGCAGTGGAATGAGTCCTTTA,  Qiagen)  or  non-targeting  control  siRNA  (Qiagen) 
and then stimulated in the presence and absence of 8Me, F/R or PMA. Cell lysates were 
then immunoblotted with anti-PKCα, anti-SOCS-3 or anti-GAPDH antibodies (Figure 4.9) 
The immunoblots show that siRNA-mediated knockdown of PKCα caused a significant 
depletion of PKCα and that there is a significant reduction in SOCS-3 induction upon 
stimulation with both 8Me and F/R, which supports the hypothesis that PKCα is involved 
in SOCS-3 induction downstream of EPAC in these cells.  
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Figure 4.7 
 
Figure 4.7 Effect of down-regulation of PKC expression on SOCS-3 induction 
COS1 cells were stimulated with 1mM PMA for 48 hours to down-regulate endogenous 
PKC  expression.  Cells  were  then  stimulated  for  5  hours  with  either  50mM  8Me,  a 
combination of either 10mM or 50mM F/R, or 10mM PMA in the presence of 6 M MG132. 
Cell  lysates  were  then  immunoblotted  with  SOCS-3,  panPKC  or  GAPDH  specific 
antibodies. The blots show that downregulation of PMA ablates SOCS-3 expression in 
response  to  8Me  and  PMA  and  significantly  reduces  SOCS-3  induction  by  F/R. 
Densitometric values were obtained from immunoblots from three separate experiments 
and plotted as a histogram with cells pre-treated with DMSO and stimulated with F/R 
treated as 100% and all other values expressed relative to this.. Significant increases in 
SOCS-3 induction relative to control cells are indicated by # = p<0.05 and ### = p<0.001, 
and significant inhibition of SOCS-3 induction in cells pre-treated with PMA are indicated 
by * = p<0.05 and *** = p<0.001. 129 
 
Figure 4.8 
 
Figure 4.8 Screen of COS1 cells for PKC isoforms. 
Equal amounts of protein from COS1, HeLa and Jurkat cell extracts were separated by 
SDS-PAGE  and  immunoblotted  with  panPKC,  RACK1  or  PKC  isoform-specific 
antibodies. The blot for PKCα indicated this isoform’s presence in COS1 cells, but not in 
HeLa or Jurkat, while probing for PKCβ showed that it was not present in either COS1 or 
HeLa cells, but was found in Jurkat cells. Of the Novel PKCs tested, PKCδ was found to 
be present in COS1 cells, but not HeLa or Jurkat, PKCε was identified in HeLa cells, but 
not in either COS1 or Jurkat, and PKCθ was only shown to be in found in Jurkat cells. The 
blot for PKCι shows it to be present in all three cell types tested, while PKCλ was neither 
in HeLa nor Jurkat, but present in COS1 cells. 
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Figure 4.9 The role of PKCa a a a in SOCS-3 induction  
 
COS1  cells  were  transfected  with  control  siRNA  or  PKCa  specific  siRNA  using 
Lipofectamine  2000  according  to  the  manufacturer’s  instructions.  Cells  were  then 
stimulated for 5 hours with 50mM 8Me, 10mM F/R, or 10mM PMA in the presence of 6 M 
MG132. Cell lysates were then immunoblotted with PKCα, SOCS-3 or GAPDH specific 
antibodies.  Knockdown  of  PKCα  by  specific  siRNA  results  in  ablation  of  SOCS-3 
expression by 8Me stimulation, and significant reduction of SOCS-3 induction by PMA 
stimulation and, to a slightly lesser extent by F/R. Densitometric values were obtained for 
the SOCS-3 immunoblots and were plotted with control siRNA treated, F/R stimulated as 
100%  and  all  other  values  relative  to  this.  Significant  differences  between  SOCS-3 
expression in PKCα siRNA treated cells and control siRNA treated cells are indicated by * 
= p<0/05 and ** = p<0.01. Results are representative of an experiment carried out on three 
separate occasions. 
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Figure 4.9 
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Although there is a significant reduction in stimulated SOCS-3 expression in cells treated 
with PKCα siRNA, the ablation was not complete. While there may be sufficient PKCα 
remaining following siRNA knockdown to cause some induction of SOCS-3 it is also 
possible  that  an  additional  PKC  isoform  activation  or  presence  may  be  necessary  for 
complete SOCS-3 induction by cyclic AMP. As PKCδ was the only other isoform shown 
to  be  present  in  COS1  cells  (Figure  4.8)  that  could  potentially  be  activated  or  down-
regulated  by  PMA,  or  products  of  PLCe activity,  a  transfection  with  control  siRNA, 
PKCα-specific  siRNA,  PKCδ-specific  siRNA  (AACTCTACCGTGCCACGTTTT, 
Qiagen) and a combination of PKCα- and PKCδ-specific siRNA was carried out. Cells 
were once again stimulated with 8Me, F/R or PMA and cell lysates were immunoblotted 
with SOCS-3, GAPDH, PKCα, PKCδ and phospho-ERK specific antibodies (Figure 4.10). 
Specificity of the PKC isoform siRNAs can be seen by the ability of PKCα siRNA to 
knockdown PKCα levels but not PKCδ and vice versa. ERK activity was measured since it 
has  been  previously  shown  that  ERK  is  activated  by  PKCa  (Kolch  et  al.,  1993)  and 
therefore serves as a further control for the effects of PKCa knockdown. Results show a 
similar level of PKCα expression upon F/R and PMA stimulation in control cells as seen in 
the previous experiment, while the PKCδ signal in response to PMA is low. Although 
MG132 is present in the experiment to prevent protein degradation it is possible that the 
concentration used is sufficient to prevent degradation of the other proteins investigated 
but  not  PKCδ  or  that  the  time  point  used  for  this  experiment  is  incompatible  with 
visualisation  of  PKCδ  activation  by  PMA  in  whole  cell  lysates.  Results  indicate  that 
knockdown of PKCδ shows a similar reduction in SOCS-3 induction to cells treated with 
PKCα  siRNA,  with  reductions  of  SOCS-3  expression  of  approximately  40%  and  45% 
respectively in F/R stimulated cells, and approximately 60% for both in PMA stimulated 
cells. However, in cells treated with a combination of these siRNAs, an almost complete 
inhibition  of  SOCS-3  induction  upon  F/R  and  PMA  stimulation  can  be  seen  with 
approximate reductions of SOCS-3 expression by 80% in F/R stimulated cells and 90% in 
PMA stimulated cells. These results indicate that both PKCα and PKCδ are required for 
SOCS-3 induction by cyclic AMP in COS1 cells. 
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Figure 4.10 The role of PKCa a a a and PKCd d d d in SOCS-3 induction  
 
COS1 cells were transfected with non-targeting control siRNA, PKCa-specific siRNA, 
PKCd-specific  siRNA  or  a  combination  of  PKCa-  and  PKCd-specific  siRNA  using 
Lipofectamine  2000  according  to  the  manufacturer’s  instructions.  Cells  were  then 
stimulated for 5 hours with 10mM F/R, or 10mM PMA in the presence of 6 M MG132. 
Cell lysates were then immunoblotted with SOCS-3, GAPDH, PKCa and PKCd specific 
antibodies. The PKCα blot shows high levels of PKCα expression in cells treated with 
control siRNA and also in cells treated with PKCδ specific siRNA. The blots show that 
treatment with PKCα siRNA shows a reduction of SOCS-3 induction with both PMA and 
F/R stimulations, as does treatment with PKCδ siRNA. Cells treated with a combination of 
PKCα and PKCδ siRNA show an almost complete ablation of SOCS-3 expression upon 
PMA stimulation, and a significant reduction of SOCS-3 induction by F/R stimulation. 
SOCS-3  immunoblots  from  three  separate  experiments  were  quantified  and  the 
densitometric units plotted with control siRNA treated, F/R stimulated cells taken as 100% 
and all other values expressed relative to this. Significant differences between SOCS-3 
expression  in  specific  siRNA  treated  cells  and  cells  treated  with  control  siRNA  are 
indicated by ** = p<0/01 and *** = p<0.001. 
 134 
 
Figure 4.10 
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4.4 DISCUSSION 
 
The  role  of  EPAC,  and  its  downstream  effects  are  part  of  a  novel  pathway  by  which 
SOCS-3 expression is regulated, thus mediating IL-6 signalling. The induction of SOCS-3 
by  cyclic AMP  elevations occurs independent of PKA, as  F/R stimulated induction of 
SOCS-3 has previously been shown to be unaffected by the PKA inhibitor H-89 (Sands et 
al., 2006; Yarwood et al., 2008). The results outlined in this chapter reiterate that EPAC1 
is involved in the control of SOCS-3 induction in COS1 cells, as previously shown in 
literature (Sands et al., 2006; Yarwood et al., 2008), as well as expounding on aspects of 
signalling downstream of EPAC1 that are involved in this pathway of SOCS-3 induction. 
Although  the  involvement  of  EPAC1  had  been  established  within  this  pathway,  the 
mechanisms  through  which  EPAC  induces  SOCS-3  expression  and  therefore  mediates 
control of IL-6 signalling were largely unknown.  
 
While it was possible for there to be other downstream effects of EPAC involved in SOCS-
3 induction, due to EPACs interaction with other Ras family members, phospholipase D, 
MAP kinases and PKB/Akt (Cheng et al., 2008; Roscioni et al., 2008), published data 
from other laboratories had indicated a connection between EPAC and PLCε through the 
small GTPase Rap2B (Schmidt et al., 2001; Bunney and Katan, 2006; Oestreich et al., 
2009) and thus this provided a starting point for investigations into what aspects of EPAC 
activation downstream might be involved in control of SOCS-3 expression. The use of the 
general PLC inhibitor U73122 to block induction of SOCS-3 by elevation of cyclic AMP 
levels (Figure 4.3) shows not only that one or more PLC isoforms are involved, but that 
their presence is essential to ensure SOCS-3 induction via this pathway. Use of PLCε 
specific siRNA confirmed this necessary role for PLCε in SOCS-3 induction, not only via 
increase in intracellular cyclic AMP by F/R stimulations but by EPAC specific induction 
via  stimulations  with  8Me.  This  places  PLCε  directly  downstream  of  EPAC1  in  this 
pathway opening up the possibility that PLCε could therefore act as a therapeutic target to 
stimulate the induction of SOCS-3. Further experimentation with over expression of PLCε 
in cells would determine whether an increase in PLCε concentration would boost SOCS-3 
induction, and therefore whether the addition of PLCε could be used to increase SOCS-3 
expression in cells. To date, little else is known about the relationship between PLCε and 
EPAC, nor on the effect of PLCε on proteins downstream of EPAC.  
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Although no PLC isoform screen was carried out to determine which PLC isoforms are 
present in COS1 cells, the degree to which knockdown of PLCε by specific siRNA leaves 
no doubt as to the requirement of this isoform for SOCS-3 induction. However, this does 
not rule out the possibility of involvement of other PLC isoforms in SOCS-3 induction in 
COS1 cells and further screening may determine whether or not other isoforms may have a 
role in this pathway. However, it is important to note that as PLCε is the only PLC isoform 
that contains a RA domain as well as a CDC25 homology domain that functions as a GEF 
for Rap1 but not other Ras family members (Jin et al., 2001). This unique ability among 
PLC isoforms to interact with Rap1 strongly suggests that PLCε alone is the PLC isoform 
acting  in  this  pathway.  The  well-documented  downstream  effects  of  PLC  activation, 
namely the production of DAG and the increase in intracellular Ca
2+ via IP3, are part of the 
classic PLC signalling  pathway, and investigation into the effects of these on SOCS-3 
induction was the next logical step. Use of the potent calcium chelator, BAPTA-AM was 
used to remove Ca
2+ from COS1 cells to determine the importance of calcium in SOCS-3 
induction. It was found to be essential in both cyclic AMP and EPAC induced SOCS-3 
expression.  Further  investigation  into  the  effects  of  PLC  activation  products  on  this 
pathway using the DAG analogue OAG indicated the presence of DAG was also required 
for SOCS-3 induction in COS1 cells. Besides its activation of PLCε, EPAC has also been 
shown  to  modulate  intracellular  calcium  release  in  cardiac  myocytes  via  calcium-
calmodulin-dependent-protein kinase (Pereira et al., 2007). Additionally, EPAC has been 
linked to calcium mobilisation via its ability to directly bind and activate R-Ras, which has 
been shown to have a role in calcium handling by activating PLCδ (Lopez de Jesus et al., 
2006), and by directly activating SERCA (sarcoplasmic reticulum Ca
2+ ATPase) and the 
ryanodine II receptor (Schmidt et al., 2007).  
 
A group of proteins that require both DAG and Ca
2+ are the conventional isoforms of PKC. 
Additionally, the novel PKC isoforms are activated by DAG and so determination as to 
what, if any, involvement of these proteins followed. The use of the PKC inhibitors GFX 
and  Ro  provided  a  way  to  initially  investigate  the  potential  role  of  PKCs  in  SOCS-3 
induction.  Cells  were  stimulated  with  not  only  F/R  and  8Me,  which  had  already  been 
shown to induce SOCS-3 expression in COS1 cells via increases in intracellular cyclic 
AMP and through EPAC respectively, but also with PMA, a potent phorbol ester known to 
specifically activate conventional and novel PKC isoforms by mimicking DAG. The level 
of  induction  of  SOCS-3  upon  PMA  stimulation  in  these  cells  was  almost  as  high  as 
stimulation  by  F/R,  indicating  that  activation  of  one  or  more  PKC  isoforms  from  the 137 
 
conventional  or  novel  families  was  able  to  induce  SOCS-3  expression  in  COS1  cells. 
Treatment  of  the  cells  with  specific  PKC  inhibitors  Ro-31-7549  and  GFX  completely 
ablated SOCS-3 expression by all stimulations, with the exception of inhibition by GFX on 
F/R stimulation, although the SOCS-3 levels were significantly reduced. This inhibition of 
SOCS-3  induction  by  these  inhibitors  indicates  the  requirement  of  one  or  more 
conventional or novel PKC isoforms for SOCS-3 induction.  It is important to note that the 
concentrations of Ro-31-7549 and GFX required to inhibit PKC in these cells are high. It 
has  been  suggested  that  PKC  isoforms  bound  to  AKAPs  display  insensitivity  to  PKC 
inhibitors (Dr. John Scott, personal communication). Therefore this requirement of higher 
than  normal  levels  of  PKC  inhibitors  suggests  a  potential  compartmentalised  PKC 
response with the isoforms anchored at specific locations by PKC-binding AKAPs (Faux et 
al., 1999).  
 
Confirmation of these findings was carried out by down-regulation of PKC due to chronic 
stimulation with PMA. Treatment by all three stimulations used above on cells where PKC 
had been ablated by prolonged exposure to PMA was unable to significantly induce SOCS-
3 expression, further indicating a crucial role of PKC isoforms in this pathway. It was 
therefore  necessary  to  narrow  down  which  isoforms  may  be  involved  in  COS1  cells. 
Screening  for  isoforms  indicated  only  two  possibilities  in  COS1  cells  that  fit  the 
requirements outlined by both the PLC product experiments and by the PMA and PKC 
inhibitor experiments. These isoforms were PKCα and PKCδ.  PKCs are integral within 
cell signalling with each isoform expressing different characteristics, activities and tissue 
distribution.  PKCα  differs  from  the  other  isotypes  as  it  is  found  in  all  tissue  types. 
Additionally, PKCα requires phosphorylation at residues located within its kinase domain 
before activation can occur (Nakashima, 2002). Like other isoforms, PKCα is involved in 
numerous  biological  processes  including  proliferation,  apoptosis,  cell  migration  and 
adhesion, and differentiation (Nakashima, 2002). PKCα has also been linked to erythrocyte 
production (Myklebust et al., 2000). Additionally, PKCα has been implicated in several 
disease states including inflammatory disorders, endothelial cancers whereby an increase 
in PKCα activity has been linked to disruption of tight junction formation between cells, 
allowing foreign molecules such as growth factors to enter cells and cause abnormal cell 
growth (Rosson et al., 1997), and in cardiac hypertrophy where increased PKCα levels 
have been shown to inhibit contractility (Dorn and Force, 2005). PKCδ has been shown to 
be  involved  in  differentiation  and  cell  growth,  and  has  also  been  linked  to  tumour 
development as well as apoptosis (Gschwendt, 1999). This novel PKC isoform is thought 138 
 
to  be  found  compartmentalised  in  cells,  with  research  indicating  association  with 
cytoskeletal  and  nuclear  cell  structures.  Further  investigation  into  possible  interaction 
between these two isoforms and their interaction, would further elucidate the involvement 
of these isoforms in this pathway. Together these results have delineated a section of the 
pathway through which EPAC is able to mediate SOCS-3 induction in COS1 cells.  
 
As both PKC and cyclic AMP can both activate ERK, it is likely that it is involved in 
SOCS-3 induction. This suggests a role for downstream effectors of ERK signalling, such 
as  the  C/EBP  transcription  factors,  in  linking  both  PKC  and  cyclic  AMP  signalling 
pathways to the induction of the SOCS-3 gene. One of these transcription factors, C/EBPβ, 
is known to be activated by ERK and has been recently shown to be required for SOCS-3 
induction mediated by cyclic AMP and PKC (Borland et al., 2009).  
 
Compartmentalisation of cyclic AMP signalling to create temporal and spatial intracellular 
cyclic AMP gradients is controlled by several factors including elevations in cyclic AMP 
production by adenylyl cyclases, degradation by PDEs and the actions of the effectors 
downstream of cyclic AMP (Houslay and Adams, 2003). As previously mentioned, F/R 
stimulated  induction  of  SOCS-3  occurs  independently  of  PKA  (Sands  et  al.,  2006;, 
Yarwood et al., 2008), thus showing a compartmentalised effect of cyclic AMP signalling 
away from classic PKA activity within the cell. As SOCS-3 induction by F/R occurs after 5 
hours stimulation, this also demonstrates a temporal compartmentalisation of cyclic AMP 
signalling. Additionally, the findings from Chapter 3, indicating the ability of PKCα to 
induce PDE4D5 activity, shows the possible control of cyclic AMP gradients within this 
pathway,  with  activation  of  EPAC  signalling  in  response  to  cyclic  AMP  elevation 
activating PKCα which in turn is able to lower cyclic AMP levels through PDE action.  
 
In conclusion, this chapter outlines a novel point of crosstalk between the cyclic AMP and 
PKC signalling pathways. We have shown that EPAC is activated by cyclic AMP and it in 
turn activates PLCε which cleaves PIP2 to form DAG and IP3. The downstream effect of 
IP3 production, increased intracellular calcium, and DAG activate the conventional PKCα, 
while DAG may activate the novel PKCδ. In turn, these PKC isoforms together induce 
SOCS-3 expression in COS1 cells. Conclusively, these results have not only indicated an 
area of cross-talk between cyclic AMP and PKC signalling pathways, but have outlined a 
potentially  useful  pathway  with  which  to  target  and  control  SOCS-3  expression  and 
therefore have an effect on IL-6 signalling. Having identified PLCε, and PKC α and δ as 139 
 
key  points  in  the  EPAC  induced  SOCS-3  pathway,  this  provides  areas  for  potential 
therapeutic targets, as inhibition of these proteins can block SOCS-3 induction as shown, 
while over-expression or the presence of protein mimics may increase SOCS-3 expression 
in COS1 cells, and thus inhibit IL-6 signalling.  
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CHAPTER 5 
 
 
 
Phosphorylation and Activation of Protein Kinase C (PKC) Isoforms by 
Cyclic AMP in COS1 Cells 
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5.1 INTRODUCTION 
 
Evidence is presented in the previous two results chapters that elevation of intracellular 
cyclic  AMP  levels  may  lead  to  the  activation  of  the  conventional  protein  kinase  C 
isoforms, PKCa and PKCd. In the following chapter attempts are made to formally test 
this hypothesis by determining the mechanisms controlling activation and phosphorylation 
of these conventional and novel PKC isoforms, in response to cyclic AMP in COS1 cells.  
 
Control of PKC activity occurs initially via three priming sites which are phosphorylated 
by kinases such as 3-phosphoinositide-dependent
 protein kinase-1 (PDK1) (Parekh et al., 
2000) following ligand binding at the cell membrane. These sites, conserved across all 
PKC isoforms, are Thr505 in the activation loop, Ser643 in the turn motif and Ser662 in 
the hydrophobic motif  (Keranen et al., 1995). Phosphorylation at these sites affords higher 
specific  activity  and  allows  for  autophosphorylation  to  further  control  PKC  isoforms. 
Autophosphorylation of PKC isoforms is an important component of activity control and 
previous  studies  have  shown,  for  example,  that  PKCα  autophosphorylation  is  closely 
linked to its enzymatic activity (Hu and Exton, 2004).  
 
PKCα  possesses  several  autophosphorylation  sites  which  control  important  aspects  of 
PKCα  activity.  Autophosphorylation  of  Thr638  has  been  shown  to  be  critical  for  the 
regulation of the rate of dephosphorylation of PKCα and its inactivation (Bornancin and 
Parker, 1996). This controls the duration of PKCα influence on its downstream effectors, 
allowing temporal regulation of PKCα activity (Garcia-Paramio et al., 1998). Additionally, 
the phosphorylation of Ser657 in this isoform has been shown to control the accumulation 
of  phosphate  at  other  sites,  maintaining  resistance  to  phosphatases  to  prevent  rapid 
dephosphorylation (Bornancin and Parker, 1997). Autophosphorylation at these residues, 
and at Thr497 and Tyr658, have also been linked to thermal stability of the isoform and 
targeting to specific subcellular localisations (Kitatani et al., 2007).  
 
For PKCδ isoforms, autophosphorylation of Ser643 is crucial to the catalytic maturation of 
the isoform (Parekh et al., 2000), and following activation by DAG or PMA PKCδ is also 
able to be autophosphorylated at Ser229, Ser302 and Ser304. The autophosphorylation of 
these sites may play a role in the translocation of PKCδ to plasma and nuclear membranes 
(Durgan et al., 2007). 
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The role of autophosphorylation in PKC subcellular localisation is of particular interest as 
numerous  cellular  processes,  including  differentiation  and  proliferation,  require 
transduction  of  signals  to  specific  intracellular  regions,  and  it  is  thought  that 
autophosphorylation  of  PKC  isoforms  induced  by  differing  stimuli  may  allow  specific 
targeting to these areas (Feng et al., 2000).  
 
PKC signal transduction is also closely  regulated by the subcellular localisation of the 
protein. Upon cell-surface receptor activation, conventional and novel PKC isoforms are 
frequently induced to translocate to cell membranes by their membrane targeting regions, 
the  C1  and  C2  domains  (Goodnight  et  al.,  1995).  PKC  isoforms  are  believed  to  be 
localised to the cytosol where there are held in place by scaffold interactions for example 
via AKAP interaction (Perkins et al., 2001) or as in the  case of PKCε binding to the 
phosphoserine/threonine  binding  protein  14-3-3  (as  reviewed  in  Newton,  2010). 
Conventional PKC isoforms are targeted to the plasma membrane by calcium (as outlined 
in section 1.4.2). Novel PKC isoforms, such as PKCδ, which lack the calcium binding 
residues are activated by interaction at the C1 domain by endogenous lipid cofactors such 
as DAG and ceramide. This interaction not only causes the conformational change that 
removes the pseudosubstrate from the catalytic site, but also promotes PKCδ translocation 
to cell membranes (Steinberg, 2004).   
 
Recent studies have indicated that PKC isoform autophosphorylation may be required for 
prevention of the C2 domain anchoring the protein to lipid membranes (Feng and Hannun, 
1998). The means by which PKC is induced to translocate to the plasma membrane may 
also effect the rate of PKC autophosphorylation (Feng and Hannun, 1998). While calcium 
and  the  DAG  analogue  PMA  induce  a  sustained  association  of  PKC  at  the  plasma 
membrane  before  autophosphorylation,  other  inducers  of  PKC  translocation  to  the 
membrane,  such  as  GPCR  activation  may  cause  a  more  transient  association  to  the 
membrane,  followed  by  a  swift  relocalisation  to  other  subcellular  regions  (Feng  and 
Hannun, 1998). This suggests that different effectors on PKC isoforms are able to elicit 
different rates of PKC activity within the cell, allowing appropriate timing and duration of 
the signal transduction, and providing both localised and temporal compartmentalisation of 
the PKC pathway.  
 
In Chapter 3, a role for PKC was established in the control of activity of the cyclic AMP-
specific  phosphodiesterase  4D5  in  response  to  elevations  in  intracellular  cyclic  AMP 143 
 
following b-adrenoceptor stimulation. In addition, an obligate role for PKCa and PKCd, in 
transducing the induction of the SOCS-3 gene in response to elevations in intracellular 
cyclic AMP levels, was also demonstrated in Chapter 4. The aims of the current chapter 
therefore are to investigate the effect of cyclic AMP on PKC activation and regulation of 
down-stream signalling through the ERK, MAP kinase cascade.  
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5.2 MATERIALS AND METHODS 
 
All Materials and Methods as outlined in Chapter 2 with variations described below.  
 
 
Densitometry and Statistical Analysis 
Non-saturating  exposures  from  multiple  experiments  were  quantified  densitometrically 
using ImageJ software. Densitometric values of PKC levels were usually normalized to the 
expression  of  RACK1  or  GAPDH  protein  levels  in  the  same  sample.  Statistical 
significance was determined using the Student’s two-tailed t-test. 
 145 
 
5.3 RESULTS 
 
5.3.1 Elevation of cyclic AMP in COS cells stimulates autophosphorylation of PKCα - 
To initially investigate the effects of cyclic AMP stimulation on PKC phosphorylation, and 
that of its downstream effectors, we tested the effect of elevated cyclic AMP levels on the 
phosphorylation of PKCα. COS1 cells were stimulated with or without the cyclic AMP-
elevating agents, the adenylyl cyclase agonist forskolin (10mM) and the phosphodiesterase 
4  inhibitor  rolipram  (10mM)  (F/R)    or  the  conventional/novel  PKC-activator,  phorbol 
myristate acetate (PMA; 10mM), over a range of time points between 0 and 960 minutes. 
Cell  lysates  were  then  immunoblotted  for  total  PKCα  protein  or  an  antibody  that 
recognises the Thr638 autophosphorylation site in PKCα (Phospho-PKCα) (Figure 5.1). 
Stimulation with PMA resulted in a reduction in the levels of PKCα and Phospho-PKCα 
after  300  minutes,  while  stimulations  with  (F/R)  showed  similar  levels  of  PKCα  and 
Phospho-PKCα across all time points tested. In this case it appears that preparation of 
whole cell lysates is insufficient to detect the phosphorylation and activation of PKCα in 
COS1 cells and are only suitable for examining the proteolytic reduction in expression of 
PKCα (Schmitz-Peiffer et al., 1996) following PMA stimulation. It is important to note 
that the absence of the proteasome inhibitor MG132, used in experiments in Chapter 4, 
may cause degradation of PKCα following PMA stimulation.  
 
As the immunoblots from lysates did not allow for visualisation of the well documented 
(Feng and Hannun, 1998) translocation of PKCα in response to PMA stimulation, nor for 
any effects F/R may have on differing localisations of PKCα, cells were fractionated by 
high-speed centrifugation to give crude membrane pellets and supernatant fractions which 
were then immunoblotted with total PKCa and Phospho-PKCα antibodies. It was decided 
to try this approach to detect active PKCa since the plasma membrane is the normal site 
for autophosphorylation (Feng et al., 2000). In fact the fractionation technique revealed a 
marked difference in the effects of both stimulants on PKCα phosphorylation between the 
fractions. Following this protocol it was found that stimulation of cells with either F/R or 
PMA provoked a physical translocation of PKCa from the S/N to the pellet fraction, which 
was concomitant with an increase in Phospho-PKCα immunoreactivity in the same fraction 
(Figure 5.2), indicating activation of PKCa in this fraction. To show that the effects of F/R 
and PMA on PKCα activation was due to specific activation of this isoform, general PKC 146 
 
Figure 5.1  
 
 
 
Figure 5.1 Cyclic AMP effects PKCα phosphorylation in COS1 cells  
COS1 cells were stimulated with either 10µM forskolin and rolipram (F/R) or PMA over a 
series  of  time  points  ranging  from  0  to  960  min.  Following  stimulation,  cells  were 
harvested  into  sample  buffer.  Equal  amounts  of  protein  from  whole  cell  lysates  were 
separated by SDS-PAGE and then immunoblotted with PKCα and Phospho-PKCα specific 
antibodies.  Results  are  representative  of  an  experiment  carried  out  on  three  separate 
occasions. 147 
 
Figure 5.2  
 
 
 
Figure 5.2  PKC inhibitors prevent phosphorylation of PKCα in response to cyclic 
AMP elevation  
COS1 cells were treated with the PKC inhibitors Ro-31-7549 or GF109203X (GFX) in the 
presence  or  absence  of  F/R  or  PMA  for  5  hours.  Following  stimulation,  cells  were 
harvested  and  fractionated  by  high-speed  centrifugation  into  pellet  and  supernatant 
fractions. Equal amounts of protein were separated by SDS-PAGE  and immunoblotted 
with Phospho-PKCα specific antibody and RACK1 specific antibody as a loading control. 
The immunoblot shows both F/R and PMA cause Phospho-PKCα expression in COS1 
cells, while treatment with GFX reduces Phospho-PKCα levels in both the supernatant and 
pellet fractions. Results are representative of an experiment carried out on three separate 
occasions. 148 
 
inhibitors Ro-31-7549 and GF109203X (GFX) were added to cells prior to stimulation 
with PMA or F/R. While both F/R and PMA stimulations caused an increase in Phospho-
PKCα  immunoreactivity  in  pellet  fractions,  Phospho-PKCα  expression  was  reduced 
following the addition of either Ro-31-7549 or GFX (Figure 5.2). These results indicate 
that the influence of F/R and PMA on PKCα autophosphorylation is largely confined to the 
plasma  membrane  and  that  elevations  in  cyclic  AMP  levels  not  only  affect  PKCα 
autophosphorylation but also translocation in COS1 cells. The fractionation technique for 
determining PKC activation was therefore used in subsequent experiments. 
 
As this experiment was carried out with stimulations at the 30 minute time point only, the 
effects of F/R and PMA stimulation on PKCα expression and phosphorylation across a 
range of time points was investigated. Cells were stimulated with either F/R or PMA for a 
range of time points between 0 and 300 minutes, fractionated by high-speed centrifugation 
and  immunoblotted  with  PKCα,  Phospho-PKCα  and  RACK1  specific  antibodies,  with 
RACK1  acting  as  a  loading  control.  The  resulting  immunoblots  for  the  pellet  fraction 
(Figure  5.3a)  shows  that  in  response  to  F/R  stimulation,  PKCα  expression  in  the  S/N 
fraction  remains  relatively  constant  until  around  the  300  minute  time  point,  while 
expression of Phospho-PKCα begins to decrease in the S/N fraction and increase in the 
pellet fraction from around the 60 minute time point. The PMA stimulation shows a rise in 
PKCα levels in the pellet fraction, peaking at 60 minutes before falling to below basal 
levels, probably due to activation-coupled proteolysis, as previously described (Schmitz-
Peiffer et al., 1996). The differing effects over time on PKCα autophosphorylation and 
activation in response to F/R or PMA can be clearly seen in the graph, Figure 5.4, where 
PKCα  autophosphorylation  is  expressed  as  a  fold  change.  This  graph  demonstrates  a 
difference  in  temporal  activity  of  PKCα  in  response  to  PMA  and  F/R.  While  PMA 
stimulation, which causes almost immediate translocation of PKCα to the pellet fraction, 
results in a greater fold change in PKCα activation, its influence is immediate and quickly 
diminished, peaking at 60 minutes after stimulation. The rapid signal decay may be a result 
of the absence of MG132 in these experiments, as discussed above, causing degradation of 
PKCα following PMA stimulation. Conversely, F/R stimulation shows a delayed effect on 
PKCα with significant PKCα levels occurring at 300 minutes. This difference in a temporal 
effect  on  PKCα  depending  on  the  stimulant  may  be  an  important  contributor  in  the 
compartmentalised activation of PKCα, whereby the localisation and temporal activation 
of a protein affects its downstream targets and therefore its influence within the cell. 
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Figure 5.3  
 
Figure  5.3  Elevation  in  cyclic  AMP  induces  phosphorylation  of  PKCα  in  the 
supernatant fraction of COS1 cells  
COS1 cells were stimulated with 10mM F/R or PMA at time points ranging from 0 – 300 
min.  Following  stimulation,  cells  were  harvested  and  fractionated  by  high-speed 
centrifugation  into  pellet  and  supernatant  fractions.  Equal  amounts  of  protein  were 
separated by SDS-PAGE and immunoblotted with PKC-α, Phospho-PKCα and RACK1 
specific antibodies. The immunoblot shows an immediate induction of Phospho-PKCα in 
the S/N fraction in response to F/R, while the pellet fraction shows phosphorylation of 
PKCα only at the end of the time course. In response to PMA stimulation, PKCα shows an 
immediate translocation from the S/N to the pellet fraction. Results are representative of an 
experiment carried out on three separate occasions. 
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Figure 5.4  
 
 
 
Figure 5.4 Cyclic AMP levels have a temporal effect of PKCα autophosphorylation  
Densitometric values obtained from three repeats of the previous experiment were plotted 
on a graph, with values expressed as a total fold change of PKCα autophosphorylation. 
The  graph  shows  a  different  temporal  response  of  PKCα  to  PMA  and  F/R,  with  F/R 
displaying a delayed effect on PKCα phosphorylation. Significant differences relative to 
non-stimulated are indicated by ** = p<0.01. 
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5.3.2 Cyclic AMP causes PKCα autophosphorylation via EPAC - Given that PKCa and 
PKCd appear to play a role in SOCS-3 induction in response to EPAC activation in COS1 
cells (Chapter 4), it was decided to determine whether the above effects of cyclic AMP 
elevation  in  response  to  F/R  treatment  on  PKCα  autophosphorylation  occurred  via 
activation of EPAC. In these experiments 8-pCPT-2’0-Me-cyclic AMP (8Me) was used as 
a stimulant on the cells. 8Me is a specific activator of EPAC that, at the concentrations 
used  in  experiments,  does  not  activate  PKA  (Holz  et  al.,  2008).  COS1  cells  were 
stimulated with varying concentrations of 8Me ranging from 0-10mM. Cells were then 
harvested  and  fractionated  by  high-speed  centrifugation  into  pellet  and  supernatant 
fractions  and  immunoblotted  with  Phospho-PKCα  specific  antibody.  The  immunoblot 
(Figure 5.5a) shows an increase in Phospho-PKCα expression in response to increasing 
levels of 8Me starting at 0.3mM, indicating that cyclic AMP is able to act via EPAC to 
induce autophosphorylation of PKCα. 
 
Next, the time course of PKCa autophosphorylation in response to EPAC activation was 
investigated. COS1 cells were stimulated with either 10mM 8Me or 10mM 8-pCPT-cAMP, 
a  non-hydrolysable  cyclic  AMP  analogue  that  activates  both  EPAC  and  cyclic  AMP 
dependent  PKA,  at  various  time  points  ranging  from  0  to  960  min.  Cells  were  then 
harvested  and  fractionated  by  high-speed  centrifugation  into  pellet  and  supernatant 
fractions  and  immunoblotted  for  PKCα,  Phospho-PKCα  and  RACK1.  The  resulting 
immunoblots (Figure 5.5b) show that PKCα translocation to the particulate fraction peaks 
after 30 minutes of 8Me stimulation and 300 minutes of 8-pCPT-cAMP stimulation, while 
Phospho-PKCα  levels  remain  fairly  constant  following  8Me  stimulation  until  the  480 
minute time point where it peaks and then is ablated by 960 minutes (Figure 5.5b). In 
response to 8-pCPT-cAMP stimulation the immunoblot shows a steady rise in Phospho-
PKCα  immunoreactivity  until  480  minutes,  following  which  it  is  also  ablated.  These 
results show that EPAC activation is sufficient to induce rapid, autophosphorylation and 
activation of PKCα in COS1 cells. 
 
To determine that it is EPAC1 and not EPAC2 that is involved in the regulation of PKCα 
activity  in  these  cells,  COS1  and  Rat  Cerebellum  (as  a  positive  control)  lysates  were 
separated by SDS-PAGE and immunoblotted with an EPAC2 specific antibody (Figure 
5.6a).  Immunoblots  demonstrated  that  while  EPAC2  is  enriched  in  samples  of  Rat 
Cerebellum, it is investigate the importance of EPAC1 in this pathway, COS1 cells were 
transfected  with  cDNAs  encoding  either  HA-tagged  PDZ-GEF1,  a  Rap1  guanine 152 
 
Figure 5.5 Cyclic AMP induces PKCα autophosphorylation via EPAC  
 
a) COS1 cells were stimulated with varying  concentrations of 8-pCPT-2’-O-Me-cAMP 
(8Me) ranging from 0-10mM for 5 hours. Cells were then harvested and fractionated by 
high-speed centrifugation into pellet and supernatant fractions. Equal amounts of protein 
from the pellet fractions were separated by SDS-PAGE and immunoblotted with Phospho-
PKCα specific antibody. The immunoblot shows an increase in Phospho-PKCα expression 
in response to increasing levels of 8Me starting at 0.3mM.  
b) COS1 cells were stimulated with 10mM 8Me or 8-pCPT-cAMP at various time points 
ranging  from  0-960  min.  Cells  were  then  harvested  and  fractionated  by  high-speed 
centrifugation into pellet and supernatant fractions and equal amounts of protein from the 
pellet  fractions  were  separated  by  SDS-PAGE.  Immunoblotting  with  PKCα,  Phospho-
PKCα and RACK1 specific antibodies was then carried out. The resulting immunoblots 
show that PKCα expression peaks after 30 min of 8Me stimulation and 300 min of 8-
pCPT-cAMP  stimulation,  while  Phospho-PKCα  levels  remain  fairly  equal  upon  8Me 
stimulation until the 480min time point where it peaks and then is ablated by 960 min. In 
response to 8-pCPT-cAMP stimulation the immunoblot shows a steady rise in expression 
of Phospho-PKCα until 480min, following which it is also ablated. This immunoblot is a 
result of a single experiment carried out.  
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Figure 5.5  
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Figure  5.6  ERK  phosphorylation  by  cyclic  AMP  in  COS1  cells  does  not  involve 
EPAC2 but may involve EPAC1 
 
a) COS1 and Rat Cerebellum lysates were separated by SDS-PAGE and immunoblotted 
with  EPAC2  specific  antibody.  The  immunoblot  demonstrates  that  while  EPAC2  is 
enriched in the Rat Cerebellum, it is not present in COS1 cells.  
b)  COS1  cells  were  transfected  with  HA-tagged  PDZ-GEF1  or  EPAC1  using  DOTAP 
according to the manufacturer’s instructions, and stimulated in the presence or absence of 
10mM  PMA.  Cells  were  harvested  and  lysates  separated  by  SDS-PAGE,  then 
immunoblotted  using  Phospho-ERK,  PDZ-GEF1,  HA  and  GAPDH  specific  antibodies. 
While the PDZ-GEF1 and HA blots show that the transfection is successful, the Phospho-
ERK blots show that ERK phosphorylation occurs in response to 5 hours PMA stimulation 
in mock transfected cells. In PDZ-GEF1 transfected cells Phospho-ERK levels are greatly 
reduced in comparison with mock transfected cells while cells transfected with EPAC1 and 
stimulated with PMA show an increase in ERK phosphorylation above levels shown in 
mock transfected cells.  
 
Results are representative of an experiment carried out on three separate occasions. 
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Figure 5.6  
 
 
 
 
not present in COS1 cells, indicating that any effects of cyclic AMP via EPAC on PKCα 
autophosphorylation and activation are occurring through the EPAC1 isoform.  To further  156 
 
nucleotide exchange factor, or EPAC1 and then stimulated in the presence or absence of 
10mM PMA. Cell lysates were immunoblotted using Phospho-ERK, PDZ-GEF1, HA and 
GAPDH specific antibodies (Figure 5.6b). While the PDZ-GEF1 and HA blots show that 
the  transfection  is  successful,  the  Phospho-ERK  blots  show  that  ERK  phosphorylation 
occurs  in  response  to  PMA  stimulation  in  mock  transfected  cells.  In  PDZ-GEF1 
transfected  cells  Phospho-ERK  levels  are  greatly  reduced  in  comparison  with  mock 
transfected  cells,  while  cells  transfected  with  EPAC1  and  stimulated  with  PMA  show 
significant increase in ERK phosphorylation. These results show that signalling through 
PDZ-GEF1 is not required for ERK phosphorylation in response to PKC activation, and 
may in fact inhibit ERK phosphorylation which is unsurprising considering Rap1 has been 
shown to have both a positive and negative effect on ERK signalling (Stork and Schmitt, 
2003). 
 
5.3.3  Elevation  of  intracellular  cyclic  AMP  levels  in  COS1  cells  does  not  affect 
autophosphorylation  and  activation  of  PKCδ  -  In  the  previous  chapter,  siRNA 
experiments  demonstrated  an  obligatory  role  for  both  PKCα  and  PKCδ  isoforms  in 
mediating cyclic AMP-induced SOCS-3 expression in COS1 cells. Having established that 
cyclic AMP promotes autophosphorylation, and hence activation of PKCα, the effect of 
cyclic  AMP  on  PKCδ  activation  was  next  investigated.  COS1  cells  were  therefore 
transiently transfected with a cDNA encoding PKCδ to boost the low endogenous levels of 
the protein and to allow easier visualisation of PKCδ response to stimulations. Protein 
overexpression is a common technique employed to investigate affects of the protein which 
may normally be difficult to measure. The inclusion of mock transfected cells as a control 
allows for detectable results to be influenced by the overexpression of the protein and not 
by  the  transfection  itself.  Cells  were  then  stimulated  with  F/R  or  PMA  as  previously 
described,  harvested  and  fractioned  by  high-speed  centrifugation  before  being 
immunoblotted with Phospho-PKCδ, ERK and  Phospho-ERK (Thr202/Tyr204) specific 
antibodies (Figure 5.7). The Phospho-PKCδ antibody is known to recognise the Ser643 
autophosphorylation  site.  Immunoblots  demonstrated  that  transfection  with  PKCδ 
increased basal levels of Phospho-PKCδ immunoreactivity in the pellet fraction of COS1 
cells  and  stimulation  with  PMA,  but  not  F/R,  further  enhanced  Phospho-PKCδ 
immunoreactivity in this fraction (Figure 5.7a). Phospho-PKCδ immunoreactivity from the 
supernatant fraction corresponds with activation-coupled translocation to the pellet fraction 
(Figure  5.7b).  Again  F/R  treatment  had  little  effect  on  the  phosphorylation  and 
translocation of PKCδ (Figure 5.7b). To demonstrate that F/R was in fact active in these  157 
 
Figure 5.7  
 
 
Figure 5.7 Cyclic AMP does not induce autophosphorylation of PKCδ 
COS1 cells were transfected with PKCδ using DOTAP according to the manufacturer’s 
instructions. Cells were then stimulated with 10mM F/R or PMA for 5 hours, harvested and 
fractioned  by  high-speed  centrifugation.  Equal  amounts  of  the  pellet  and  supernatant 
fractions were separated by SDS-PAGE and immunoblotted with Phospho-PKCδ, ERK 
and Phospho-ERK specific antibodies. The blots show expression of Phospho-PKCδ in 
response  to  PMA  stimulation,  but  not  in  response  to  F/R  in  the  pellet  fraction.  The 
Phospho-ERK blots show that ERK is phosphorylated by F/R and PMA stimulation in 
untransfected  cells,  while  transfection  with  PKCδ  as  no  effect  on  Phospho-ERK 
expression.  Results  are  representative  of  an  experiment  carried  out  on  three  separate 
occasions. 158 
 
experiments,  supernatant  fractions  were  probed  with  Phospho-ERK  antibodies  which 
demonstrated that transfection with PKCδ and F/R and PMA all caused an increase in ERK 
activation as determined by immunoblotting with Phospho-ERK antibodies (Figure 5.7c). 
These  results  indicate  that  while  overexpression  of  PKCδ  is  sufficient  to  induce 
phosphorylation and activation of the downstream effector, ERK, and that stimulation with 
PMA  produces  an  increase  in  levels  of  Phospho-PKCδ  immunoreactivity  in  the  pellet 
fraction of COS1 cells, elevation of cyclic AMP by F/R appears to have no significant 
influence on PKCδ autophosphorylation and activation in COS1 cells. 
 
5.3.4 Cyclic AMP induced ERK phosphorylation in COS1 cells - As both F/R and PMA 
stimulations caused increases in Phospho-ERK levels in untransfected COS1 cells (Figure 
5.7), that appear to be unrelated to PKCδ activation, we therefore tested an involvement of  
PKCα in this signalling cascade. COS1 cells were stimulated with F/R or PMA at various 
time points ranging from 0 to 960 minutes. Cells were then harvested, fractionated and 
immunoblotted with Phospho-PKCα, RACK1, ERK and Phospho-ERK specific antibodies. 
The  pellet  fraction  (Figure  5.8a)  shows  F/R  induced  Phospho-PKCα  immunoreactivity 
peaking at 300 minutes, coinciding with in increases in Phospho-ERK immunoreactivity in 
the same fraction. PMA stimulation caused a peak of Phospho-PKCα immunoreactivity in 
this fraction at 30 minutes while ERK phosphorylation levels remain steady between 30 
and 300 minutes before peaking at 480 minutes. In the supernatant fraction (Figure 5.8b) 
small increases in Phospho-PKCα levels were observed in response to F/R stimulation, 
with  ERK  phosphorylation  levels  significantly  increased  following  300  minutes  of 
stimulation. However, it is possible that this increase in ERK phosphorylation is a result of 
other effects of cyclic AMP elevation rather than as a direct result due to the long time 
period  between  F/R  stimulation  and  detectable  ERK  phosphorylation.  Long-term 
stimulation with PMA caused activation-coupled translocation of Phospho-PKCα from this 
fraction,  while  Phospho-ERK  levels  were  observed  to  peak  at  30  minutes  stimulation 
before steadily declining. The immunoblots show that ERK phosphorylation in response to 
F/R occurs in a similar fashion to that of PKCα, indicating that phosphorylation of PKCα 
in response to cyclic AMP may lead to localised phosphorylation and activation of its 
downstream effector ERK in COS1 cells.   
 
Finally, the effect of inhibition of PKC on ERK phosphorylation in response to cyclic 
AMP elevation and PMA stimulation was investigated by pre-treatment of COS1 cells in 
the presence or absence of 50mM Ro-31-7549 or 50mM GFX before being stimulated by  159 
 
Figure 5.8 Cyclic AMP induces ERK phosphorylation in COS1 cells 
 
COS1 cells were transfected with 10mM F/R or PMA at various time points ranging from 
0-960  min,  harvested  and  fractionated  by  high-speed  centrifugation  into  pellet  and 
supernatant  fractions.  Equal  amounts  of  protein  from  both  fractions  were  separated  by 
SDS-PAGE and immunoblotted with Phospho-PKCα, RACK1, ERK and Phospho-ERK 
specific antibodies. 
a) The pellet fraction shows F/R induced Phospho-PKCα expression peaking at 300 min, 
which is mimicked in the Phospho-ERK blot. PMA stimulation in this fraction causes a 
peak of Phospho-PKCα expression at 30 min while ERK phosphorylation levels remain 
steady at 30-300min before peaking at 480 min.  
b) The supernatant fraction shows small increases of Phospho-PKCα levels are shown in 
response to the F/R stimulation time course, with ERK phosphorylation levels significantly 
observed  from  300  min  of  stimulation.  Stimulation  with  PMA  shows  an  ablation  of 
Phospho-PKCα in this fraction, while Phospho-ERK levels peak at 30 min stimulation 
before steadily declining. Results are representative of an experiment carried out on three 
separate occasions. 
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Figure 5.8  
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the presence or absence of F/R or PMA. Cell extracts were immunoblotted with ERK and 
Phospho-ERK  specific  antibodies  (Figure  5.9)  to  show  that  F/R  stimulation  alone 
significantly increases Phospho-ERK levels in comparison to unstimulated cells, while the 
addition of Ro-31-7549 or GFX had little effect on this activation. Stimulation with PMA 
alone greatly increased ERK phosphorylation levels which were reduced to near that of the 
unstimulated cells following addition of Ro-31-7549 or GFX. These results indicate that 
while PMA induced phosphorylation of ERK is greatly reduced by the inhibition of PKC, 
the inhibition of PKC does not reduce ERK phosphorylation levels in response to F/R. This 
suggests that although the time-course of ERK activation in response to F/R stimulation is 
compatible to that of PKCα activation, the stimulation of ERK in response to elevations in 
intracellular  cyclic  AMP  occurs  independently  of  EPAC1-activated  PKCα  and  likely 
involves PKA or EPAC1 independent of PKCα. A similar experiment utilising 8Me and 
PKA  inhibitors  such  as  H89,  as  well  as  experimentation  to  determine  via  which  Raf 
isoform ERK phosphorylation occurs would further elucidate this pathway.  
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Figure 5.9 Cyclic AMP induction of ERK phosphorylation can occur independently of 
EPAC1 activated PKCα  
 
COS1 cells were pre-treated in the presence or absence of 50mM Ro-31-7549 or GFX 
before being stimulated by the presence or absence of 10mM F/R or PMA for 5 hours. 
Cells were then harvested and fractionated by high-speed centrifugation into pellet and 
supernatant  fractions.  Equal  amounts  of  protein  from  the  supernatant  fractions  were 
separated  by  SDS-PAGE  and  immunoblotted  with  ERK  and  Phospho-ERK  specific 
antibodies. Densitometry was carried out and the values plotted on a histogram. The blots 
show expression of Phospho-ERK in response to F/R stimulation that is not inhibited by 
the  addition  of  Ro-31-7549  or  GFX.  Densitometric  values  were  obtained  from  the 
Phospho-ERK immunoblots and plotted as a percent of maximum, with significant changes 
in  ERK  phosphorylation  indicated  by  **  =  p<0.01  and  ***  =  p<0.001.  Results  are 
representative of an experiment carried out on three separate occasions. 
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Figure 5.9 
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5.4 DISCUSSION 
 
Autophosphorylation of PKC isoforms has been shown to be important in the regulation of 
enzyme  activity  (Hu  and  Exton,  2004).  It  has  also  been  linked  to  effective 
compartmentalisation of the PKC signalling pathway by both localisation and temporal 
activity, in response to differing stimuli (Kitatani et al., 2007). Such compartmentalisation 
of PKC signal transduction is important in several important cellular processes. Having 
established  a  role  for  PKC  in  the  cyclic  AMP-induced  activation  of  the  cyclic  AMP-
specific phosphodiesterase 4D5, through which levels of cyclic AMP can be regulated, and 
in the induction of the SOCS-3 gene by cyclic AMP, an investigation into the effect of 
cyclic  AMP  levels  on  PKC  isoform  activation  was  important  to  fully  understand  the 
interactions between these two pathways.  
 
Currently, little is known about the role of cyclic AMP in PKC regulation, although its 
affects on PKC appear to be cell specific. In skeletal myoblasts, cyclic AMP has been 
shown to reduce PKC activity (Nishizuka, 1986), and to inhibit PKC activity in human 
platelets (Kroll et al., 1988), while in PC12 cells cyclic AMP has been found to activate 
atypical PKC isoforms (Wooten et al., 1996) and cause translocation of PKCε (Graness et 
al., 1997). Similarly, the effect of cyclic AMP on upstream effectors of PKC, such as 
calcium, appears to differ between cell types, with cyclic AMP inhibiting the hydrolysis of 
PLC to IP3 in neuroblastoma/glioma hybrid cells (Campbell et al., 1990) but increasing 
intracellular calcium levels in other cell lines (Chase and Wong, 1988). In light of this, the 
evidence presented in this chapter may only be representative of the actions of cyclic AMP 
in specifically COS1 cells. 
 
Our  investigations  in  this  chapter  have  identified  a  role  for  cyclic  AMP  in  the 
autophosphorylation and activation of the PKCα isoform, but not PKCd. Results show that 
elevation of cyclic AMP induces PKCα autophosphorylation differently than stimulation 
with  the  phorbol  ester  PMA  (Figure  5.3),  with  PMA  inducing  a  more  immediate 
translocation  to  the  plasma  membrane  and  subsequent  phosphorylation  of  the  isoform 
which is sustained for an extended time period. Cyclic AMP stimulation does not appear to 
induce a gross translocation of PKCα however levels of autophosphorylated forms of the 
enzyme  accumulate  slowly  in  the  pellet  fraction  of  COS1  cells.  Such  differences  in 
temporal phasing may play an important role in the compartmentalised effect of this PKC 
isoform.  165 
 
Further  experiments  established  that  cyclic  AMP  is  able  to  affect  PKCα 
autophosphorylation via activation of EPAC1 (Figure 5.5a). Although PKA can also be 
seen to effect PKCα autophosphorylation (Figure 5.5b), the majority of the effect of cyclic 
AMP appears to occur via EPAC, with PKA influence occurring, as with PMA, as a more 
immediate but transient effect in lysate samples. Furthermore, this effect by EPAC1 in 
COS1 cells appears to be limited to PKCα, as cyclic AMP elevation in cells expressing 
PKCd, the other PKC isoform shown to be abundantly present in COS1 cells and linked to 
SOCS-3 induction, does not induce autophosphorylation of PKCd (Figure 5.7). 
 
Although ERK phosphorylation in response to cyclic AMP elevation appears to follow a 
similar trend to PKCα autophosphorylation by F/R stimulation, PMA stimulation induces 
ERK phosphorylation at time points differing from its induction of PKCα phosphorylation 
(Figure 5.8). However, PMA stimulation can be seen to induce ERK phosphorylation at a 
greater extent in cells overexpressing EPAC1, suggesting the presence of EPAC1 in COS1 
cells is required for phosphorylation of ERK. EPAC has been reported previously to affect 
ERK phosphorylation and activity. EPAC mediated activation of Rap GTPase has been 
shown to stimulate ERK (Wang et al., 2006) and has also been shown to influence ERK 
phosphorylation by blocking the cyclic AMP elevating hormone calcitonin (Holz et al., 
2006). Here we have shown that the action of EPAC on ERK phosphorylation appears to 
occur  independently  of  PKC,  as  use  of  specific  PKC  inhibitors  does  not  reduce  ERK 
phosphorylation by F/R and in some cases can be seen to increase Phospho-ERK levels 
(Figure 5.9). Further work to determine which Raf isoform cyclic AMP exerts this effect 
on  ERK  phosphorylation  would  confirm  whether  EPAC  is  able  to  cause  effects 
downstream of PKC without directly affecting PKC itself, or if its effects are on PKC 
itself. As EPAC acts on B-Raf (Roscioni et al., 2008), and PKC on Raf-1 (Kolch et al., 
1993), activation assays or siRNA on these isoforms would provide greater understanding 
into the route by which cyclic AMP is able to induce phosphorylation of ERK via EPAC1.  
Although cyclic AMP is known to activate ERK, evidence indicating that it is able to do so 
via EPAC1 shows that cyclic AMP can control ERK activation in a PKA independent 
manner.  This  allows  for  ERK  signalling  and  the  mediation  of  transcription  to  occur 
separately from activation of PKA and other components of the PKA signalling pathway.  
 
In conclusion, this chapter outlines a role not only for cyclic AMP influence by EPAC on 
PKC autophosphorylation, but also a potential role for EPAC in the phosphorylation of 
ERK independent of PKC activation. 166 
 
 
 
 
CHAPTER 6 
 
 
 
General Discussion 
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6.1 Overview 
 
Biological  functions  are  mediated  by  complex  signal  transduction  pathways.  Such 
pathways require tight regulation to elicit the correct cellular response and this regulation 
is often a result of crosstalk between different signalling pathways (Stork and Schmitt, 
2002). Investigation of mechanisms of action and  control of signalling pathways, and in 
particular  the  control  exerted  by  other  pathways  is  important  not  only  to  gain  a  more 
complete understanding into the workings of the pathway, but also to provide potential 
areas of therapeutic drug targeting. The pathway outlined in this thesis not only combines 
two separate signalling  pathways which have been shown to influence and control the 
action of the other, but also provides understanding and access into the potential control of 
several biological functions and disease states. 
 
 
6.2 The role of cyclic AMP in inflammation 
 
The  cyclic  AMP  signalling  pathway  is  a  well  documented,  compartmentalised  signal 
transduction  cascade  that  is involved  in  numerous  cellular  processes  ranging  from  cell 
differentiation and growth to the regulation of glycogen and lipid metabolism (Cheng et 
al.,  2008).  Although  PKA  was  once  believed  to  be  the  sole  route  for  cyclic  AMP 
signalling, the recent discovery of EPAC (Exchange Protein Activated by Cyclic AMP) 
provided a new avenue of research in cyclic AMP signalling (Roscioni et al., 2008). EPAC 
was identified in a database search for proteins containing sequence homology to both 
cyclic  AMP  binding  sites  and  Ras  and  Rap1  GEFs  following  the  discovery  that  Rap1 
activation by cyclic AMP occurred independently of PKA (de Rooij et al., 1998). The two 
EPAC  isoforms  identified  were  hypothesised  to  be  involved  in  cyclic  AMP  effects 
previously believed to act solely through PKA action and as, like PKA, EPAC isoforms are 
found ubiquitously in tissue, they provide an additional means for precise control of cyclic 
AMP signalling. This allows cyclic AMP to affect multiple pathways (Cheng et al., 2008), 
with regulation of EPAC localisation and specific subcellular locations suggesting that 
compartmentalisation  of  EPAC  plays  an  important  role  in  its  signalling  properties 
(Roscioni et al., 2008). There are a wide range of downstream effectors of EPAC, PLC and 
ERK (Roscioni et al., 2008).  
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To date, the effects of EPAC and its regulation are not fully understood, although it has 
been shown to play important roles in calcium signalling through both direct interaction 
with intracellular calcium receptors and through control of exocytosis, which alongside 
insulin secretion links EPAC to a role in diabetes (Holz et al., 2006; Roscioni et al., 2008) 
and in anti-inflammatory signalling. In 2006, Sands et al, identified the ability of cyclic 
AMP level elevations in vascular endothelial cells to inhibit IL-6 signalling. This inhibition 
involved the induction of SOCS-3, which was found to occur independently of PKA and to 
instead require the activation of EPAC. From this data, a pathway was outlined, through 
which an increase in intracellular cyclic AMP activated Rap1 via EPAC to cause induction 
of SOCS-3 and mediate the pro-inflammatory effect of IL-6 receptor signalling (Sands et 
al., 2006).  
 
As  IL-6  initiates  and  mediates  immune  and  inflammatory  responses,  disruption  of  this 
tightly controlled signalling has been linked to diseases such as Crohn’s and rheumatoid 
arthritis  (Ishihara  and  Hirano,  2002),  while  increased  IL-6  levels  have  been  linked  to 
diseases including osteoporosis (Jones et al., 2001) and renal cancer (Takenawa et al., 
1991). The pathway outlined in this study may therefore provide drug targets by which 
control of IL-6 signalling can be asserted via SOCS-3. Additionally, EPAC has been linked 
to  several  important  cellular  functions,  including  exocytosis,  cell  differentiation  and 
proliferation, and apoptosis (as reviewed in Borland et al., 2009) that need tight regulation. 
EPAC  has  also  been  identified  as  having  a  role  in  a  range  of  neurodegenerative, 
inflammatory and metabolic disorders such as Alzheimer’s, diabetes and asthma (McPhee 
et al., 2005). The wide ranging cellular functions and diseases linked to the components of 
the pathway outlined in this work demonstrates that elucidation of these areas of crosstalk 
provides  important  understanding  into  the  importance  of  the  control  exhibited  by  this 
pathway. EPAC has also been shown to mediate the induction of SOCS-3 in several cell 
types (Sands et al., 2006; Yarwood et al., 2008; Borland et al., 2009). SOCS-3 is capable 
of  inhibiting  the  JAK-STAT  pathway,  allowing  control  of  IL-6  signalling,  a  cytokine 
involved in the maintenance of the inflammatory  and immune responses. However the 
pathway by which cyclic AMP is able to induce SOCS-3 has not been fully outlined.  
 
The pathway elucidated here between EPAC and SOCS-3 expands upon the identification 
of the involvement of EPAC1 in the control of SOCS-3 induction (Sands et al., 2006; 
Yarwood et al., 2008; Borland et al., 2009). A link between EPAC and PKCε via the small 
GTPase Rap2B has been well established (Schmidt et al., 2001; Bunney and Katan, 2006; 169 
 
Oestreich et al., 2009), providing a starting point for investigations, although no known 
effects of PLCε on SOCS-3 had been reported. PLC inhibitor treatment and PLCε specific 
siRNA experiments indicated that PLCε is necessary for SOCS-3 induction by EPAC in 
COS1  cells.  Further  investigation  into  downstream  effectors  of  PLC  action  led  to  the 
identification of PKCα and PKCδ as essential components of this pathway by which EPAC 
is able to induce SOCS-3 in COS1 cells. As  further investigation within our group also 
recently identified that this route of induction of SOCS-3 by cyclic AMP via EPAC and 
PKC is dependent on activation of ERK and the transcription factor C/EBPβ (Borland et 
al., 2009), this work goes some way towards fully delineating a mechanism by which 
cyclic AMP can affect inflammation. Identification of these key points in the pathway may 
provide  areas  for  potential  therapeutic  targeting  as  elevating  cyclic  AMP  levels  or 
activating  components  in  the  pathway  would  increase  SOCS-3  induction,  thereby 
inhibiting IL-6 signalling. 
 
 
6.3 Activation of PKC by cyclic AMP 
 
As outlined above, we have identified a role for PKC isoforms in a pathway induced by 
cyclic AMP. This discovery led to further investigation into the effect of cyclic AMP, via 
EPAC, on PKCα and δ activation and autophosphorylation. Autophosphorylation of PKC 
isoforms has been shown to be important not only for PKC activity but also for subcellular 
localisation and compartmentalisation, indicating it plays an important role in tight enzyme 
control and disruption of this activity can effect biological functions which in turn can lead 
to  disease  pathologies  (Feng  and  Hannun,  1998).  As  activity  of  PKC  isoforms  effects 
biological  processes  ranging  from  cell  proliferation  and  adhesion  to  apoptosis,  tight 
regulation of PKC activity and signalling is crucial as disruption can be linked to several 
disease states ranging from immunodeficiency disorders to cardiac hypertrophy to a range 
of cancers (Mackay and Twelves, 2007).  To date, little is understood about the effects of 
cyclic AMP on PKC regulation. What is known suggests that any effect occurs in a cell 
specific manner, with cyclic AMP causing inhibition of PKC activity in platelets (Kroll et 
all 1988) but inhibiting activity in skeletal myoblats (Nishizuka, 1986). 
 
 
Activation of PKC occurs following ligand binding at the cell membrane. Three priming 
sites,  conserved  across  PKC  isoforms  are  phosphorylated,  allowing  for  control  by 170 
 
autophosphorylation  (Parekh  et  al.,  2000).  For  PKCα,  autophosphorylation  has  been 
identified as important in targeting of the protein to specific subcellular locations (Kitatani 
et  al.,  2007).  Similarly,  autophosphorylation  in  PKCδ  has  been  linked  to  its  ability  to 
translocate to cell membranes (Durgan et al., 2007). 
 
The role of autophosphorylation in PKC subcellular localisation is of particular interest as 
numerous  cellular  processes,  including  differentiation  and  proliferation,  require 
transduction  of  signals  to  specific  intracellular  regions,  and  it  is  thought  that 
autophosphorylation  of  PKC  isoforms  induced  by  differing  stimuli  may  allow  specific 
targeting  to  these  areas  (Feng  et  al.,  2000).  There  is  therefore  a  clear  importance  of 
understanding the mechanisms by which PKC isoforms can be autophosphorylated, and in 
particular how effectors outside of the PKC signalling pathway may exert control over 
PKC activation.  
 
In this study, a role for cyclic AMP was found in the activation and autophosphorylation of 
PKCα,  but  not  for  PKCδ,  occurring  largely  via  EPAC.  As  results  show  that  PKCα  is 
activated by EPAC stimulation while PKCδ is not, it is likely that PKCδ plays a supportive 
role in the induction of SOCS-3 by EPAC. It is possible that PKCδ is involved in targeting 
of PKCα or in some other facilitator role, and further investigation is required to determine 
the precise role of PKCδ in this pathway. Further investigation would also expand on to 
what degree cyclic AMP exerts control on PKC and on its downstream effectors. 
 
 
6.4 Control of cyclic AMP by PKC 
 
In this work we have outlined a role for cyclic AMP in control of PKC signalling. This 
forms part of a negative feedback loop, as we have also identified a point of crosstalk 
between the two signalling pathways whereby PKC is able to exert control over cyclic 
AMP. In 1999, Yarwood et al. used a yeast two-hybrid screen to identify the interaction 
between  the  scaffold  protein  RACK1  and  the  cyclic  AMP-specific  phosphodiesterase 
PDE4D5, demonstrating a potential area of crosstalk between the PKC and cyclic AMP 
signalling pathways. As phosphodiesterases are the only means of reducing intracellular 
cyclic AMP levels, and an understanding of their control would provide a mechanism to 
artificially control cyclic AMP signalling. Although binding between these two proteins 
was shown to be unique and specific (Yarwood et al., 1999) with RACK1 as the only 171 
 
WD40  protein  bound  by  PDE4D5  and  RACK1  showing  no  ability  to  bind  other 
phosphodiesterases, the function of this complex remains largely unknown.  
 
Here we have outlined evidence that binding of RACK1 to PDE4D5 is important in control 
of  its  enzymatic  activity.  Unlike  the  β-arrestin/PDE4D5  complex  which  blocks  cyclic 
AMP synthesis and allows hydrolysis of cyclic AMP in the vicinity of the β2-Adrenergic 
receptor (Bolger et al., 2003), the RACK1/PDE4D5 complex did not appear to translocate, 
indicating that RACK1 does not target PDE4D5 to specific cellular localisations. It does 
however  affect  the  structural  stability  of  the  phosphodiesterase,  providing  PDE4D5 
protection against denaturation as well as affording high affinity binding of PDE4D5 to 
cyclic AMP. Additionally this study confirmed the results of Yarwood et al. (1999) which 
showed that binding to RACK1 increased the susceptibility of PDE4D5 to inhibition by the 
PDE4-specific inhibitor rolipram. Rolipram is used therapeutically to treat diseases such as 
depression and Alzheimer’s, it has an emetic effect on patients (Houslay et al., 2005). It is 
possible therefore that treatment with RACK1 or a synthetic analogue could allow a lower 
dosage of rolipram to be administered to obtain the same results with lessened side effects.   
 
In the initial study identifying the RACK1/PDE4D5 complex (Yarwood et al., 1999) it was 
hypothesised that RACK1 could potentially act as a scaffold protein, recruiting not only 
PDE4D5 but also other proteins to form a signalling complex. In this investigation we have 
identified the ability of activated PKCα to activate RACK1-bound PDE4D5, increasing 
cyclic AMP degradation as a result. This indicates a role of negative regulation by PKC on 
cyclic AMP in HEK293 cells, whereby through activating PDE4D5 to hydrolyse cyclic 
AMP, PKC is able to cause a reduction in intracellular cyclic AMP levels. 
 
Both cyclic AMP and PKC signalling have been implicated in similar biological functions 
and disease states. For example, both cyclic AMP and PKC signalling have recently been 
implicated in control of the mammalian circadian clock, involving EPAC (O'Neill et al., 
2008) and the PKCα isoform in complex with RACK1 (Receptor for Activated Protein 
Kinase C 1) (Robles et al., 2010) respectively. As components between both pathways 
form integral parts of the negative feedback loops which control the circadian pacemaker, 
the  work  presented  here  indicates  that  it  is  likely  that  these  pathways  are  working  in 
conjunction with each other. 
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6.5 Future Directions 
 
Although a clear pathway containing points of crosstalk between cyclic AMP and PKC 
signalling  pathways  has  been  outlined,  there  are  several  directions  in  which  this 
investigation  could  be  carried  forward  in  the  future.  There  is  the  potential  to  provide 
therapeutic targets for the control of inflammation due to the effect of SOCS-3 on IL-6 
signalling as well as other biological roles and diseases associated with this cytokine, and 
the potential role of the PDE4D5/RACK1 complex in treatment of disorders with the anti-
depressant and anti-inflammatory drug rolipram, as well as potential control over other 
functions and disease states associated with components of this pathway. Several areas of 
investigation would therefore provide a deeper understanding into the control and effects 
of the pathway.  
 
Other areas in which this study could be taken forward include conclusive determination as 
to  whether  ERK  phosphorylation  in  this  pathway  is  a  consequence  of  EPAC  or  PKC 
activation,  by  investigating  which  Raf  isoform  is  involved  in  the  pathway.  Further 
elucidation  into  the  supportive  role  of  PKCδ  in  the  pathway,  and  whether  any  other 
proteins associated with components of the pathway, such as AKAPs assert any level of 
control, or if they themselves are affected by the pathway would expand on the work laid 
out in this thesis.  
 
Additionally, many of the components of the pathway are found in almost all cell types, so 
determination as to whether there is a role for this pathway in cells other than COS1 or 
HEK293, both of which are kidney cells, would provide further evidence for the role of the 
pathway  in  cellular  function  and  the  suitability  of  its  areas  of  crosstalk  as  therapeutic 
targets. This is particularly important as the pathway may not be viable in all cell types, 
which  may  further  determine  the  suitability  of  its  use  in  therapeutic  control  of  cell 
functions, due to components which have been shown to have different effects in different 
cell types. For example EPAC has been identified as stimulating cell division in COS1 
cells  (Qiao  et  al.,  2002),  while  in  Jurkat  cells  the  opposite  effect  has  been  shown 
(Boussiotis et al., 1997).  
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6.6 Conclusions 
 
To  conclude,  the  evidence  presented  in  this  work  goes  some  way  towards  outlining  a 
pathway through which the cyclic AMP and PKC pathways act together to control and 
regulate  each  other  and  their  activity  via  novel  areas  of  crosstalk  (Figure  6.1).  In  this 
pathway, cyclic AMP activity via EPAC is able to induce SOCS-3 and influence IL-6 
control  through  the  activation  of  PKC  isoforms.  PKC  is  also  able  to  effect  negative 
feedback on cyclic AMP through the ability to increase cyclic AMP degradation through 
activation of PDE4D5 when bound to RACK1. The discoveries made in this thesis may 
also provide avenues for drug therapies for a range of disorders linked with components of 
the pathway.  
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Figure 6.1 
 
 
Figure 6.1 Proposed pathway of crosstalk between cyclic AMP and PKC signalling 
pathways  
In response to cyclic AMP elevation, EPAC is able to induce SOCS-3 expression via PLCε 
and  activation  of  PKCα.  PKCα  negatively  regulates  cyclic  AMP  levels  by  activating 
PDE4D5 while in complex with RACK1. PKCα may also influence ERK activation of 
C/EBP to induce SOCS-3 expression.  
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